US20040151725A1 - CTLA-4 immunoglobulin fusion proteins having modified effector functions and uses therefor - Google Patents
CTLA-4 immunoglobulin fusion proteins having modified effector functions and uses therefor Download PDFInfo
- Publication number
- US20040151725A1 US20040151725A1 US10/792,637 US79263704A US2004151725A1 US 20040151725 A1 US20040151725 A1 US 20040151725A1 US 79263704 A US79263704 A US 79263704A US 2004151725 A1 US2004151725 A1 US 2004151725A1
- Authority
- US
- United States
- Prior art keywords
- ctla4
- nucleic acid
- acid molecule
- domain
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 288
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 288
- 230000006870 function Effects 0.000 title abstract description 49
- 239000012636 effector Substances 0.000 title abstract description 43
- 108060003951 Immunoglobulin Proteins 0.000 title description 26
- 102000018358 immunoglobulin Human genes 0.000 title description 26
- 102000008203 CTLA-4 Antigen Human genes 0.000 title description 16
- 108010021064 CTLA-4 Antigen Proteins 0.000 title description 16
- 229940045513 CTLA4 antagonist Drugs 0.000 title 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims abstract description 217
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims abstract description 205
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 83
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 80
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 239000013604 expression vector Substances 0.000 claims abstract description 42
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims abstract description 36
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims abstract description 36
- 238000006467 substitution reaction Methods 0.000 claims description 50
- 239000002773 nucleotide Substances 0.000 claims description 39
- 125000003729 nucleotide group Chemical group 0.000 claims description 39
- 125000000539 amino acid group Chemical group 0.000 claims description 37
- 230000024203 complement activation Effects 0.000 claims description 34
- 108010087819 Fc receptors Proteins 0.000 claims description 33
- 102000009109 Fc receptors Human genes 0.000 claims description 33
- 230000002829 reductive effect Effects 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 230000010799 Receptor Interactions Effects 0.000 claims description 18
- 238000007792 addition Methods 0.000 claims description 18
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 102000043321 human CTLA4 Human genes 0.000 claims description 10
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 8
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 8
- 238000003259 recombinant expression Methods 0.000 claims description 7
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 129
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 81
- 102000004169 proteins and genes Human genes 0.000 abstract description 80
- 239000003446 ligand Substances 0.000 abstract description 64
- 230000001404 mediated effect Effects 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 38
- 230000003993 interaction Effects 0.000 abstract description 22
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract description 19
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract description 19
- 230000028993 immune response Effects 0.000 abstract description 19
- 102000005962 receptors Human genes 0.000 abstract description 15
- 108020003175 receptors Proteins 0.000 abstract description 15
- 238000002054 transplantation Methods 0.000 abstract description 12
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 11
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract description 9
- 208000024908 graft versus host disease Diseases 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000006472 autoimmune response Effects 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 154
- 239000013615 primer Substances 0.000 description 89
- 238000003752 polymerase chain reaction Methods 0.000 description 85
- 235000018102 proteins Nutrition 0.000 description 74
- 230000027455 binding Effects 0.000 description 53
- 238000000034 method Methods 0.000 description 49
- 239000012634 fragment Substances 0.000 description 48
- 230000000295 complement effect Effects 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 38
- 230000002441 reversible effect Effects 0.000 description 38
- 230000004927 fusion Effects 0.000 description 35
- 108010076504 Protein Sorting Signals Proteins 0.000 description 29
- 239000000427 antigen Substances 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 28
- 238000003556 assay Methods 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- 239000013598 vector Substances 0.000 description 22
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 21
- 210000003719 b-lymphocyte Anatomy 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 238000012408 PCR amplification Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000023275 Autoimmune disease Diseases 0.000 description 13
- 241001529936 Murinae Species 0.000 description 12
- 230000005867 T cell response Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000000139 costimulatory effect Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- -1 i.e. Proteins 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 238000010561 standard procedure Methods 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000006052 T cell proliferation Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 206010062016 Immunosuppression Diseases 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 102000047918 Myelin Basic Human genes 0.000 description 6
- 101710107068 Myelin basic protein Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000007423 screening assay Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000961 alloantigen Effects 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000004940 costimulation Effects 0.000 description 5
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 5
- 230000016396 cytokine production Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 235000004400 serine Nutrition 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 238000011537 Coomassie blue staining Methods 0.000 description 4
- 101150091887 Ctla4 gene Proteins 0.000 description 4
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 238000011685 brown norway rat Methods 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000014207 opsonization Effects 0.000 description 3
- 101150040383 pel2 gene Proteins 0.000 description 3
- 101150050446 pelB gene Proteins 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033885 Paraparesis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 230000020385 T cell costimulation Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007896 negative regulation of T cell activation Effects 0.000 description 2
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 150000003355 serines Chemical class 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108010035053 B7-1 Antigen Proteins 0.000 description 1
- 102000038504 B7-1 Antigen Human genes 0.000 description 1
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101710122625 Low affinity immunoglobulin gamma Fc region receptor II Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010070517 Type 2 lepra reaction Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000015240 negative regulation of T cell cytokine production Effects 0.000 description 1
- 230000019079 negative regulation of cytokine secretion Effects 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- T cell receptor TCR
- MHC major histocompatibility complex
- Costimulation induces T cells to proliferate and become functional (Schwartz, R. H. (1990) Science 248:1349-1356).
- Costimulation is neither antigen-specific, nor MHC restricted and is thought to be provided by one or more distinct cell surface molecules expressed by APCs (Jenkins, M. K., et al. (1988) J. Immunol. 140:3324-3330; Linsley, P. S., et al. (1991) J. Exp. Med. 173:721-730; Gimmi, C. D., et al., (1991) Proc. Natl. Acad. Sci. USA. 88:6575-6579; Young, J. W., et al.
- B7-1 protein (CD80; originally termed B7), expressed on APCs, is one such critical costimulatory molecule (Linsley, P. S., et al., (1991) J. Exp. Med. 173:721-730; Gimmi, C. D., et al., (1991) Proc. Natl. Acad. Sci. USA. 88:6575-6579; Koulova, L., et al., (1991) J. Exp. Med. 173:759-762; Reiser, H., et al. (1992) Proc. Natl. Acad. Sci. USA. 89:271-275; Linsley, P. S.
- human B lymphocyte antigen B7-2 (CD86) has been cloned and is expressed by human B cells at about 24 hours following stimulation with either anti-immunoglobulin or anti-MHC class II monoclonal antibody (Freeman G. J., et al. (1993) Science 262:909-911).
- human B cells express both B7-1 and a third CTLA4 counter-receptor which is identified by a monoclonal antibody BB-1, which also binds B7-1 (Yokochi, T., et al. (1982) J. Immunol. 128:823-827).
- the BB-1 antigen is also expressed on B7-1 negative activated B cells and can costimulate T cell proliferation without detectable IL-2 production, indicating that the B7-1 and BB-1 molecules are distinct (Boussiotis V. A., et al. (1993) Proc. Natl. Acad. Sci. USA 90:11059-11063).
- the presence of these costimulatory molecules on the surface of activated B lymphocytes indicates that T cell costimulation is regulated, in part, by the temporal expression of these molecules following B cell activation.
- B7-1 is a counter-receptor for two ligands expressed on T lymphocytes.
- the first ligand termed CD28
- CD28 The first ligand, termed CD28, is constitutively expressed on resting T cells and increases after activation. After signaling through the T cell receptor, ligation of CD28 induces T cells to proliferate and secrete IL-2 (Linsley, P. S., et al. (1991) J. Exp. Med. 173: 721-730; Gimmi, C. D., et al. (1991) Proc. Natl. Acad. Sci. USA. 88:6575-6579; Thompson, C. B., et al. (1989) Proc. Natl. Acad. Sci. USA.
- CTLA4 The second ligand, termed CTLA4, is homologous to CD28, but is not expressed on resting T cells and appears following T cell activation (Brunet, J. F., et al., (1987) Nature 328:267-270). Like B7-1, B7-2 is a counter-receptor for both CD28 and CTLA4 (Freeman G. J., et al. (1993) Science 262:909-911).
- CTLA4 was first identified as a mouse cDNA clone, in a library of cDNA from a cytotoxic T cell clone subtracted with RNA from a B cell lymphoma (Brunet, J. F., et al. (1987) supra). The mouse CTLA4 cDNA was then used as a probe to identify the human and mouse CTLA4 genes (Harper, K., et al. (1991) J. Immunol. 147:1037-1044; and Dariavich, et al. (1988) Eur. J. Immunol. 18(12):1901-1905, sequence modified by Linsley, P. S., et al. (1991) J. Exp. Med. 174:561-569). A probe from the V domain of the human gene was used to detect the human cDNA which allowed the identification of the CTLA4 leader sequence (Harper, K., et al. (1991) supra).
- Soluble derivatives of cell surface glycoproteins in the immunoglobulin gene superfamily have been made consisting of an extracellular domain of the cell surface glycoprotein fused to an immunoglobulin constant (Fc) region (see e.g., Capon, D. J. et al. (1989) Nature 337:525-531 and Capon U.S. Pat. Nos. 5,116,964 and 5,428,130 [CD4-IgG1 constructs]; Linsley, P. S. et al. (1991) J. Exp. Med. 173:721-730 [a CD28-IgG1 construct and a B7-1-IgG1 construct]; and Linsley, P. S. et al. (1991) J.
- Fc immunoglobulin constant
- CTLA4-IgG immunoglobulin fusion protein was used to study interactions between CTLA4 and its natural ligands (Linsley, P. S. , et al., (1991) J. Exp. Med. 174:561-569; International Application WO93/00431; and Freeman G. J. , et al. (1993) Science 262:909-911).
- This invention pertains to CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant (IgC) region-mediated effector functions and to nucleic acids encoding the proteins.
- the fusion proteins of the present invention have been constructed by fusing a peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region to create a CTLA4Ig fusion protein.
- the variable regions of immunoglobulin heavy and light chains have been replaced by the B7-binding extracellular domain of CTLA4 to create CTLA4-Ab fusion proteins.
- CTLA4-immunoglobulin fusion protein refers to both the CTLA4Ig and CTLA4-Ab forms.
- the fusion proteins of the invention have been modified to reduce their ability to activate complement and/or bind to Fc receptors.
- an IgC region of an isotype other than C ⁇ 1 is used in the fusion protein and the modified effector function(s) can be assessed relative to a C ⁇ 1-containing molecule (e.g., an IgG1 fusion protein).
- a mutated IgC region (of any isotype) is used in the fusion protein and the modified effector function can be assessed relative to an antibody or Ig fusion protein containing the non-mutated form of the IgC region.
- CTLA4-immunoglobulin fusion proteins of the invention are useful for inhibiting the interaction of CTLA4 ligands (e.g., B7 family members such as B7-1 and B7-2) with receptors on T cells (e.g., CD28 and/or CTLA4) to thereby inhibit delivery of a costimulatory signal in the T cells and thus downmodulate an immune response.
- CTLA4 ligands e.g., B7 family members such as B7-1 and B7-2
- T cells e.g., CD28 and/or CTLA4
- Use of the CTLA4-immunoglobulin fusion proteins of the invention is applicable in a variety of situations, such as to inhibit transplant rejection or autoimmune reactions in a subject.
- CTLA4-immunoglobulin fusion proteins of the invention exhibit reduced IgC region-mediated effector functions compared to a CTLA4-immunoglobulin fusion protein in which the IgG1 constant region is used and, thus are likely to have improved immunoinhibitory properties.
- These compositions can also be used for immunomodulation, to produce anti-CTLA4 antibodies, to purify CTLA4 ligands and in screening assays.
- the CTLA4-Ab fusion proteins are particularly useful when bivalent preparations are preferred, i.e. when crosslinking is desired.
- One aspect of the invention pertains to isolated nucleic acid molecules encoding modified CTLA4-immunoglobulin fusion proteins.
- the nucleic acids of the invention comprise a nucleotide sequence encoding a first peptide having a CTLA4 activity and a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function.
- a peptide having a CTLA4 activity is defined herein as a peptide having at least one biological activity of the CTLA4 protein, e.g., the ability to bind to the natural ligand(s) of the CTLA4 antigen on immune cells, such as B7-1 and/or B7-2 on B cells, or other known or as yet undefined ligands on immune cells, and inhibit (e.g., block) or interfere with immune cell mediated responses.
- the peptide having a CTLA4 activity binds B7-1 and/or B-2 and comprises an extracellular domain of the CTLA4 protein.
- the extracellular domain includes amino acid residues 20-144 of the human CTLA4 protein (amino acid positions 20-144 of SEQ ID NO: 24, 26 and 28).
- the present invention also contemplates forms of the extracellular domain of CTLA4 which are expressed without Ig constant regions and are expressed in E. coli. These soluble forms of the CTLA4 extracellular domain, although not glycosylated, are fully functional and have similar uses as the CTLA4 immunoglobulin fusion proteins of the invention.
- the nucleic acids of the invention further comprise a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one Ig constant region-mediated biological effector function.
- the immunoglobulin constant region comprises a hinge region, a CH2 domain and a CH3 domain derived from C ⁇ 1, C ⁇ 2, C ⁇ 3 or C ⁇ 4.
- the constant region segment is altered (e.g., mutated at specific amino acid residues by substitution, deletion or addition of amino acid residues) to reduce at least one IgC region-mediated effector function.
- a constant region other than C ⁇ 1 that exhibits reduced IgC region-mediated effector functions relative to C ⁇ 1 is used in the fusion protein.
- the CH2 domain is modified to reduce a biological effector function, such as complement activation, Fc receptor interaction, or both complement activation and Fc receptor interaction.
- a biological effector function such as complement activation, Fc receptor interaction, or both complement activation and Fc receptor interaction.
- at least one amino acid residue selected from a hinge link region of the CH2 domain is modified by substitution, addition or deletion of amino acids.
- a constant region which lacks the ability to activate complement such as C ⁇ 4 or C ⁇ 2 is used in the fusion protein (instead of a C ⁇ 1 constant region which is: capable of activating complement).
- the variable region of the heavy and light chain is replaced with a polypeptide having CTLA4 activity creating a CTLA4-Ab molecule.
- the heavy chain constant region of the CTLA4-Ab molecule comprises a hinge region, a CH2 domain and a CH3 domain derived from C ⁇ 1, C ⁇ 2, C ⁇ 3 or C ⁇ 4.
- the light chain constant region of the CTLA4-Ab molecule comprises an Ig signal sequence, the CTLA4 extracellular domain, and the light chain (kappa or lambda) constant domain.
- nucleic acids obtained in accordance with this invention can be inserted into various expression vectors, which in turn direct the synthesis of the corresponding protein in a variety of hosts, particularly eucaryotic cells, such as mammalian or insect cell culture and procaryotic cells, such as E. coli.
- Expression vectors within the scope of the invention comprise a nucleic acid as described herein and a promotor operably linked to the nucleic acid. Such expression vectors can be used to transfect host cells to thereby produce fusion proteins encoded by nucleic acids as described herein.
- Another aspect of the invention pertains to isolated CTLA4-immunoglobulin fusion proteins comprising a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein.
- a preferred CTLA4-immunoglobulin fusion protein comprises an extracellular domain of the CTLA4 protein (e.g., amino acid positions 20-144 of the human CTLA4-immunoglobulin fusion protein shown in SEQ ID NO: 24, 26 and 28) linked to an immunoglobulin constant region comprising a hinge region, a CH2 domain and a CH3 domain derived from C ⁇ 1, C ⁇ 2, C ⁇ 3 or C ⁇ 4.
- a preferred constant domain used to reduce the complement activating ability of the fusion protein is C ⁇ 4.
- the CH2 domain of the immunoglobulin constant region is modified to reduce at least one biological effector function, such as complement activation or Fc receptor interaction.
- the CTLA4-immunoglobulin fusion protein includes a CH2 domain which is modified by substitution of an amino acid residue at position 234, 235 and/or 237 of an intact heavy chain protein.
- a CTLA4-immunoglobulin fusion protein fused to IgG4 comprising an amino acid sequence shown in SEQ ID NO: 28 or a CTLA4-immunoglobulin fused to IgG1 fusion protein comprising an amino acid sequence shown in SEQ ID NO: 24.
- CTLA4-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) and a receptor therefor (e.g., CD28 and/or CTLA4) on the surface of a T cell, to thereby suppress cell-mediated immune responses in vivo.
- a CTLA4 ligand e.g., B7-1 and/or B7-2
- a receptor therefor e.g., CD28 and/or CTLA4
- Inhibition of the CTLA4 ligand/receptor interaction may be useful for both general immunosuppression and to induce antigen-specific T cell tolerance in a subject for use in preventing transplantation rejection (solid organ, skin and bone marrow) or graft versus host disease, particularly in allogeneic bone marrow transplantation.
- CTLA4-immunoglobulin fusion proteins can also be used therapeutically in the treatment of autoimmune diseases, allergy and allergic reactions, transplantation rejection and established graft versus host disease in a subject.
- CTLA4-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-CTLA4 antibodies in a subject, to purify CTLA4 ligands and in screening assays to identify molecules which inhibit the interaction of CTLA4 with a CTLA4 ligand.
- FIG. 1 is a schematic diagram of the “zip up” polymerase chain reaction (PCR) procedure used to contrust gene fusions.
- FIG. 2A-B show the amino acid mutations introduced into the hinge and CH2 domains of hCTLA4-IgG1m (panel A) and hCTLA4-IgG4m (panel B). Mutated amino acid residues are underlined.
- FIG. 3 is a schematic diagram of the expression vector pNRDSH.
- FIG. 4A-B are graphic representations of competition ELISAs depicting the ability of unlabeled hCTLA4-IgG1 or unlabeled hCTLA4-IgG4m to compete for the binding of biotinylated hCTLA4-IgG1 to hB7-1-Ig (panel A) or hB7-2-Ig (panel B).
- FIG. 5A-B are graphic representations of Fc receptor binding assays depicting the ability of CTLA4-IgG1 or CTLA4-IgG4 to bind to Fc receptors.
- panel A the ability of unlabeled CTLA4-IgG1 or unlabeled CTLA4-IgG4 to compete for the binding of 125 I-labeled CTLA4-IgG1 to FcRI-positive U937 cells is depicted.
- panel B the percent specific activity of unlabeled CTLA4-IgG1, CTLA4-IgG4 or hIgG1 used to compete itself for binding to U937 cells is depicted.
- FIG. 6A-C are graphic representations of complement activation assays depicting the ability of CTLA4-IgG1, CTLA4-IgG4m or anti-B7-1 mAb (4B2) to activate complement-mediated lysis of CHO-B7-1 cells.
- panel A guinea pig complement is used as the complement source.
- panel B human serum is used as the complement source.
- panel C control untransfected CHO cells are used as the target for complement-mediated lysis.
- FIG. 7 is a graphic representation of the binding of CTLA4-IgG1, CTLA4-IgG4m or anti-B7-1 mAb (4B2) to CHO-B7-1 cells, demonstrating that despite the inability of CTLA4-IgG4m to activate complement it can still bind to CHO-B7-1 cells.
- FIG. 8 is a graphic representation of a competition curve demonstrating that soluble CTLA4 expressed in E. coli is functional and competes with unlabeled CTLA4Ig for binding to plate-bound B7-1.
- This invention features isolated CTLA4-immunoglobulin fusion proteins which have been modified to reduce immunoglobulin constant (IgC) region-mediated effector functions.
- the invention also features isolated nucleic acids encoding the proteins, methods for producing the CTLA4-immunoglobulin fusion proteins of the invention and methods for using the CTLA4-immunoglobulin fusion proteins of the invention for immunomodulation. E. coli -expressed forms of CTLA4 are also disclosed.
- the invention provides isolated nucleic acids encoding CTLA4-immunoglobulin fusion proteins.
- the CTLA4-immunoglobulin fusion proteins are comprised of two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which, in certain embodiments is modified to reduce at least one constant region-mediated biological effector function.
- the isolated nucleic acids of the invention comprise a first nucleotide sequence encoding the first peptide having a CTLA4 activity and a second nucleotide sequence encoding the second peptide comprising an immunoglobulin constant region which, in a preferred embodiment, is modified to reduce at least one constant region-mediated biological effector function.
- the first and second nucleotide sequences are linked (i.e., in a 5′ to 3′ orientation by phosphodiester bonds) such that the translational frame of the CTLA4 and IgC coding segments are maintained (i.e., the nucleotide sequences are joined together in-frame).
- expression i.e., transcription and translation
- the heavy chain gene is constructed such that the CTLA4 extracellular binding domain is linked to a 5′ signal sequence and a 3′ immunoglobulin CH1, hinge, CH2, and CH3 domain.
- CTLA4-light chain constructs are prepared in which an Ig signal sequence, an intron, the CTLA4 extracellular domain, an intron, and the light chain constant domain are linked.
- the DNA encoding the heavy and light chains is then expressed using an appropriate expression vector as described in the Examples.
- nucleic acid as used herein is intended to include fragments or equivalents thereof.
- equivalent is intended to include nucleotide sequences encoding functionally equivalent CTLA4-immunoglobulin fusion proteins, i.e., proteins which have the ability to bind to the natural ligand(s) of the CTLA4 antigen on immune cells, such as B7-1 and/or B7-2 on B cells, and inhibit (e.g., block) or interfere with immune cell mediated responses.
- isolated refers to a nucleic acid or fusion protein substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
- An isolated nucleic acid is also free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the organism from which the nucleic acid is derived.
- the nucleic acids of the invention can be prepared by standard recombinant DNA techniques.
- a chimeric CTLA4-immunoglobulin gene fusion can be constructed using separate template DNAs encoding CTLA4 and an immunoglobulin constant region and a “zip up” polymerase chain reaction (PCR) procedure as described in Example 1 and illustrated schematically in FIG. 1.
- PCR polymerase chain reaction
- a nucleic acid segment encoding CTLA4 can be ligated in-frame to a nucleic acid segment encoding an immunoglobulin constant region using standard techniques.
- a nucleic acid of the invention can also be chemically synthesized using standard techniques.
- An isolated nucleic acid of the invention encodes a first peptide having a CTLA4 activity.
- the phrase “peptide having a CTLA4 activity” or “peptide having an activity of CTLA4” is used herein to refer to a peptide having at least one biological activity of the CTLA4 protein, i.e., the ability to bind to the natural ligand(s) of the CTLA4 antigen on immune cells, such as B7-1 and/or B7-2 on B cells, or other known or as yet undefined ligands on immune cells, and which, in soluble form, can inhibit (e.g., block) or interfere with immune cell mediated responses.
- the CTLA4 protein is a human CTLA4 protein, the nucleotide and amino acid sequences of which are disclosed in Harper, K., et al. (1991) J. Immunol. 147:1037-1044 and Dariavich, et al. (1988) Eur. J. Immunol. 18(12): 1901-1905.
- the peptide having a CTLA4 activity binds B7-1 and/or B7-2 and comprises at least a portion of an extracellular domain of the CTLA4 protein.
- the extracellular domain includes amino acid residues 1-125 of the human CTLA4 protein (amino acid positions 20-144 of SEQ ID NO: 24, 26 and 28).
- CTLA4 proteins from other species are also encompassed by the invention.
- the nucleotide and amino acid sequences of mouse CTLA4 are disclosed in Brunet, J. F., et al., (1987) Nature 328:267-270.
- the nucleic acids of the invention can be DNA or RNA.
- Nucleic acid encoding a peptide having a CTLA4 activity may be obtained from mRNA present in activated T lymphocytes. It is also possible to obtain nucleic acid encoding CTLA4 from T cell genomic DNA.
- the gene encoding CTLA4 can be cloned from either a cDNA or a genomic library in accordance with standard protocols.
- a cDNA encoding CTLA4 can be obtained by isolating total mRNA from an appropriate cell line. Double stranded cDNAs can then prepared from the total mRNA.
- the cDNAs can be inserted into a suitable plasmid or bacteriophage vector using any one of a number of known techniques.
- Genes encoding CTLA4 can also be cloned using established polymerase chain reaction techniques in accordance with the nucleotide sequence information provided by the invention (see Example 1).
- a DNA vector containing a CTLA4 cDNA can be used as a template in PCR reactions using oligonucleotide primers designed to amplify a desired region of the CTLA4 cDNA, e.g., the extracellular domain, to obtain an isolated DNA fragment encompassing this region using standard techniques.
- nucleic acids encoding the CTLA4-immunoglobulin fusion proteins of the invention exist.
- different cell lines can be expected to yield DNA molecules having different sequences of bases.
- variations may exist due to genetic polymorphisms or cell-mediated modifications of the genetic material.
- nucleotide sequence of a CTLA4-immunoglobulin fusion protein of the invention can be modified by genetic techniques to produce proteins with altered amino acid sequences that retain the functional properties of CTLA4 (e.g., the ability to bind to B7-1 and/or B7-2).
- the chimeric gene fusion encoding the CTLA4-immunoglobulin fusion protein typically includes a nucleotide sequence encoding a signal sequence which, upon transcription and translation of the chimeric gene, directs secretion of the fusion protein.
- a native CTLA4 signal sequence e.g., the human CTLA4 signal sequence disclosed in Harper, K., et al. (1991) J. Immunol. 147, 1037-1044
- a heterologous signal sequence can be used.
- the oncostatin-M signal sequence (Malik N., et al. (1989) Mol. Cell.
- an immunoglobulin signal sequence e.g., amino acid positions 1 to 19 of SEQ ID NO: 24, 26 and 28
- a nucleotide sequence encoding a signal sequence can be incorporated into the chimeric gene fusion by standard recombinant DNA techniques, such as by “zip up” PCR (described further in Example 1) or by ligating a nucleic acid fragment encoding the signal sequence in-frame at the 5′ end of a nucleic acid fragment encoding CTLA4.
- the CTLA4-immunoglobulin fusion protein of the invention further comprises a second peptide linked to the peptide having a CTLA4 activity.
- the second peptide comprises a light chain constant region.
- the light chain is a kappa light chain.
- the second peptide comprises a heavy chain constant region.
- the constant region comprises an immunoglobulin hinge region, a CH2 domain and a CH3 domain.
- the constant region also comprises a CH1 domain.
- the constant region is preferably derived from C ⁇ 1, C ⁇ 2, C ⁇ 3 or C ⁇ 4.
- the heavy chain constant region is modified to reduce at least one constant region-mediated biological effector function.
- the constant region segment (either C ⁇ 1 or another isotype) is altered (e.g., mutated from the wild-type sequence at specific amino acid residues by substitution, deletion or addition of amino acid residues) to reduce at least one IgC region-mediated effector function.
- the effector functions of this altered fusion protein can be assessed relative to an unaltered IgC region-containing molecule (e.g., a whole antibody or Ig fusion protein).
- a constant region other than C ⁇ 1 that exhibits reduced IgC region-mediated effector functions is used in the fusion protein.
- the effector functions of this fusion protein can be assessed relative to a C ⁇ 1-containing molecule (e.g., an IgG1 antibody or IgG1 fusion protein).
- the fusion protein comprises a constant region other than C ⁇ 1 that is also mutated to further reduce effector function.
- a preferred IgC region is a mutated C ⁇ 4 region.
- immunoglobulin constant (IgC) region-mediated biological effector function is intended to include biological responses which require or involve, at least in part, the constant region of an immunoglobulin molecule.
- effector functions include complement activation, Fc receptor interactions, opsonization and phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), release of reactive oxygen intermediates and placental transfer. While such effector functions are desirable in many immune responses, they are undesirable in situations where an immune response is to be downmodulated.
- the CTLA4-immunoglobulin fusion proteins of the invention exhibit reduced IgC region-mediated biological effector functions and thus are efficient agents for downregulating immune responses. Additionally, the CTLA4-immunoglobulin fusion proteins of the invention display a long plasma half life in vivo. The long plasma half-life makes the proteins particularly useful as therapeutic agents.
- All immunoglobulins have a common core structure of two identical light and heavy chains held together by disulfide bonds. Both the light chains and the heavy chains contain a series of repeating, homologous units, each about 110 amino acid residues in length, which fold independently in a common globular motif, called an immunoglobulin domain.
- one domain (V) has a variable amino acid sequence depending on the antibody specificity of the molecule.
- the other domains (C) have a constant sequence common among molecules of the same isotype.
- Heavy chains are designated by the letter of the Greek alphabet corresponding to the overall isotype of the antibody: IgA1 contains ⁇ 1 heavy chains; IgA2, ⁇ 2; IgD, ⁇ ; IgE, ⁇ ; IgG1, ⁇ 1; IgG2, ⁇ 2; IgG3, ⁇ 3; IgG4, ⁇ 4; and IgM, ⁇ .
- Each heavy chain includes four domains; an amino terminal variable, or VH domain which displays the greatest sequence variation among heavy chains and three domains which form the constant region (CH1, CH2 and CH3) in order from the amino to the carboxy terminus of the heavy chain.
- VH domain amino terminal variable, or VH domain which displays the greatest sequence variation among heavy chains
- three domains which form the constant region (CH1, CH2 and CH3) in order from the amino to the carboxy terminus of the heavy chain.
- ⁇ , ⁇ and ⁇ heavy chains there is a nonglobular region of amino acid sequence, known as the hinge, located between the first and second constant region domains (
- the immunoglobulin constant region segment of the CTLA4-immunoglobulin fusion protein can be mutated at particular regions necessary for Fc receptor (FcR) interactions (see Canfield, S. M. and S. L. Morrison (1991) J. Exp. Med. 173:1483-1491; and Lund, J. et al. (1991) J. of Immunol. 147:2657-2662).
- the constant region is mutated within a region of the CH2 domain referred to as the “hinge link” or “lower hinge” region. This region encompasses amino acid residues 234-239 in a full-length native immunoglobulin heavy chain.
- IgC region amino acid residue positions described herein refer to the position within the full-length intact native immunoglobulin heavy chain; it will be apparent to those skilled in the art that depending upon the length of the CTLA4 segment used in the CTLA4-immunoglobulin fusion protein, the positions of the corresponding IgC amino acid residues within the fusion protein will vary (Kabat, E. A, T. T. Wu, M. Reid-Miller, H. M. Perry, and K. S. Gottesman eds. (1987) “Sequences of Proteins of Immunological Interest” National Institutes of Health, Bethesda, Md.).
- the hinge link region can be mutated by substitution, addition or deletion of amino acid residues.
- a preferred CTLA4-immunoglobulin fusion protein of the invention is one in which the IgG1 constant region has substitution mutations at positions 234, 235 and/or 237 of the C ⁇ 1 segment.
- Leu at 234 is substituted with Ala
- Leu at 235 is substituted with Glu
- Gly at 237 is substituted with Ala
- a preferred CTLA4-immunoglobulin fusion protein of the invention is one in which IgG4 has substitution mutations at positions 235 and/or 237 of the C ⁇ 4 segment.
- Leu at 235 is substituted with Glu and Gly at 237 is substituted with Ala (see Example 1).
- the Fc receptor binding capability of the CTLA4-immunoglobulin fusion protein is reduced by mutating a region of the CH2 domain referred to as the “hinge-proximal bend” region (amino acid residues at positions 328-333 within a full-length intact heavy chain).
- This region can be mutated by substitution, addition or deletion of amino acid residues.
- position 331 of C ⁇ 1 or C ⁇ 3 is mutated.
- a preferred mutation in C ⁇ 1 or C ⁇ 3 is substitution of Pro with Ser.
- the immunoglobulin constant region segment of the fusion protein can be mutated at particular regions important for complement activation, such as regions involved in IgC region binding to the C1q component of complement.
- one or more residues present within the CH2 domain of IgG subclasses that are involved in C1q binding are altered.
- positions 318, 320 and/or 322 are mutated (see Duncan and Winter (1988) Nature 332, 738-740).
- Glu at 318 is substituted with Ala or Val
- Lys at 320 is substituted with Ala or Gln
- Lys at 322 is substituted with Ala or Gln.
- a constant region which lacks the ability to activate complement can be used in the fusion protein.
- a CTLA4-immunoglobulin fusion protein utilizing a C ⁇ 4 constant region exhibits reduced complement activation ability relative to a CTLA4-immunoglobulin fusion protein comprising IgG1 (as demonstrated in Example 2).
- the hinge region of the IgC segment is altered to inhibit complement activation ability.
- the hinge regions of the human IgG molecules vary in amino acid sequence and composition as well as length.
- IgG1, IgG2 and IgG4 have hinge regions consisting of 12 to 15 amino acids
- IgG3 has an extended hinge region, consisting of 62 amino acids.
- the hinge region is believed to be essential for binding with the first component of complement, C1q (see Tan et al. (1990) Proc. Natl. Acad. Sci. USA 87:162-166).
- chimeric human IgG3 and IgG4 molecules with different hinge lengths and amino acid composition have been produced, confirming the role of the hinge region in C1q binding and complement activation.
- CTLA4-immunoglobulin (IgG1) or CTLA4-immunoglobulin (IgG3) construct it may be necessary to modify, by substitution, addition or deletion, at least one amino acid residue in the hinge region.
- the hinge region of C ⁇ 1 or C ⁇ 3 is substituted with a hinge region derived from C ⁇ 2 or C ⁇ 4, each of which lack the ability to activate complement.
- the fusion proteins can be further modified for other purposes, e.g., to increase solubility, enhance therapeutic or prophylactic efficacy, or stability (e.g., shelf life ex vivo and resistance to proteolytic degradation in vivo).
- modified proteins are considered functional equivalents of the CTLA4-immunoglobulin fusion proteins as defined herein.
- amino acid residues of the CTLA4 portion of the fusion protein which are not essential for CTLA4 ligand interaction can be modified by being replaced by another amino acid whose incorporation may enhance, diminish, or not affect reactivity of the fusion protein.
- a CTLA4-immunoglobulin fusion protein which binds only B7-1 or B7-2 but not both could be created by mutating residues involved in binding to one ligand or the other.
- Another example of a modification of a CTLA4-immunoglobulin fusion protein is substitution of cysteine residues, preferably with alanine, serine, threonine, leucine or glutamic acid residues, to minimize dimerization via disulfide linkages.
- a particularly preferred modification is substitution of cysteine residues in the hinge region of the immunoglobulin constant region with serine.
- amino acid side chains of a CTLA4-immunoglobulin fusion protein can be chemically modified.
- a particularly preferred embodiment of the invention features a nucleic acid encoding a CTLA4-immunoglobulin fusion protein comprising a nucleotide sequence encoding a first peptide having a CTLA4 activity and a nucleotide sequence encoding a second peptide comprising an IgG4 immunoglobulin constant region, C ⁇ 4.
- the nucleic acid is a DNA and the first peptide comprises an extracellular region of CTLA4 which binds B7-1.
- Such a CTLA4-IgG4 construct can comprise a nucleotide sequence show in SEQ ID NO: 25 and an amino acid sequence shown in SEQ ID NO: 26.
- the CH2 domain of the C ⁇ 4 portion of this CTLA4IgG4 fusion protein is modified to reduce Fc receptor interaction.
- the CH2 domain can be modified by substitution of Leu at position 235 (e.g., with Glu) and/or substitution of Gly at position 237 (e.g., with Ala).
- a particularly preferred CTLA4-IgG4 fusion protein comprises the extracellular domain of human CTLA4 (i.e., amino acid residues 1-125), has reduced Fc receptor interaction due to two substitutions in the CH2 domain (i.e., substitution of Leu at position 235 with Glu and substitution of Gly at position 237 with Ala).
- CTLA4-IgG4 fusion protein comprises an amino acid sequence shown in SEQ ID NO: 28 and a nucleotide sequence shown in SEQ ID NO: 27.
- This construct referred to as CTLA4-IgG4m, exhibits markedly reduced complement activation ability and FcR binding activity relative to a wild-type CTLA4-IgG1 construct (see Example 2).
- nucleic acid encoding a CTLA4-IgG1 fusion protein comprising a nucleotide sequence encoding a first peptide having a CTLA4 activity and a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region, C ⁇ 1, which is modified to reduce at least one constant region-mediated biological effector functions.
- the nucleic acid is a DNA and the first peptide comprises an extracellular region of CTLA4 which binds B7-1.
- CTLA4-IgG1 fusion protein comprises the extracellular domain of human CTLA4 (i.e., amino acid residues 1-125), has reduced Fc receptor interaction due to three substitutions in the CH2 domain (i.e., substitution of Leu at position 234 with Ala, substitution of Leu at position 235 with Glu and substitution of Gly at position 237 with Ala).
- CTLA4-IgG1 fusion protein referred to herein as CTLA4-IgG1m, comprises an amino acid sequence shown in SEQ ID NO: 24 and a nucleotide sequence shown in SEQ ID NO: 23.
- Nucleic acid encoding a peptide comprising an immunoglobulin constant region can be obtained from human immunoglobulin mRNA present in B lymphocytes. It is also possible to obtain nucleic acid encoding an immunoglobulin constant region from B cell genomic DNA. For example, DNA encoding C ⁇ 1 or C ⁇ 4 can be cloned from either a cDNA or a genomic library or by polymerase chain reaction (PCR) amplification in accordance with protocols herein described.
- the nucleic acids of the invention can be DNA or RNA.
- a preferred nucleic acid encoding an immunoglobulin constant region comprises all or a portion of the following: the DNA encoding human C ⁇ 1 (Takahashi, N. S. et al.
- a number of processes are known in the art for modifying a nucleotide or amino acid sequence to thereby mutate the IgC regions as described herein.
- mutations can be introduced into a DNA by any one of a number of methods, including those for producing simple deletions or insertions, systematic deletions, insertions or substitutions of clusters of bases or substitutions of single bases, to generate CTLA4-immunoglobulin fusion proteins of the invention and equivalents thereof.
- amino acid substitutions, deletions or additions such as in the CH2 domain of the immunoglobulin constant region, are created by PCR mutagenesis as described in Example 1 or by standard site-directed mutagenesis.
- Site directed mutagenesis systems are well known in the art. For example, protocols and reagents can be obtained commercially from Amersham International PLC, Amersham, U.K.
- the CTLA4-immunoglobulin fusion proteins of the invention can be expressed by incorporating a chimeric CTLA4-immunoglobulin fusion gene described herein into an expression vector and introducing the expression vector into an appropriate host cell. Accordingly, the invention further pertains to expression vectors containing a nucleic acid encoding a CTLA4-immunoglobulin fusion protein and to host cells into which such expression vectors have been introduced.
- An expression vector of the invention, as described herein, typically includes nucleotide sequences encoding the CTLA4-immunoglobulin fusion protein operably linked to at least one regulatory sequence.
- operably linked is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence in a host cell (or by a cell extract). Regulatory sequences are art-recognized and can be selected to direct expression of the desired protein in an appropriate host cell.
- the term regulatory sequence is intended to include promoters, enhancers, polyadenylation signals and other expression control elements. Such regulatory sequences are known to those skilled in the art and are described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transfected and/or the type and/or amount of protein desired to be expressed.
- An expression vector of the invention can be used to transfect cells, either procaryotic or eucaryotic (e.g., mammalian, insect or yeast cells) to thereby produce fusion proteins encoded by nucleotide sequences of the vector.
- procaryotic or eucaryotic e.g., mammalian, insect or yeast cells
- Expression in procaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promotors.
- Certain E. coli expression vectors are designed to add a number of amino acid residues to the expressed recombinant protein, usually to the amino terminus of the expressed protein.
- Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the target recombinant protein; and 3) to aid in the purification of the target recombinant protein by acting as a ligand in affinity purification.
- Examples of fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia) and pMAL (New England Biolabs, Beverly, Mass.) which fuse glutathione S-tranferase and maltose E binding protein, respectively, to the target recombinant protein.
- a chimeric CTLA4-immunoglobulin fusion gene may be linked to additional coding sequences in a procaryotic fusion vector to aid in the expression, solubility or purification of the fusion protein.
- a proteolytic cleavage site is introduced at the junction of the fusion moiety and the target recombinant protein to enable separation of the target recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
- enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
- Inducible non-fusion expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89).
- Target gene expression from the pTrc vector relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter.
- Target gene expression from the pET11d vector relies on transcription from the T7 gn10-lac 0 fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident ⁇ prophage harboring a T7 gn1 under the transcriptional control of the lacUV 5 promoter.
- CTLA4-immunoglobulin fusion protein in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128).
- Another strategy would be to alter the nucleotide sequence of the CTLA4-immunoglobulin fusion protein to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed E. coli proteins (Wada et al., (1992) Nuc. Acids Res. 20:2111-2118).
- Such alteration of nucleic acid sequences are encompassed by the invention and can be carried out by standard DNA synthesis techniques.
- a soluble CTLA4 extracellular domain is expressed in E coli using an appropriate expression vector.
- a CTLA4-immunoglobulin fusion protein can be expressed in a eucaryotic host cell, such as mammalian cells (e.g., Chinese hamster ovary cells (CHO) or NS 0 cells), insect cells (e.g., using a baculovirus vector) or yeast cells.
- mammalian cells e.g., Chinese hamster ovary cells (CHO) or NS 0 cells
- insect cells e.g., using a baculovirus vector
- yeast cells e.g., yeast cells.
- Other suitable host cells may be found in Goeddel, (1990) supra or are known to those skilled in the art.
- Eucaryotic, rather than procaryotic, expression of a CTLA4-immunoglobulin fusion protein may be preferable since expression of eucaryotic proteins in eucaryotic cells can lead to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of a recombinant protein.
- the expression vector's control functions are often provided by viral material.
- commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
- COS cells Gluzman, Y., (1981) Cell 23:175-182
- pCDM8 Seed, B., (1987) Nature 329:840
- CHO dhfr ⁇ Chinese Hamster Ovary
- a preferred cell line for production of recombinant protein is the NS 0 myeloma cell line available from the ECACC (catalog #85110503) and described in Galfre, G. and Milstein, C. ((1981) Methods in Enzymology 73(13):3-46; and Preparation of Monoclonal Antibodies: Strategies and Procedures , Academic Press, New York, N.Y.).
- yeast e.g., S. cerivisae
- yeast include pYepSec1 (Baldari. et al, (1987) Embo J.
- Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow, V. A., and Summers, M. D., (1989) Virology 170:31-39).
- Vector DNA can be introduced into procaryotic or eucaryotic cells via conventional transformation or transfection techniques such as calcium phosphate or calcium choloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming host cells can be found in Sambrook et al. ( Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.
- a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
- selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate.
- Nucleic acid encoding a selectable marker may be introduced into a host cell on the same plasmid as the gene of interest or may be introduced on a separate plasmid.
- Cells containing the gene of interest can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die). The surviving cells can then be screened for production of CTLA4-immunoglobulin fusion proteins by, for example, immunoprecipitation from cell supernatant with an anti-CTLA4 monoclonal antibody.
- the invention also features methods of producing CTLA4-immunoglobulin fusion proteins.
- a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding a CTLA4-immunoglobulin fusion protein can be cultured in a medium under appropriate conditions to allow expression of the protein to occur.
- a recombinant expression vector containing DNA encoding a CTLA4-IgG1 fusion protein having modified constant region-mediated effector functions is produced.
- a recombinant expression vector containing DNA encoding a CTLA4-IgG4 fusion protein having modified constant region-mediated effector functions is produced.
- one or more expression vector containing DNA encoding, for example, a CTLA4-IgG1 fusion protein and another fusion protein such as a CTLA4-IgG4 fusion protein can be used to transfect a host cell to coexpress these fusion proteins.
- Fusion proteins produced by recombinant technique may be secreted and isolated from a mixture of cells and medium containing the protein. Alternatively, the protein may be retained cytoplasmically and the cells harvested, lysed and the protein isolated.
- a cell culture typically includes host cells, media and other byproducts. Suitable mediums for cell culture are well known in the art. Protein can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins.
- CTLA4-immunoglobulin fusion proteins having modified effector functions compared to a CTLA4-IgG1 protein.
- Such proteins comprise a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein.
- a peptide having a CTLA4 activity has been previously defined herein.
- the first peptide comprises an extracellular domain of the human CTLA4 protein (e.g., amino acid residues 20-144 of SEQ ID NO: 24, 26 and 28) and binds B7-1 and/or B7-2.
- the second peptide comprising an immunoglobulin constant region preferably includes a hinge region, a CH2 domain and a CH3 domain derived from C ⁇ 1, C ⁇ 2, C ⁇ 3, or C ⁇ 4.
- the CH2 domain is modified to reduce constant region-mediated biological effector functions, such as complement activation and/or Fc receptor interaction as previously described in detail herein.
- Another embodiment of the invention provides a substantially pure preparation of a CTLA4-immunoglobulin fusion protein as described herein.
- a preparation is substantially free of proteins and peptides with which the protein naturally occurs in a cell or with which it naturally occurs when secreted by a cell.
- CTLA4-immunoglobulin fusion proteins expressed in mammalian cells or elsewhere, can be purified according to standard procedures of the art, including ammonium sulfate precipitation, fractionation column chromatography (e.g., ion exchange, gel filtration, electrophoresis, affinity chromatography, etc.) and ultimately, crystallization (see generally, “Enzyme Purification and Related Techniques”, Methods in Enzymology, 22:233-577 (1971)).
- the CTLA4-immunoglobulin fusion proteins are purified using an immobilized protein A column (Repligen Corporation, Cambridge, Mass.). Once purified, partially or to homogeneity, the recombinantly produced CTLA4-immunoglobulin fusion proteins or portions thereof can be utilized in compositions suitable for pharmaceutical administration as described in detail herein.
- the CTLA4-immunoglobulin fusion protein is an antibody form in which the heavy and light chains have been replaced with the extracellular domain of CTLA4.
- This molecule has a different valency and higher affinity for CTLA4 ligands, thus making it possible to obtain similar results while using less of the agent.
- the fact that this molecule has a true antibody tail which is fully glycosylated means that numerous cell lines for producing the CTLA4Ab fusion protein and data regarding the clinical use of antibodies may be relied on.
- CTLA4-immunoglobulin fusion proteins which have been modified to reduce at least one constant region-mediated biological effector function as described herein can be accomplished using one or more of several different assays which measure different effector functions.
- a monomeric IgG binding assay can be conducted (see Example 2).
- a cell which expresses an Fc receptor such as a mononuclear phagocyte or the U937 cell line (Fc ⁇ RI expression), a hematopoietic cell (Fc ⁇ RII expression; Rosenfeld, S. I., et al. (1985) J. Clin. Invest.
- a neutrophil (Fc ⁇ RIII expression; Fleit, H. B., et al. (1982) Proc. Natl. Acad. Sci. USA 79:3275-3279 and Petroni, K. C., et al. (1988) J. Immunol. 140:3467-3472) is contacted with, for example, 125 I-labeled immunoglobulin of the IgG1 isotype in the presence or absence of a modified CTLA4-immunoglobulin fusion protein of the invention and in the presence or absence of an appropriate control molecule (e.g., an unlabeled IgG1 antibody or a CTLA4-IgG1 fusion protein).
- an appropriate control molecule e.g., an unlabeled IgG1 antibody or a CTLA4-IgG1 fusion protein.
- the amount of 125 I-labeled IgG1 bound to the cells and/or the amount of free 125 I-labeled IgG in the supernatant is determined.
- a CTLA4-immunoglobulin fusion protein having reduced Fc receptor binding is identified by a reduced ability (or lack of ability) to inhibit binding of the 125 I-labeled IgG1 to the cells (relative to the control molecule).
- Monomeric IgG binding assay are described further in Lund, J., et al. (1991) J. Immunol. 147:2657-2662; and Woof, J. M., et al. (1986) Mol. Immunol. 23:319.
- a complement activation assay such as that described in Example 2 can be used.
- a cell which expresses a CTLA4 ligand e.g., B7-1 or B7-2
- a detectable substance e.g., a fluorescent dye
- a complement source e.g., purified guinea pig complement or human serum as a source of human complement.
- Cell lysis as determined by release of the fluorescent dye from the cells, is determined as an indication of activation of the complement cascade upon binding of CTLA4-immunoglobulin to the CTLA4 ligand on the cell surface.
- Cells which do not express a CTLA4 ligand on their surface are used as a negative control.
- a CTLA4-immunoglobulin fusion protein with reduced ability (or lack of the ability) to activate complement relative to an appropriate control molecule e.g., anti-B7-1 antibody of the IgG1 isotype or a CTLA4-IgG1 fusion protein
- an appropriate control molecule e.g., anti-B7-1 antibody of the IgG1 isotype or a CTLA4-IgG1 fusion protein
- C1q binding can be determined using a solid phase assay in which 125 I-labeled human C1q is added to an amount of CTLA4-immunoglobulin fusion protein complexed with a CTLA4 ligand, such as B7-1 or B7-2, and the amount of bound 125 I-labeled human C1q quantitated.
- a CTLA4 ligand such as B7-1 or B7-2
- a CTLA4-immunoglobulin fusion protein having a reduced complement activation activity is identified by a reduction in or absence of the ability to bind the 125 I-labeled human C1q relative to an appropriate control molecule (e.g., an IgG1 antibody or a CTLA4-IgG1 fusion protein).
- an appropriate control molecule e.g., an IgG1 antibody or a CTLA4-IgG1 fusion protein.
- CTLA4-immunoglobulin fusion proteins which have a CTLA4 activity as described herein can be accomplished using one or more of several different assays.
- the fusion proteins can be screened for specific reactivity with an anti-CTLA4 antibody (e.g., a monoclonal or polyclonal anti-CTLA4 antibody) or with a soluble form of a CTLA4 ligand, such as a B7-1 or B7-2 fusion protein (e.g., B7-1Ig or B7-2Ig).
- an anti-CTLA4 antibody e.g., a monoclonal or polyclonal anti-CTLA4 antibody
- a soluble form of a CTLA4 ligand such as a B7-1 or B7-2 fusion protein (e.g., B7-1Ig or B7-2Ig).
- appropriate cells such as CHO or NS 0 cells
- a DNA encoding a CTLA4-immunoglobulin fusion protein can be transfected with a DNA encoding a CTLA4-immunoglobulin fusion protein and the cell supernatant analyzed for expression of the resulting fusion protein using an anti-CTLA4 monoclonal antibody or B7-1Ig or B7-2Ig fusion protein in a standard immunoprecipitation assay.
- the binding of a CTLA4-immunoglobulin fusion protein to a cell which expresses a CTLA4 ligand, such as a B7-1 or B7-2, on its surface can be assessed.
- a cell expressing a CTLA4 ligand such as a CHO cell transfected to express B7-1, is contacted with the CTLA4-immunoglobulin fusion protein and binding detected by indirect immunostaining using, for example, a FITC-conjugated reagent (e.g., goat anti-mouse Ig serum for murine monoclonal antibodies or goat anti-human IgC ⁇ serum for fusion proteins) and fluorescence analyzed by FACS® analysis(Becton Dickinson & Co., Mountain View, Calif.).
- a FITC-conjugated reagent e.g., goat anti-mouse Ig serum for murine monoclonal antibodies or goat anti-human IgC ⁇ serum for fusion proteins
- CTLA4-immunoglobulin fusion protein Other suitable assays take advantage of the functional characteristics of the CTLA4-immunoglobulin fusion protein.
- the ability of T cells to synthesize cytokines depends not only on occupancy or cross-linking of the T cell receptor for antigen (“the primary activation signal provided by, for example antigen bound to an MHC molecule, anti-CD3, or phorbol ester to produce an “activated T cell”), but also on the induction of a costimulatory signal, in this case, by interaction of a B7 family protein (e.g., B7-1 or B7-2) with its ligand (CD28 and/or CTLA4) on the surface of T cells.
- a B7 family protein e.g., B7-1 or B7-2
- ligand CD28 and/or CTLA4
- the B7:CD28/CTLA4 interaction has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2, which in turn stimulates the proliferation of the T lymphocytes.
- the CTLA4-immunoglobulin fusion proteins of the invention have the functional property of being able to inhibit the B7:CD28/CTLA4 interaction.
- CTLA4-immunoglobulin fusion protein involve assaying for the ability of the fusion protein to inhibit synthesis of cytokines, such as interleukin-2, interleukin-4 or other known or unknown novel cytokines and/or the ability to inhibit T cell proliferation by T cells which have received a primary activation signal.
- cytokines such as interleukin-2, interleukin-4 or other known or unknown novel cytokines
- a CTLA4-immunoglobulin fusion protein of the invention to inhibit or block an interaction between a B7 family protein (e.g., B7-1 or B7-2) with its receptor on T cells (e.g., CD28 and/or CTLA4) can be assessed in an in vitro T cell culture system by stimulating T cells with a source of ligand (e.g., cells expressing B7-1 and/or B7-2 or a secreted form of B7-1 and/or B7-2) and a primary activation signal such as antigen in association with Class II MHC (or alternatively, anti-CD3 antibodies or phorbol ester) in the presence or absence of the CTLA4-immunoglobulin fusion protein.
- a source of ligand e.g., cells expressing B7-1 and/or B7-2 or a secreted form of B7-1 and/or B7-2
- a primary activation signal such as antigen in association with Class II MHC (or alternatively, anti-
- the culture supernatant is then assayed for cytokine production, such as interleukin-2, gamma interferon, or other known or unknown cytokine.
- cytokine production such as interleukin-2, gamma interferon, or other known or unknown cytokine.
- any one of several conventional assays for interleukin-2 can be employed, such as the assay described in Proc. Natl. Acad. Sci. USA, 86:1333 (1989).
- An assay kit for interferon production is also available from Genzyme Corporation (Cambridge, Mass.).
- T cell proliferation can be measured in vitro by determining the amount of 3 H-labeled thymidine incorporated into the replicating DNA of cultured cells. The rate and amount of DNA synthesis and, in turn, the rate of cell division can thus be quantified.
- a lack of or reduction in the amount of cytokine production and/or T cell proliferation by stimulated T cells upon culture with a CTLA4-immunoglobulin fusion protein of the invention indicates that the fusion protein is capable of inhibiting the delivery of a costimulatory signal to the T cell by inhibiting an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) and a receptor therefor (e.g., CD28 and/or CTLA4).
- a CTLA4 ligand e.g., B7-1 and/or B7-2
- a receptor therefor e.g., CD28 and/or CTLA4
- CTLAIg fusion protein to induce antigen-specific T cell unresponsiveness or anergy can also be assessed using the in vitro T cell culture system described above.
- T cells Following stimulation of the T cells with a specific antigen bound to MHC molecules on an antigen presenting cell surface and CTLA4 ligand (e.g., B7-1 on the antigen presenting cell surface) in the presence of CTLA4-immunoglobulin fusion protein, the T cells are subsequently restimulated with the antigen in the absence of CTLA4-immunoglobulin fusion protein.
- CTLA4 ligand e.g., B7-1 on the antigen presenting cell surface
- a lack of cytokine production and/or T cell proliferation upon antigenic restimulation by T cells previously treated with a CTLA4-immunoglobulin fusion protein of the invention indicates that the fusion protein has induced a state of antigen-specific anergy or non-responsiveness in the T cells. See, e.g., Gimmi, C. D. et al. (1993) Proc. Natl. Acad. Sci. USA 90:6586-6590; and Schwartz (1990) Science 248:1349-1356, for assay systems that can used to examine T cell unresponsiveness in accordance with the present invention.
- the ability of a CTLA4-immunoglobulin fusion protein of the invention to inhibit T cell dependent immune responses in vitro is determined.
- the effect of a CTLA4-immunoglobulin fusion protein on T h -induced immunoglobulin production by B cells can be assessed by contacting antigen-specific CD4 + T cells with syngeneic antigen-specific B cells, antigen and the CTLA4-immunoglobulin fusion protein.
- the cell culture supernatant is assayed for the production of immunoglobulin, such as IgG or IgM, using, for example, a solid phase ELISA or a standard plaque assay.
- Inhibition of B cell immunoglobulin production by treatment of the culture with the CTLA4-immunoglobulin fusion protein indicates that the protein is capable inhibiting T helper cell responses and, consequently, T cell dependent B cell responses.
- the CTLA4-immunoglobulin fusion proteins of the invention can be incorporated into compositions suitable for administration to subjects to thereby modulate immune responses or for other purposes (e.g., antibody production).
- the CTLA4-immunoglobulin fusion protein in such compositions is in a biologically compatible form suitable for pharmaceutical administration in vivo.
- biologically compatible form suitable for administration in vivo is meant a form of the protein to be; administered in which any toxic effects are outweighed by the therapeutic effects of the protein.
- subject is intended to include living organisms in which an immune response can be elicited, e.g., mammals. Examples of subjects include humans, monkeys, dogs, cats, mice, rats, and transgenic species thereof.
- Administration of a CTLA4-immunoglobulin fusion protein as described herein can be in any pharmacological form including a therapeutically active amount of protein and a pharmaceutically acceptable carrier.
- Administration of a therapeutically active amount of the therapeutic compositions of the invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result.
- a therapeutically active amount of a CTLA4-immunoglobulin fusion protein may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of protein to elicit a desired response in the individual. Dosage periods may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- the active compound e.g., CTLA4-immunoglobulin fusion protein
- the active compound may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration.
- the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
- a CTLA4-immunoglobulin fusion protein may be administered to an individual in an appropriate carrier, diluent or adjuvant, co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes.
- Pharmaceutically acceptable diluents include saline and aqueous buffer solutions.
- Adjuvant is used in its broadest sense and includes any immune stimulating compound, such as interferon.
- Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.
- Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol.
- Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan et al., (1984) J. Neuroimmunol 7:27).
- the active compound may also be administered parenterally or intraperitoneally.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound (e.g., CTLA4-immunoglobulin fusion protein) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- the active compound e.g., CTLA4-immunoglobulin fusion protein
- dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (e.g., peptide) plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the protein may be orally administered, for example, with an inert diluent or an assimilable edible carrier.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
- the invention provides methods for downregulating immune responses.
- the reduced IgC-region mediated biological effector functions exhibited by the mutated CTLA4-immunoglobulin fusion proteins of the invention compared to a CTLA4-IgG1 fusion protein may result in more effective downregulation of immune responses in vivo without unwanted side effects (e.g., complement activation, antibody-dependent cellular cytotoxicity, etc.) than if a CTLA4-IgG1 fusion protein were used.
- CTLA4-immunoglobulin fusion proteins can be assessed by a variety of assays known to those skilled in the art, including various animal organ (heart, liver, kidney, bone marrow) transplantation models and in animal autoimmune disease models including, but not limited to lupus, multiple sclerosis, diabetes, and arthritis models.
- Downregulation of an immune response by a CTLA4-immunoglobulin fusion protein of the invention may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response.
- the functions of activated T cells such as T cell proliferation and cytokine (e.g., IL-2) secretion, may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both.
- Immunosuppression of T cell responses is generally an active process which requires continuous exposure of the T cells to the suppressive agent and is often not antigen-specific.
- T cell unresponsiveness or anergy can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.
- Immunosuppression and/or T cell unresponsiveness is achieved by blocking the interaction of a CTLA4 ligand on an antigen presenting cell with CTLA4 itself and/or with another receptor for the CTLA4 ligand (e.g., CD28) on the surface of a T cell, e.g., blocking the interaction of a B7 family protein, such as B7-1 and/or B7-2, with a counter-receptor, such as CD28 or CTLA4, on the surface of a T cell.
- a CTLA4 ligand e.g., CD28
- antigen presenting cell is intended to include B lymphocytes, professional antigen presenting cells (e.g., monocytes, dendritic cells, Langerhan cells) and others cells (e.g., keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes) which can present antigen to T cells.
- professional antigen presenting cells e.g., monocytes, dendritic cells, Langerhan cells
- others cells e.g., keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes
- CTLA4-immunoglobulin fusion proteins of the invention can be used to inhibit CTLA4 ligand/receptor interactions in many clinical situations, as described further below.
- Organ Transplantation/GVHD Inhibition of T cell responses by a CTLA4-immunoglobulin fusion protein of the invention is useful in situations of cellular, tissue, skin and organ transplantation and in bone marrow transplantation (e.g., to inhibit graft-versus-host disease (GVHD)).
- GVHD graft-versus-host disease
- inhibition of T cell proliferation and/or cytokine secretion may result in reduced tissue destruction in tissue transplantation and induction of antigen-specific T cell unresponsiveness may result in long-term graft acceptance without the need for generalized immunosuppression.
- rejection of the graft is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the graft.
- a CTLA4-immunoglobulin fusion protein of the invention administered to a transplant recipient inhibits triggering of a costimulatory signal in alloantigen-specific T cells, thereby inhibiting T cell responses to alloantigens and, moreover, may induce graft-specific T cell unresponsiveness in the recipient.
- the transplant recipient can be treated with the CTLA4-immunoglobulin fusion protein alone or together with one or more additional agents that inhibit the generation of stimulatory signals in the T cells (e.g., anti-B7-1 and/or anti-B7-2 antibodies, an anti-IL-2 receptor antibody) or induce general immunosuppression (e.g., cyclosporin A or FK506).
- CTLA4-immunoglobulin fusion protein to inhibit triggering of a costimulatory signal in T cells can similarly be applied to the situation of bone marrow transplantation to specifically inhibit the responses of alloreactive T cells present in donor bone marrow and thus inhibit GVHD.
- a CTLA4-immunoglobulin fusion protein can be administered to a bone marrow transplant recipient to inhibit the alloreactivity of donor T cells.
- donor T cells within the bone marrow graft can be tolerized to recipient alloantigens ex vivo prior to transplantation.
- donor bone marrow can be cultured with cells from the recipient (e.g., irradiated hematopoietic cells) in the presence of a CTLA4-immunoglobulin fusion protein of the invention prior to transplantation.
- Additional agents that inhibit the generation of stimulatory signals in the T cells e.g., anti-B7-1 and/or anti-B7-2 antibodies, an anti-IL-2R antibody etc., as described above
- the recipient may be further treated by in vivo administration of CTLA4-immunoglobulin (alone or together with another agent(s) which inhibits the generation of a costimulatory signal in T cells in the recipient or inhibits the production or function of a T cell growth factor(s) (e.g., IL-2) in the recipient).
- CTLA4-immunoglobulin an agent which inhibits the generation of a costimulatory signal in T cells in the recipient or inhibits the production or function of a T cell growth factor(s) (e.g., IL-2) in the recipient).
- CTLA4-immunoglobulin fusion protein in inhibiting organ transplant rejection or GVHD can be assessed using animal models that may be predictive of efficacy in humans. Given the homology between CTLA4 molecules of different species, the functionally important aspects of CTLA4 are believed to be conserved structurally among species thus allowing animal systems to be used as models for efficacy in humans.
- Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4-IgG1 fusion proteins in vivo as described in Lenschow et al., Science, 257: 789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci. USA, 89: 11102-11105 (1992).
- murine models of GVHD see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of treatment with a CTLA4-immunoglobulin fusion protein of the invention on the development of that disease.
- a CTLA4-immunoglobulin fusion protein of the invention can be used in a rat model of organ transplantation to ascertain the ability of the fusion protein to inhibit alloantigen responses in vivo.
- Recipient Lewis rats receive a Brown-Norway rat strain cardiac allograft which is anastamosed to vessels in the neck as described in Bolling, S. F. et al., Transplant. 453:283-286 (1992). Grafts are monitored for mechanical function by palpation and for electrophysiologic function by electrocardiogram. Graft rejection is said to occur on the last day of palpable contractile function.
- mice are treated with daily injections of a CTLA4-immunoglobulin fusion protein of interest, an isotype-matched control Ig fusion protein and/or CTLA4-IgG1 (for comparison purposes) for 7 days. Fusion proteins are administered at a dosage range between approximately 0.015 mg/day and 0.5 mg/day. Untreated Lewis rats typically reject heterotopic Brown-Norway allografts in about 7, days. The rejection of allografts by fusion protein-treated animals is assessed in comparison to untreated controls.
- An untreated animal and a fusion protein-treated animal are sacrificed for histological examination. Cardiac allografts are removed from the untreated animal and the treated animal four days after transplantation. Allografts are fixed in formalin, and tissue sections are stained with hematoxylin-eosin. The heart tissue of the untreated and treated animals is examined histologically for severe acute cellular rejection including a prominent interstitial mononuclear cell infiltrate with edema formation, myocyte destruction, and infiltration of arterlolar walls. The effectiveness of the fusion protein treatment in inhibiting graft rejection is supported by a lack of an acute cellular rejection in the heart tissue of the fusion protein treated animals.
- fusion protein therapy establishes long term graft acceptance that persists following treatment
- animals treated for 7 days with daily injections of fusion protein are observed without additional therapy until cessation of graft function.
- Graft survival is assessed daily as described above. Allografts are examined histologically from animals in which the graft stops functioning as described above. Induction of graft tolerance by fusion protein treatment is indicated by the continued functioning of the graft following the cessation of treatment with the fusion protein.
- a fusion protein-treated animal can be sacrificed and the lymphocytes from the recipient can be tested for their functional responses. These responses are compared with those of lymphocytes from a control (non-transplanted) Lewis rat, and results are normalized as a percentage of the control response.
- the T cell proliferative response to ConA and to cells from a Brown-Norway rat and a third party ACI rat can be examined. Additionally, the thymus and spleen from the untreated and treated animals can be compared in size, cell number and cell type (e.g. by flow cytometic analyses of thymus, lymph nodes and spleen cells).
- autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue (i.e., reactive against autoantigens) and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells thus may reduce or eliminate disease symptoms.
- a CTLA4-immunoglobulin fusion protein of the invention may inhibit autoantigen-specific T cell responses and induce autoantigen-specific T cell unresponsiveness, thereby inhibiting or preventing production of autoantibodies or T cell-derived cytokines which may be involved in the disease process.
- a CTLA4-immunoglobulin fusion protein of the invention is administered to a subject in need of treatment.
- a CTLA4-immunoglobulin fusion protein of the invention is administered to a subject in need of treatment.
- This method can be used to treat a variety of autoimmune diseases and disorders having an autoimmune component, including diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, including keratoconjunctivitis sicca secondary to Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, ulceris, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proc
- CTLA4-immunoglobulin fusion protein of the invention in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology , Raven Press, New York, 1989, pp. 840-856).
- EAE Experimental Autoimmune Encephalomyelitis
- MBP Myelin Basic Protein
- CFA Complete Freund's Adjuvant
- mice develop a remitting, relapsing disease and are evaluated utilizing the following criteria: 0 normal, healthy 1 limp tail, incontinence; occasionally the first sign of the disease is a “tilt” 2 hind limb weakness, clumsiness 3 mild paraparesis 4 severe paraparesis 5 quadriplegia 6 death
- mice e.g., the PLSJLF1/J strain.
- Culture of lymph node cells in vitro with MBP is performed either in the presence or the absence of about 30 ⁇ g/ml of a CTLA4-immunoglobulin fusion protein of the invention, an isotype matched control Ig fusion protein or CTLA4IgG1 (for comparison purposes).
- the treated cells are then introduced into a syngeneic recipient mouse.
- the effect of fusion protein treatment of donor cells on the severity of the recipient's first episode of disease as compared to mice receiving untreated cells can be determined using the above-described criteria to assess disease severity.
- ensuing relapses in the mice receiving fusion protein-treated cells versus untreated cells can be assessed using the above-described criteria.
- a CTLA4-immunoglobulin fusion protein of the invention or control fusion protein is directly administered to mice immunized with MBP and treated with pertussis toxin (PT).
- Mice e.g., the PLSJLFI/J strain
- PT pertussis toxin
- Mice are immunized with MBP on day 0, injected with PT intravenously on days 0 and 2, and given either a CTLA4-immunoglobulin fusion protein of the invention or a control fusion protein on days 0 to 7.
- the effect of direct fusion protein treatment of the MBP-immunized mice on the severity of the ensuing disease is then assessed using the above-described criteria.
- a reduced severity in disease symptoms in the passive and/or active EAE model as a result of CTLA4-immunoglobulin treatment may be predictive of the therapeutic efficacy of the CTLA4-immunoglobulin fusion proteins of the invention in human autoimmune diseases.
- the IgE antibody response in atopic allergy is highly T cell dependent and, thus, inhibition of CTLA4 ligand/receptor induced T cell activation may be useful therapeutically in the treatment of allergy and allergic reactions.
- a CTLA4-immunoglobulin fusion protein of the invention can be administered to an allergic subject to inhibit T cell mediated allergic responses in the subject.
- Inhibition of costimulation of T cells through inhibition of a CTLA4 ligand/receptor interaction may be accompanied by exposure to allergen in conjunction with appropriate MHC molecules. Exposure to the allergen may be environmental or may involve administering the allergen to the subject.
- Allergic reactions may be systemic or local in nature, depending on the route of entry of the allergen and the pattern of deposition of IgE on mast cells or basophils. Thus, it may be necessary to inhibit T cell mediated allergic responses locally or systemically by proper administration of a CTLA4-immunoglobulin fusion protein of the invention.
- a CTLA4-immunoglobulin fusion protein of the invention and an allergen are coadminstered subcutaneously to an allergic subject.
- Virally Infected or Malignant T Cells Inhibition of T cell activation through blockage of the interaction of a CTLA4 ligand with a receptor therefor on T cells may also be important therapeutically in viral infections of T cells.
- AIDS acquired immune deficiency syndrome
- Blocking a CTLA4 ligand/receptor interaction, such as the interaction of B7-1 and/or B7-2 with CD28 and/or CTLA4 could lead to a lower level of viral replication and thereby ameliorate the course of AIDS.
- HTLV-I infected T cells express B7-1 and B7-2.
- This expression may be important in the growth of HTLV-I infected T cells and the blockage of B7-1 function together with the function of B7-2 with a CTLA4-immunoglobulin fusion protein, possibly in conjunction with another blocking reagent (such as an anti-B7-2 blocking antibody or a CD28Ig fusion protein) may slow the growth of HTLV-I induced leukemias.
- another blocking reagent such as an anti-B7-2 blocking antibody or a CD28Ig fusion protein
- some tumor cells are responsive to cytokines and the inhibition of T cell activation and cytokine production could help to inhibit the growth of these types of cancer cells.
- the methods of the invention for inhibiting T cell responses can essentially be applied to any antigen (e.g., protein) to clonally delete T cells responsive to that antigen in a subject.
- any antigen e.g., protein
- administration of a CTLA4-IgG1 fusion protein to mice in vivo suppressed primary and secondary T cell-dependent antibody responses to antigen (Linsley P. S., et al. (1992) Science 257, 792-795).
- a subject treated with a molecule capable of inducing a T cell response can be treated with CTLA4-immunoglobulin fusion protein to inhibit T cell responses to the molecule.
- an increasing number of therapeutic approaches utilize a proteinaceous molecule, such as an antibody, fusion protein or the like, for treatment of a clinical disorder.
- a proteinaceous molecule such as an antibody, fusion protein or the like
- a limitation to the use of such molecules therapeutically is that they can elicit an immune response directed against the therapeutic molecule in the subject being treated (e.g., the efficacy of murine monoclonal antibodies in human subjects is hindered by the induction of an immune response against the antobodies in the human subject).
- a CTLA4-immunoglobulin fusion protein to inhibit antigen-specific T cell responses can be applied to these therapeutic situations to enable long term usage of the therapeutic molecule in the subject without elicitation of an immune response.
- a therapeutic antibody e.g., murine mAb
- a subject e.g., human
- the therapeutic antibody is administered to the subject together with a CTLA4-immunoglobulin fusion protein of the invention.
- a CTLA4-immunoglobulin fusion protein of the invention can be used alone or in conjunction with one or more other reagents that influence immune responses.
- a CTLA4-immunoglobulin fusion protein and another immunomodulating reagent can be combined as a single composition or administered separately (simultaneously or sequentially) to downregulate T cell mediated immune responses in a subject.
- immunomodulating reagents examples include blocking antibodies, e.g., against B7-1, B7-2 or other B cell surface antigens or cytokines, other fusion proteins, e.g., CD28Ig, or immunosuppressive drugs, e.g., cyclosporine A or FK506.
- CTLA4-immunoglobulin fusion proteins of the invention may also be useful in the construction of therapeutic agents which block immune cell function by destruction of the cell.
- a CTLA4-immunoglobulin fusion protein to a toxin such as ricin or diptheria toxin
- an agent capable of preventing immune cell activation would be made.
- Infusion of one or a combination of immunotoxins into a patient would result in the death of immune cells, particularly of activated B cells that express higher amounts of B7-1 and/or B7-2.
- CTLA4-immunoglobulin fusion proteins of the invention Another application of the CTLA4-immunoglobulin fusion proteins of the invention is the use the protein in screening assays to discover as yet undefined molecules which inhibit an interaction between CTLA4 and a CTLA4 ligand, such as B7-1 or B7-2.
- the CTLA4-immunoglobulin fusion protein can be used in a solid-phase binding assay in which panels of molecules are tested.
- the screening method of the invention involves contacting a CTLA4-immunoglobulin fusion protein of the invention with a CTLA4 ligand and a molecule to be tested.
- Either the CTLA4-immunoglobulin fusion protein or the CTLA4 ligand is labeled with a detectable substance, such as a radiolabel or biotin, which allows for detection and quantitation of the amount of binding of CTLA4-immunoglobulin to the CTLA4 ligand.
- a detectable substance such as a radiolabel or biotin
- unbound labeled CTLA4-immunoglobulin fusion protein or unbound labeled CTLA4 ligand is removed and the amount of CTLA4-immunoglobulin fusion protein bound to the CTLA4 ligand is determined.
- a reduced amount of binding of CTLA4-immunoglobulin fusion protein to the CTLA4 ligand in the presence of the molecule tested relative to the amount of binding in the absence of the molecule is indicative of an ability of the molecule to inhibit binding of CTLA4 to the CTLA4 ligand.
- Suitable CTLA4 ligands for use in the screening assay include B7-1 or B7-2 (e.g., B7-1Ig or B7-2Ig fusion proteins can be used).
- either the unlabeled CTLA4-immunoglobulin fusion protein or the unlabeled CTLA4 ligand is immobilized on a solid phase support, such as a polystyrene plate or bead, to facilitate removal of the unbound labeled protein from the bound labeled protein.
- a solid phase support such as a polystyrene plate or bead
- CTLA4-immunoglobulin fusion proteins produced from the nucleic acid molecules of the invention can also be used to produce antibodies specifically reactive with the fusion protein and in particular with the CTLA4 moiety thereof (i.e., anti-CTLA4 antibodies).
- anti-CTLA4 antibodies i.e., anti-CTLA4 antibodies
- a mammal e.g., a mouse, hamster, or rabbit
- an immunogenic form of the fusion protein which elicits an antibody response in the mammal.
- Techniques for conferring immunogenicity on a protein include conjugation to carriers or other techniques well known in the art.
- the protein can be administered in the presence of adjuvant.
- the progress of immunization can be monitored by detection of antibody titers in plasma or serum.
- Standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies.
- An ELISA or other immunoassay which distinguishes antibodies reactive with the CTLA4 portion of the fusion protein from those which react with the IgC region are preferred (e.g., the extracellular domain of CTLA4 alone can be used in a standard ELISA to detect anti-CTLA4 antibodies).
- antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.
- antibody producing cells can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells.
- myeloma cells can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells.
- Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with CTLA4 and monoclonal antibodies isolated.
- antibody as used herein is intended to include fragments thereof which are also specifically reactive with a CTLA4-immunoglobulin fusion protein as described herein.
- Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab′) 2 fragments can be generated by treating antibody with pepsin. The resulting F(ab′) 2 fragment can be treated to reduce disulfide bridges to produce Fab′ fragments.
- antibody is further intended to include bispecific and chimeric molecules having an anti-CTLA4-immunoglobulin fusion protein portion, chimeric, antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region, and humanized antibodies in which parts of the variable regions, especially the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin.
- Techniques for preparing chimeric or humanized antibodies are well known in the art (see e.g., Morrison et al., Proc. Natl. Acad. Sci. U.S.A.
- Another method of generating specific antibodies, or antibody fragments, reactive against a CTLA4-immunoglobulin fusion protein is to screen expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with a fusion protein produced from the nucleic acid molecules of the invention.
- a fusion protein produced from the nucleic acid molecules of the invention For example, complete Fab fragments, V H regions, F V regions and single chain F V regions can be expressed in bacteria using phage expression libraries.
- An anti-CTLA4 antibody generated using the CTLA4-immunoglobulin fusion proteins described herein can be used therapeutically to inhibit immune cell activation through blocking receptor:ligand interactions necessary for stimulation of the cell.
- blocking antibodies can be identified by their ability to inhibit T cell proliferation and/or cytokine production when added to an in vitro costimulation assay as described herein. The ability of blocking antibodies to inhibit T cell functions may result in immunosuppression and/or tolerance when these antibodies are administered in vivo.
- the CTLA4-immunoglobulin fusion proteins of the invention can be used to isolate CTLA4 ligands from cell extracts or other preparations.
- a CTLA4-immunoglobulin fusion protein can be used to immunoprecipitate B7-1, B7-2 or an as yet unknown CTLA4 ligand from a whole cell, cytosolic or membrane protein extract prepared from B cells or other antigen presenting cell using standard techniques.
- anti-CTLA4 polyclonal or monoclonal antibodies prepared as described herein using a CTLA4-immunoglobulin fusion protein as an immunogen can be used to isolate the native CTLA4 antigen from cells.
- antibodies reactive with the CTLA4 portion of the CTLA4-immunoglobulin fusion protein can be used to isolate the naturally-occurring or native form of CTLA4 from activated T lymphocytes by immunoaffinity chromatography using standard techniques.
- the extracellular portion of the T cell surface receptor CTLA4 was prepared as a fusion protein coupled to an immunoglobulin constant region.
- the immunoglobulin constant region was genetically modified to reduce or eliminate effector activity inherent in the immunoglobulin structure. Briefly, DNA encoding the extracellular portion of CTLA4 was joined to DNA encoding the hinge, CH2 and CH3 regions of human IgC ⁇ 1 or IgC ⁇ 4 modified by directed mutagenesis. This was accomplished as follows:
- DNA fragments corresponding to the DNA sequences of interest were prepared by polymerase chain reaction (PCR) using primer pairs described below.
- PCR reactions were prepared in 100 ⁇ l final volume composed of Taq polymerase buffer (Gene Amp PCR Kit, Perkin-Elmer/Cetus, Norwalk, Conn.) containing primers (1 ⁇ M each), dNTPs (200 ⁇ M each), 1 ng of template DNA, and Taq polymerase (Saiki, R. K., et al. (1988) Science 239:487-491).
- thermocycler Ericomp, San Diego, Calif.
- PCR DNA amplifications were run on a thermocycler (Ericomp, San Diego, Calif.) for 25 to 30 cycles each composed of a denaturation step (1 minute at 94° C.), a renaturation step (30 seconds at 54° C.), and a chain elongation step (1 minute at 72° C.).
- “zip up” PCR was used. This procedure is diagrammed schematically in FIG. 1. A first set of forward (A) and reverse (C) primers was used to amplify the first gene segment of the gene fusion. A second set of forward (B) and reverse (D) primers was used to amplify the second gene segment of the gene fusion. Primers B and C were designed such that they contained complimentary sequences capable of annealing. The PCR products amplified by primers A+C and B+D are combined, annealed and extended (“zipped up”). The full-length gene fusion was then amplified in a third PCR reaction using the “zip up” fragment as the template and primers A and D as the forward and reverse primers, respectively.
- each CTLA4 genetic fusion consisted of a signal sequence, to facilitate secretion, coupled to the extracellular domain of CTLA4 and the hinge, CH2 and CH3 domains of human IgC ⁇ 1 or IgC ⁇ 4.
- the IgC ⁇ 1 and IgC ⁇ 4 sequences were modified to contain nucleotide changes within the hinge region to replace cysteine residues available for disulfide bond formation and to contain nucleotide changes in the CH2 domain to replace amino acids thought to be required for IgC binding to Fc receptors and complement activation.
- the hinge region and CH2 domain amino acid mutations introduced into IgC ⁇ 1 and IgC ⁇ 4 are illustrated in FIGS. 2A and 2B, respectively.
- PCR amplification was used to generate an immunoglobulin signal sequence suitable for secretion of the CTLA4-Ig fusion protein from mammalian cells.
- the Ig signal sequence was prepared from a plasmid containing the murine IgG heavy chain gene (described in Orlandi, R., et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837) using the oligonucleotide 5′CATTCTAGAACCTCGACAAGCTTGAGATCACAGT (SEQ ID NO: 1) TCTCTCTAC-3′
- the reverse PCR primer (SEQ ID NO: 1) contains recognition sequences for restriction enzymes XbaI and HindIII and is homologous to sequences 5′ to the initiating methionine of the Ig signal sequence.
- the reverse PCR primer (SEQ ID NO: 2) is composed of sequences derived from the 5′ end of the extracellular domain of CTLA4 and the 3′ end of the Ig signal sequence. PCR amplification of the murine Ig signal template DNA using these primers resulted in a 233 bp product which is composed of XbaI and HindIII restriction sites followed by the sequence of the Ig signal region fused to the first 25 nt of the coding sequence of the extracellular domain of CTLA4.
- the junction between the signal sequence and CTLA4 is such that protein translation beginning at the signal sequence will continue into and through CTLA4 in the correct reading frame.
- the extracellular domain of the CTLA4 gene was prepared by PCR amplification of plasmid phCTLA4.
- This plasmid contained the sequences corresponding to the human CTLA4 cDNA (see Darivach, P., et al., (1988) Eur. J. Immunol. 18:1901 1905; Harper, K., et al., (1991) J. Immunol.
- the reverse PCR primer (SEQ ID NO: 3) was composed of sequences derived from the 3′ end of the Ig signal sequence and the 5′ end of the extracellular domain of CTLA4. This PCR primer is the complementary to murine Ig signal reverse PCR primer (SEQ ID NO: 2).
- the reverse PCR primer (SEQ ID NO: 4) was homologous to the 3′ end of the extracellular domain of CTLA4, added a BclI restriction site and an additional G nucleotide at the end of the extracellular domain. This created a unique BclI restriction site and added a glutamine codon to the C-terminus of the extracellular domain.
- the final PCR product was 413 bp.
- PCR fragments containing the signal and CTLA4 sequences were joined together via a third PCR reaction. Both PCR fragments (1 ng each) were mixed together along with the Ig signal forward PCR primer (SEQ ID NO: 1) and the CTLA4 reverse PCR primer (SEQ ID NO: 4) and PCR amplified as described. In this reaction, the 3′ end of the Ig signal fragment hybridizes with the 5′ end of the CTLA4 fragment and the two strands are extended to yield a full length 600 bp fragment. Subsequent PCR amplification of this fragment using forward (SEQ ID NO: 1) and reverse (SEQ ID NO: 4) yielded sufficient amounts of the signal-CTLA4 gene fusion fragment for cloning. This fragment contains a 5′ XbaI and a 3′ BclI restriction sites flanking the Ig signalCTLA4 gene fusion segment for subsequent cloning.
- Plasmid pSP721gG1 was prepared by cloning the 2000 bp segment of human IgG1 heavy chain genomic DNA (Ellison, J. W., et al., (1982) Nucl. Acids. Res. 10:4071-4079) into the multiple cloning site of cloning vector pSP72 (Promega, Madison, Wis.). Plasmid pSP721gG1 contained genomic DNA encoding the CH1, hinge, CH2 and CH3 domain of the heavy chain human IgC ⁇ 1 gene. PCR primers designed to amplify the hinge-CH2-CH3 portion of the heavy chain along with the intervening genomic DNA were prepared as follows. The forward PCR primer, 5′-GCATTTTAAGCTTTTTCCTGATCAGGAGCCCAA (SEQ ID NO: 5) ATCTTCTGACAAAACTCACACATCTCCACCGTCTCC AGGTAAGCC-3′,
- [0136] contained HindIII and BclI restriction sites and was homologous to the hinge domain sequence except for five nucleotide substitutions which changed the three cysteine residues to serines.
- the reverse PCR primer 5′-TAATACGACTCACTATAGGG-3′, (SEQ ID NO: 6)
- the reverse PCR primer contains a BclI restriction site followed by the coding sequence for the hinge domain of IgC ⁇ 4. Nucleotide substitutions have been made in the hinge region to replace the cysteines residues with serines.
- the reverse PCR primer contains a PspAI restriction site. PCR amplification with these primers results in a 1179 bp DNA fragment.
- the PCR product was digested with BclI and PspAI and ligated to pNRDSH/IgG1 digested with the same restriction enzymes to yield plasmid pNRDSH/IgG4. In this reaction, the IgC ⁇ 4 domain replaced the IgC ⁇ 1 domain present in pNRDSH/IgG1.
- Plasmid pNRDSH/IgG1 served as template for modifications of the IgC ⁇ 1 CH2 domain and plasmid pNRDSH/IgG4 served as template for modifications of the IgC ⁇ 4 CH2 domain.
- Plasmid pNRDSH/IgG1 was PCR amplified using a forward PCR primer (SEQ ID NO: 5) and oligonucleotide 5′-GGGTTTTGGGGGGAAGAGGAAGACTGACGGTGC (SEQ ID NO: 9) CCCC TCGGCTTCAGGTGCTGAGGAAG-3′
- the reverse PCR primer (SEQ ID NO: 5) has been previously described and the reverse PCR primer (SEQ ID NO: 9) was homologous to the amino terminal portion of the CH2 domain of IgG1 except for five nucleotide substitutions designed to change amino acids 234, 235, and 237 from Leu to Ala, Leu to Glu, and Gly to Ala, respectively (Canfield, S. M. and Morrison, S. L. (1991) J. Exp. Med. 173: 1483-1491; see FIG. 2A). Amplification with these PCR primers will yield a 239 bp DNA fragment consisting of a modified hinge domain, an intron and modified portion of the CH2 domain.
- Plasmid pNRDSH1IgG1 was also PCR amplified with the oligonucleotide 5′-CATCTCTTCCTCAGCACCTGAAGCCGAGGGG (SEQ ID NO: 10) GCACCGTCAGTCTTCCTCTTCCCCC-3′
- the forward primer and oligonucleotide (SEQ ID NO: 6) as the reverse PCR primer.
- the forward PCR primer (SEQ ID NO: 10) is complementary to primer (SEQ ID NO: 9) and contains the five complementary nucleotide changes necessary for the CH2 amino acid replacements.
- the reverse PCR primer (SEQ ID NO: 6) has been previously described. Amplification with these primers yields a 875 bp fragment consisting of the modified portion of the CH2 domain, an intron, the CH3 domain, and 3′ additional sequences.
- the complete IgC ⁇ 1 segment consisting of modified hinge domain, modified CH2 domain and CH3 domain was prepared by an additional PCR reaction.
- the purified products of the two PCR reactions above were mixed, denatured (95° C., 1 minute) and then renatured (54° C., 30 seconds) to allow complementary ends of the two fragments to anneal.
- the strands were filled in using dNTP and Taq polymerase and the entire fragment amplified using forward PCR primer (SEQ ID NO: 5) and reverse PCR primer (SEQ ID NO: 6).
- the resulting fragment of 1050 bp was purified, digested with HindIII and EcoRI and ligated to pNRDSH previously digested with the same restriction enzymes to yield plasmid pNRDSH/IgG1m.
- Plasmid pNRDSH/IgG4 was PCR amplified using the forward primer (SEQ ID NO: 7) and the oligonucleotide 5′CGCACGTGACCTCAGGGGTCCGGGAGATCATG (SEQ ID NO: 11) AGAGTGTCCTTGGGTTTTGGGGGGAACAGGAAGA CTGATGGTGCCCCCTCGAACTCAGGTGCTGAG G-3′
- the reverse primer has been previously described and the reverse primer was homologous to the amino terminal portion of the CH2 domain, except for three nucleotide substitutions designed to replace the amino acids described above.
- This primer also contained a PmlI restriction site for subsequent cloning. Amplification with these primers yields a 265 bp fragment composed of the modified hinge region, and intron, and the modified 5′ portion of the CH2 domain.
- Plasmid pNRDSH/IgG4 was also PCR amplified with the oligonucleotide 5′-CCTCAGCACCTGAGTTCGAGGGGGCACCATC (SEQ ID NO: 12) AGTCTTCCTGTTCCCCCCAAAACCCAAGGACACT CTCATGATCTCCCGGACCCCTGAGGTCACGTGC G-3′
- the forward primer and oligonucleotide (SEQ ID NO: 8) as the reverse PCR primer.
- the forward PCR primer (SEQ ID NO: 12) is complementary to primer (SEQ ID NO: 11) and contains the three complementary nucleotide changes necessary for the CH2 amino acid replacements.
- the reverse PCR primer (SEQ ID NO: 8) has been previously described. Amplification with these primers yields a 1012 bp fragment consisting of the modified portion of the CH2 domain, an intron, the CH3 domain, and 3′ additional sequences.
- the complete IgC ⁇ 4 segment consisting of modified hinge domain, modified CH2 domain and CH3 domain was prepared by an additional PCR reaction.
- the purified products of the two PCR reactions above were mixed, denatured (95° C., 1 minute) and then renatured (54° C., 30 seconds) to allow complementary ends of the two fragments to anneal.
- the strands were filled in using dNTP and Taq polymerase and the entire fragment amplified using forward PCR primer (SEQ ID NO: 7) and reverse PCR primer (SEQ ID NO: 8).
- the resulting fragment of 1179 bp was purified, digested with BclI and PspAI and ligated to pNRDSH previously digested with the same restriction enzymes to yield plasmid pNRDSH/IgG4m.
- the PCR fragment corresponding to the Ig signal-CTLA4 gene fusion prepared as described above was digested with HindIII and BclI restriction enzymes and ligated to pNRDSH/IgG1, pNRDSH/IgG1m, pNRDSH/IgG4, and pNRDSH/IgG4m previously digested with the same restriction enzymes to create expression plasmids in which the signal-CTLA4-IgG gene fusion segment is placed-under the control of the CMV promoter.
- the ligated plasmids were transformed into E.
- Plasmids isolated from the transformed E. coli were analyzed by restriction enzyme digestion. Plasmids with the expected restriction pattern were sequenced to verify all portions of the signal-CTLA4-IgG gene fusion segments.
- the final plasmids were named pNRDSH/sigCTLA4-IgG1, pNRDSH/sigCTLA4-IgG1m, pNRDSH/sigCTLA4-IgG4 and pNRDSH/sigCTLA4-IgG4m.
- the signal-CTLA4-IgG gene fusion segments from each of these constructs were also transferred to the pEE12 expression vector ( Biotechnology (1992) 10:169-175).
- nucleotide and predicted amino acid sequences of the signal-CTLA4-IgG gene fusion segments are shown in the Sequence Listing as follows: sigCTLA4-IgGm-SEQ ID NOS: 23 and 24, sigCTLA4-IgG4-SEQ ID NOS: 25 and 26 and sigCTLA4-IgG4m-SEQ ID NOS: 27 and 28.
- the extracellular domain of CTLA4 is an immunoglobulin superfamily member and is responsible for binding to its ligands B7-1 and B7-2.
- the replacement of the heavy and light chain variable domains of an antibody molecule with the extracellular domain of CTLA4 will result in an antibody-like protein which can bind specifically to B7-1, B7-2 and other CTLA4 ligands with high affinity.
- the construction of such a molecule using human IgG1 antibody heavy and light chains is described below.
- the Ig signal sequence was prepared from template plasmid pSP72IgG1 by PCR amplification using oligonucleotide 5′CATTCGCTTACCTCGACAAGCTTGAGATCAC AGTTCTCTCTAC-3′ (SEQ ID NO: 13) as the forward PCR primer and oligonucleotide 5′-GGAGTGGACACCTGTGGAGAG-3′ (SEQ ID NO: 14) as the reverse primer.
- the forward PCR primer (SEQ ID NO: 13) contains a Hindi restriction site and part of the 5′ untranslated segment of the Ig signal domain.
- the reverse PCR primer corresponds to the C-terminus of the natural Ig signal peptide. Amplification with these primers resulted in a 208 bp fragment encoding the entire Ig signal sequence.
- the CTLA4 extracellular domain was prepared from plasmid phCTLA4, which contained the entire CTLA4 cDNA sequence, by PCR amplification using oligonucleotide 5′-CTCCACAGGTGTCCACTCCGCAATGCACGTGGCCCAGCC-3′ (SEQ ID NO: 15) as the forward PCR primer and oligonucleotide 5′GAGGTTGTAAGGACTCACCTGAAA TCTGGGCTCCGTTGC-3′ (SEQ ID NO: 16) as the reverse primer.
- the forward primer contained sequences homologous to the 5′ end of the CTLA4 extracellular domain and to the 3′ end of the Ig signal domain.
- the reverse primer (SEQ ID NO: 16) contained the 3′ end of the CTLA4 extracellular domain and intervening sequences, including a splice acceptor site. Amplification with these primers yielded a 379 bp fragment containing the CTLA4 extracellular domain.
- An intervening sequence DNA fragment derived from the intron between the antibody variable and constant (CH1) domains was prepared by PCR amplification using oligonucleotide 5′GCAACGGAGCCCAGATTTCAGGTGAGTCCTTACAACCTC-3′ (SEQ ID NO: 17) as the forward PCR primer and oligonucleotide 5′GGCTAGATATCTCTAGACT ATAAATCTCTGGCCATGAAG-3′ (SEQ ID NO: 18) as the reverse PCR primer.
- the forward PCR primer (SEQ ID NO: 17) contains intron sequence and is complementary to the 3′ end of the extracellular domain of CTLA4 and is complimentary to the CTLA4 reverse PCR primer (SEQ ID NO: 16).
- the reverse primer (SEQ ID NO: 18) contains intron sequences and an additional XbaI restriction site. Amplification with these primers yields a 197 bp fragment.
- the PCR fragments encoding the Ig signal, CTLA4 extracellular domain and the intervening sequence were mixed, denatured and renatured to allow hybridization of complementary ends.
- the strands were filled in and the product amplified using forward (SEQ ID NO: 13) and reverse (SEQ ID NO: 18) PCR primers.
- the product was a 764 bp fragment which encoded the Ig signal, the CTLA4 extracellular domain, an intron sequence flanked by HindIII and XbaI restriction sites.
- This DNA fragment was digested with HindIII and XbaI and ligated to pSP72IgG1, resulting in the CTLA4 extracellular domain being linked to a 5′ Ig signal sequence and a 3′ antibody CH1, hinge, CH2, and CH3 domains.
- the reverse primer contained sequences of the 3′ end of the CTLA4 extracellular domain, a splice receptor, and intervening sequence DNA containing an XbaI restriction site.
- the Ig signal fragment and the CTLA4 extracellular domain were joined by mixing the DNA fragment, denaturing, and renaturing to anneal their complementary ends.
- the strands were filled in and the fragment PCR amplified using forward (SEQ ID NO: 13) and reverse (SEQ ID NO: 19) PCR primers previously described.
- the resulting DNA fragment was digested with the HindIII and XbaI and ligated to immunoglobulin light chain vector p ⁇ LYS17 digested with the same enzymes.
- the resulting plasmid pCTLA4kappa contains an Ig signal sequence, an intron, the CTLA4 extracellular domain, an intron, and the light chain (kappa) constant domain.
- the DNA segments encoding the recombinant heavy and light chains were transferred to the pEE12 vector or the pNRDSH vector and stable NS 0 or CHO expression cell lines established as described below.
- CHO and NS 0 supernatants were assayed for the production of CTLA4 light chain and CTLA4 heavy chain fusion proteins by ELISA and binding to B7-1 was measured using CHO/hB7-1 expressing cells and FACS (as described in Example 2). It is also contemplated that the heavy and light chain constructs of the present invention be expressed in the same vector and host cells transfected in one step.
- CTLA4-immunoglobulin fusion proteins were expressed in CHO cells as follows. Briefly, 5 ⁇ 10 5 CHO-DG44 cells (subline of CHO-K1, available from ATCC) were transfected with 10 ⁇ g of the appropriate expression plasmid (pNRDSH series) by the calcium phosphate method (described in Molecular Cloning: A Laboratory Manual (1982) Eds. Maniatis, T., Fritsch, E. E., and Sambrook, J. Cold Spring Harbor Laboratory) using a commercially available kit (5 Prime to 3′ Prime Inc., Boulder, Colo.) according to the manufacturer's instructions.
- the transfected cells were allowed to recover in nonselective media (alpha MEM medium containing 10% heat inactivate fetal bovine serum (FBS), Gibco/BRL, Gaithersburg, Md.) for two days and then plated in selective media (alpha MEM minus nucleoside medium containing 10% FBS and 550 ⁇ g/ml G418; Gibco/BRL, Gaithersburg, Md.). Individual subclones were obtained by dilution cloning in selective media. Culture media was assayed for the presence of secreted CTLA4-immunoglobulin by a standard ELISA designed to detect human IgG.
- nonselective media alpha MEM medium containing 10% heat inactivate fetal bovine serum (FBS), Gibco/BRL, Gaithersburg, Md.
- selective media alpha MEM minus nucleoside medium containing 10% FBS and 550 ⁇ g/ml G418; Gibco/BRL, Gaithersburg, Md
- NS 0 cells The various CTLA4-immunoglobulin and CTLA4Ab fusion proteins were expressed in NS 0 cells (Golfre, G. and Milstein C. P. (1981) Methods Enzymol. 73B: 3-46) as follows. Briefly, 10 7 NS 0 cells were transfected by electroporation (using a BioRad Gene Pulser, Hercules, Calif.) with 40 ⁇ g of the appropriate expression plasmid (pEE12 series) previously linearized by digestion with SalI restriction endonuclease. The transfected cells were selected using DMEM media deficient in glutamine (Gibco/BRL, Gaithersberg Md.). Individual subclones were isolated by dilution cloning in selective media. Culture media assayed for the presence of secreted CTLA4-Ig or CTLA4Ab fusion protein by a standard ELISA assay designed to detect human IgG.
- transfection of either the pNRDSH/sigCTLA4-IgG4m and pEE12/sigCTLA4-IgG4m expression vector into CHO or NS 0 host cells resulted in selected subclones that secreted hCTLA4IgG4m fusion protein into culture supernatants at a concentration of 75-100 ⁇ g/ml.
- CTLA4-Ig and CTLA4Ab fusion proteins are purified from the culture medium of transfected CHO or NS 0 cells as follows. Culture medium was concentrated 10 fold by ultra filtration (Ultrasette, Filtron Technology Corp., Northborough, Mass.) and batch bound overnight to immobilized protein A (IPA-300, Repligen Corp., Cambridge, Mass.). The protein-bound resin was poured into a chromatography column, washed with 10 column volumes of optimal binding buffer (1.5 M glycine, 3M NaCl, pH 8.9) and the bound CTLA4-Ig or CTLA4Ab was eluted by the addition of 0.1 M Na citrate, pH 3.0.
- optimal binding buffer 1.5 M glycine, 3M NaCl, pH 8.9
- the cell bound CTLA4 was detected by reaction with anti-human Ig-FITC (Dako Corporation, Carpintera, Calif.) or protein A-FITC (Dako) for 30 mintues on ice in the dark.
- the cells were washed twice with FACS wash solution and then fixed in 1% paraformaldehyde in PBS. The cells were analyzed for fluorescence intensity using a Becton Dickinson (San Jose, Calif.) FACS analyzer.
- Murine anti-human mAbs reactive with either hB7-1 or hB7-2 served as positive control reagents for the hB7-1 and hB7-2 receptor expressing cells.
- Biotinylated hCTLA4-IgG1 (prepared according to manufacturers instructions (Pierce, Rockford, Ill.) at 10 ⁇ g/ml serially diluted in twofold steps to 15.6 ng/ml; 50 ⁇ l/well) was added to each well and incubated for 2.5 hours at room temperature. The wells were washed again as above. The bound biotinylated hCTLA4IgG1 was detected by the addition of 50 ⁇ l of a 1:2000 dilution of streptavidin-HRP (Pierce Chemical Co., Rockford, Ill.) for 30 minutes at room temperature. The wells were washed as above and 50 ⁇ l of ABTS (Zymed, Calif.) added and the developing blue color monitored at 405 nm after 30 min.
- FIG. 4A A graphic representation of a typical binding assay illustrating the competition of biotinylated hCTLA4-IgG1 with hCTLA4-IgG1 (itself) or hCTLA4-IgG4m is shown in FIG. 4A for binding to hB7-1 and FIG. 4B for binding to hB7-2.
- the competition curves show that the mutant IgG4 form competes with hCTLA4-IgG1 for binding to B7-1 or B7-2 with the same binding kinetics as the unlabeled IgG1 form itself. Accordingly, mutation of the hinge region and CH2 domain of IgC ⁇ 4 in the CTLA4 fusion protein as described herein does not detrimentally affect the ligand binding activity of the CTLA4 fusion protein.
- CTLA4 forms were analyzed by SDS-PAGE followed by detection using Coomassie Blue staining or Western blotting.
- the CTLA4 proteins were separated on both reducing and non-reducing SDS-PAGE gels (9, 12, or 15% gels with 5% stacking gel) and stained with Coomassie Blue using standard methods. Protein size was estimated from comparison to commercial size standards (BioRad, Hercules, Calif.). Western blots were performed using standard procedures and Immobilon blotting membranes (Millipore, New Bedford, Mass.).
- the CTLA4 was detected using a polyclonal antisera raised in rabbit immunized with the extracellular domain of CTLA4 produced in E. coli (described in Lindsten, T. et al.
- Preparations of unlabeled CTLA4-IgG1, CTLA4-IgG4 and human IgG1 were serially diluted to a concentration of 2 ⁇ 10 ⁇ 10 M.
- a fixed amount of 125 I-labeled protein e.g., CTLA4-IgG1, CTLA4-IgG4 or human IgG1 was added.
- the U937 cells were then added to the mixture and incubated for three hours. The cells were separated from unbound labeled and unlabeled protein by centrifugation through silicone oil for one minute at 14000 ⁇ g. The tips of the tubes with the pelleted cells were then cut off and analyzed in a gamma counter.
- FIG. 5A graphically illustrates the amount of labeled CTLA4-IgG1 bound to U937 cells (expressed in counts per minute) in the presence of unlabeled CTLA4-IgG1 or CTLA4-IgG4. Unlabeled CTLA4-IgG1 was able to compete with labeled CTLA4-IgG for binding to FcR1 on U937 cells (i.e., the amount of bound labeled protein was reduced), whereas unlabeled CTLA4-IgG4 did not compete for binding.
- FIG. 5B graphically illustrates the percent specific activity of labeled human IgG1, CTLA4-IgG1 and CTLA4-IgG4 being competed with themselves (unlabeled).
- the IC 50 for human IgG1 was approximately 7.5 ⁇ 10 ⁇ 8 M.
- the IC 50 for CTLA4-IgG1 was approximately 7 ⁇ 10 ⁇ 8 M.
- An IC 50 for CTLA4-IgG4 could not be determined because this protein did not bind to the FcR1.
- CTLA4-immunoglobulin forms were tested in a ligand-specific assay for complement activation.
- CHO cells expressing hB7-1 on their surface were grown to confluence in tissue culture dishes. After washing away serum and medium, the cells were exposed to BCECF/AM ([2′,7-bis-(carboxyethyl)-5,(6′)-carboxylfluorescein acetoxymethyl)-ester] Calbiochem, La Jolla, Calif.) a fluorescent dye that irreversibly loads into the cells.
- BCECF/AM [2′,7-bis-(carboxyethyl)-5,(6′)-carboxylfluorescein acetoxymethyl)-ester] Calbiochem, La Jolla, Calif.
- BCECF/AM [2′,7-bis-(carboxyethyl)-5,(6′)-carboxylfluorescein acetoxymethyl)-ester] Calbiochem, La
- Complement sources tested included guinea pig complement and human serum (as a source of human complement). After incubation with the complement source, lysis was measured by monitoring the release of the fluorescent dye from the cells using a fluorometer. Controls included parallel experiments with hB7-1 negative CHO cells. Identical cultures were also tested for their ability to bind the hCTLA4 forms under similar assay conditions. Additionally, to distinguish a lack of an ability to activate complement from a lack of an ability to bind B7-1, an ELISA-type assay of CTLA4 binding to CHO-B7-1 cells was performed as a control (described further below).
- FIGS. 6 A-C The results of typical complement activation assays are shown in FIGS. 6 A-C.
- FIG. 6A graphically illustrates guinea pig complement-mediated lysis of CHO-B7-1 cells by CTLA4-IgG1, CTLA4-IgG4m and the anti-B7-1 monoclonal antibody 4B2.
- hCTLA4-IgG1 reproducibly activated guinea pig complement as well or better than the 4B2 mAb.
- the hCTLA4-IgG4m did not activate complement in this assay, even at concentration 100-fold higher than that needed for CTLA4-IgG1.
- the results were confirmed by repeating the work with human serum as the complement source, shown in FIG. 6B.
- All three B7-1 specific proteins (mAb 4B2, hCTLA4-IgG1 and hCTLA4-IgG4m) bound to the cells.
- the corresponding experiment using untransfected CHO cells showed no binding of the proteins to the cells.
- the difference in the maximal O.D. signals for the different proteins is likely due to the different affinities of the forms of Fc regions for the HRP-conjugated secondary antibodies.
- CD4 + T cells are prepared from human blood by density gradient centrifugation on Ficoll-Hypaque (Sigma, St. Louis, Mo.). Monocytes were removed by adherence to plastic and the CD4 + cells further enriched by removal of residual monocytes, B cells, NK cells and CD8+ T cells by lysis with complement and mAbs (anti-CD14, antiCD11b, anti-CD20, anti-CD16 and anti-CD8) or by negative selection using the same immunomagnetic beads (Advanced Magnetics, Cambridge, Mass.) (as described in Boussioutis, V.
- CD4 + T cells (10 5 ) were cultured in the presence of immobilized anti-CD3 mAb (coated at 1 ug/well, overnight) and CHO cells expressing hB7-1 or hB7-2 (2 ⁇ 10 4 ) in a microtiter plate with or without one of the CTLA4 forms and incubated for 3 days.
- Thymidine incorporation as a measure of mitogenic activity was assessed after overnight incubation in the presence of [ 3 H] thymidine (Gimmi, C. D., et al., (1991) Proc. Natl. Acad. Sci USA 88:6575-6579).
- CTLA4IgG1 and CTLA4IgG4m have similar clearance rates, with a rapid (4-16 min) ⁇ phase and a more prolonged (214-288 min) ⁇ phase indicating a serum half life of approximately 4 hours.
- CTLA4 The extracellular domain of CTLA4 was expressed in E. coli after cloning into expression vector pETCm11a. This vector was derived from expression vector pET-11a (Novagen Inc., Madison Wis.) by cloning a chloramphenicol resistance gene cassette into the ScaI restriction site within the ampicillin resistance gene. The extracellular domain of CTLA4 was prepared from plasmid phCTLA4 by PCR amplification using oligonucleotide 5′GCAGAGAGACAT ATGGCAATGCACGTGGCCC (SEQ ID NO: 20) AGCCTGCTGTGG-3′
- the forward PCR primer (SEQ ID NO: 20) contains an NdeI restriction site in which the ATG sequence in the NdeI restriction site is followed immediately by the codon for the first amino acid of mature CTLA4 (Dariavach, P., et al. (1988) Eur. J. Immunol. 18:1901).
- the reverse PCR primer (SEQ ID NO: 21) contains a BamHI restriction site preceded by translation stop codons in all three reading frames preceded by the last amino acid just prior to the CTLA4 transmembrane domain.
- PCR amplification with these primer yields a 416 bp fragment bounded by NdeI and BamHI restriction sites which contains DNA sequences encoding the extracellular domain of CTLA4 preceded by a methionine codon.
- the PCR product was digested with NdeI plus BamHI and ligated to expression vector pETCm11a digested with the same restriction enzymes.
- the ligated DNA was transfected into E. coli strains BL21, HMS 174, RGN714 and RGN715 containing the lambda DE3 helper phage by standard techniques. Transformants were selected in L-agar containing chloramphenicol at 50 ug/ml. Individual transformants were selected and tested for CTLA4 expression after induction by treatment of cells with 0.5 mM IPTG. Whole cell extracts were analyzed on SDS-PAGE gel followed by Coomassie Blue staining and Western blot analysis. The majority of the CTLA4 protein in these cells was found in inclusion bodies.
- Recombinant CTLA4 was recovered from cell pellets by treating the washed cells in lysis buffer (50 mM Tris-HCl pH 8.0, 1 mM PMSF, 5 mM EDTA, 0.5% Triton X-100, and lysozyme at 0.3 mg/ml) followed by sonication.
- the inclusion bodies were recovered by centrifugation at 20,000 ⁇ g and solubilized by treatment with solubilization buffer (50 mM Tris-HCl pH8.0, 8 M urea, 50 mM 2-mercaptoethanol (2-ME)). The solubilization was assisted by mixing for two hours at room temperature.
- the soluble fraction contained CTLA4.
- the CTLA4 was purified by chromatography on S-sepharose (Pharmacia, Piscataway, N.J.) as follows.
- the CTLA4 containing supernatant was adjusted to pH 3.4 by the addition of glacial acetic and applied to a S-sepharose column equilibrated in column buffer (100 mM Na-acetate, pH6.5, 8 M urea, 50 mM 2-ME, and 5 mM EDTA).
- the column was washed with column buffer and the bound CTLA4 eluted with a linear salt gradient (NaCl, 0 to 1 M) prepared in column buffer.
- a linear salt gradient NaCl, 0 to 1 M
- Peak fractions exhibiting high Abs 280nm values were pooled and dialyzed against dialysis buffer (100 mM Tris-HCl, pH8.0, 8 M urea, 50 mM, 2-ME, 5 mM EDTA). Remaining contaminating proteins were eliminated by chromatography on a Sephacryl S-100 (Pharmacia, Piscataway, N.J.) sizing column. The resulting preparation was greater than 95% pure CTLA4 as estimated by SDS-PAGE followed by Coomassie Blue staining and Western blot analysis. Since the estimated size of monomeric recombinant CTLA4 produced in E. coli was approximately 15 kDa, all steps of the purification protocol were tested for the presence of a 15 kDa protein by SDS-PAGE and the presence of CTLA4 verified by Western blotting.
- dialysis buffer 100 mM Tris-HCl, pH8.0, 8 M urea, 50 mM, 2-ME, 5 mM EDTA.
- CTLA4 protein purified from inclusion bodies is fully reduced and denatured and must be properly refolded in a physiological buffer, with intact disulfide bridges, to be in “active” form (i.e., able to bind hB7-1).
- a step gradient dialysis procedure was used to remove urea, detergents and reductants. The most successful refolding was obtained when the secondary and tertiary protein structure was encouraged first, by gradient dialysis, removing all urea and detergent while in the presence of the reductant DTT. Subsequent slow removal of the DTT appeared to reduce the number of random intradisulfide bonds.
- a sample of CTLA4 was dialyzed directly from gel filtration buffer to PBS.
- CTLA4 A secreted form of CTLA4 was prepared from E. coli as follows. The extracellular domain of CTLA4 was joined to the pelB signal sequence (Lei. S.-P., et al., (1987) J. Bacteriol. 169: 4379-4383) by PCR using plasmid phCTLA4 as template and oligonucleotide 5′GGCACTAGTCATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACT (SEQ ID NO: 20) CGCTGCCCAACCAGCGATGGCCGCAGCAATGCACGTGGCCCAGCCTGCTGTGG3′
- the forward primer [0212] as the forward primer and a reverse primer (SEQ ID NO: 21) previously described.
- [0213] contains a unique BspHI restriction site, the complete pelB signal sequence and the 5′ end of the extracellular domain of CTLA4.
- the reverse PCR primer (SEQ ID NO: 21) contains a unique BamH1 restriction site preceded by translational stop codons in all three reading frames preceded by the last amino acid before the transmembrane domain of CTLA4. PCR amplification with these primers yielded a 480 by fragment bounded by unique BspHI and BamHI restriction sites encoding the pelB signal sequence joined to the CTLA4 extracellular domain.
- Extracts were prepared from the culture medium after concentration or by release from periplasm.
- periplasmic extracts cells were incubated in 20% sucrose, 10 mM Tris-HCl pH7.5 for 15 minutes at room temperature, collected by centrifugation, and resuspended in 4° C. water and held on ice for 10 min. Extracts were assayed for the presence of CTLA4 by SDS-PAGE, Western blotting and competitive B7-1binding ELISA (as described in Example 2).
- soluble CTLA4 prepared from periplasmic extracts of E. coli or from the media of these cultures was able to compete for binding to B7-1 with unlabelled CTLA4Ig.
- periplasmic extracts from E coli transfected with the vector alone or media from these cultures was not able to compete for binding to B7-1.
- SEQ ID NO: 1 5′ -CATTCTAGAACCTCGACAAGCTTGAGATCACAGTTCTCTCTAC-3′
- SEQ ID NO: 2 5′ -CAGCAGGCTGGGCCACGTGCATTGCGGAGTGGACACCTGTGGAGAG-3′
- SEQ ID NO: 3 5′ -CTCTCCACAGGTGTCCACTCCGCAATGCACGTGGCCCAGCCTGCTG-3′
- SEQ ID NO: 4 5′ -TGTGTGTGGAATTCTCATTACTGATCAGAATCTGGGCACGGTTCTG-3′
- SEQ ID NO: 6 5′TAATACGACTCACTATAGGG-3′
- SEQ ID NO: 7 5′GAGCATTTTCCTGATCAGGAGTCCAAATA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g., CD28 and/or CTLA4) on the surface of T cells to thereby suppress an immune response in the subject, for example to inhibit transplantation rejection, graft versus host disease or autoimmune responses.
Description
- The present is a continuation of U.S. patent application Ser. No. 08/595,590, filed on Feb. 2, 1996, which is expressly incorporated by reference.
- To induce antigen-specific T cell activation and clonal expansion, two signals provided by antigen-presenting cells (APCs) must be delivered to the surface of resting T lymphocytes (Jenkins, M. and Schwartz, R. (1987)J. Exp. Med. 165:302-319; Mueller, D. L., et al. (1990) J. Immunol. 144:3701-3709; Williams, I. R. and Unanue, E. R. (1990) J. Immunol. 145:85-93). The first signal, which confers specificity to the immune response, is mediated via the T cell receptor (TCR) following recognition of foreign antigenic peptide presented in the context of the major histocompatibility complex (MHC). The second signal, termed costimulation, induces T cells to proliferate and become functional (Schwartz, R. H. (1990) Science 248:1349-1356). Costimulation is neither antigen-specific, nor MHC restricted and is thought to be provided by one or more distinct cell surface molecules expressed by APCs (Jenkins, M. K., et al. (1988) J. Immunol. 140:3324-3330; Linsley, P. S., et al. (1991) J. Exp. Med. 173:721-730; Gimmi, C. D., et al., (1991) Proc. Natl. Acad. Sci. USA. 88:6575-6579; Young, J. W., et al. (1992) J. Clin. Invest. 90:229-237; Koulova, L., et al. (1991) J. Exp. Med. 173:759-762; Reiser, H., et al. (1992) Proc. Natl. Acad. Sci. USA. 89:271-275; van-Seventer, G. A., et al. (1990) J. Immunol. 144:4579-4586; LaSalle, J. M., et al., (1991) J. Immunol. 147:774-80; Dustin, M. I., et al., (1989) J. Exp. Med. 169:503; Armitage, R. J., et al. (1992) Nature 357:80-82; Liu, Y., et al. (1992) J. Exp. Med. 175:437-445).
- Considerable evidence suggests that the B7-1 protein (CD80; originally termed B7), expressed on APCs, is one such critical costimulatory molecule (Linsley, P. S., et al., (1991)J. Exp. Med. 173:721-730; Gimmi, C. D., et al., (1991) Proc. Natl. Acad. Sci. USA. 88:6575-6579; Koulova, L., et al., (1991) J. Exp. Med. 173:759-762; Reiser, H., et al. (1992) Proc. Natl. Acad. Sci. USA. 89:271-275; Linsley, P. S. et al. (1990) Proc. Natl. Acad. Sci. USA. 87: 5031-5035; Freeman, G. J. et al. (1991) J. Exp. Med. 174:625-631.). Recent evidence suggests the presence of additional costimulatory molecules on the surface of activated B lymphocytes (Boussiotis V. A., et al. (1993) Proc. Natl. Acad. Sci. USA, 90:11059-11063; Freeman G. J., et al. (1993) Science 262:907-909; Freeman G. J., et al. (1993) Science 262:909-911; and Hathcock K. S., et al. (1993) Science 262:905-907). The human B lymphocyte antigen B7-2 (CD86) has been cloned and is expressed by human B cells at about 24 hours following stimulation with either anti-immunoglobulin or anti-MHC class II monoclonal antibody (Freeman G. J., et al. (1993) Science 262:909-911). At about 48 to 72 hours post activation, human B cells express both B7-1 and a third CTLA4 counter-receptor which is identified by a monoclonal antibody BB-1, which also binds B7-1 (Yokochi, T., et al. (1982) J. Immunol. 128:823-827). The BB-1 antigen is also expressed on B7-1 negative activated B cells and can costimulate T cell proliferation without detectable IL-2 production, indicating that the B7-1 and BB-1 molecules are distinct (Boussiotis V. A., et al. (1993) Proc. Natl. Acad. Sci. USA 90:11059-11063). The presence of these costimulatory molecules on the surface of activated B lymphocytes indicates that T cell costimulation is regulated, in part, by the temporal expression of these molecules following B cell activation.
- B7-1 is a counter-receptor for two ligands expressed on T lymphocytes. The first ligand, termed CD28, is constitutively expressed on resting T cells and increases after activation. After signaling through the T cell receptor, ligation of CD28 induces T cells to proliferate and secrete IL-2 (Linsley, P. S., et al. (1991)J. Exp. Med. 173: 721-730; Gimmi, C. D., et al. (1991) Proc. Natl. Acad. Sci. USA. 88:6575-6579; Thompson, C. B., et al. (1989) Proc. Natl. Acad. Sci. USA. 86:1333-1337; June, C. H., et al. (1990) Immunol. Today. 11:211-6; Harding, F. A., et al. (1992) Nature. 356:607-609.). The second ligand, termed CTLA4, is homologous to CD28, but is not expressed on resting T cells and appears following T cell activation (Brunet, J. F., et al., (1987) Nature 328:267-270). Like B7-1, B7-2 is a counter-receptor for both CD28 and CTLA4 (Freeman G. J., et al. (1993) Science 262:909-911). CTLA4 was first identified as a mouse cDNA clone, in a library of cDNA from a cytotoxic T cell clone subtracted with RNA from a B cell lymphoma (Brunet, J. F., et al. (1987) supra). The mouse CTLA4 cDNA was then used as a probe to identify the human and mouse CTLA4 genes (Harper, K., et al. (1991) J. Immunol. 147:1037-1044; and Dariavich, et al. (1988) Eur. J. Immunol. 18(12):1901-1905, sequence modified by Linsley, P. S., et al. (1991) J. Exp. Med. 174:561-569). A probe from the V domain of the human gene was used to detect the human cDNA which allowed the identification of the CTLA4 leader sequence (Harper, K., et al. (1991) supra).
- Soluble derivatives of cell surface glycoproteins in the immunoglobulin gene superfamily have been made consisting of an extracellular domain of the cell surface glycoprotein fused to an immunoglobulin constant (Fc) region (see e.g., Capon, D. J. et al. (1989)Nature 337:525-531 and Capon U.S. Pat. Nos. 5,116,964 and 5,428,130 [CD4-IgG1 constructs]; Linsley, P. S. et al. (1991) J. Exp. Med. 173:721-730 [a CD28-IgG1 construct and a B7-1-IgG1 construct]; and Linsley, P. S. et al. (1991) J. Exp. Med. 174:561-569 and U.S. Pat. No. 5,434,131[a CTLA4-IgG1]). Such fusion proteins have proven useful for studying receptor-ligand interactions. For example, a CTLA4-IgG immunoglobulin fusion protein was used to study interactions between CTLA4 and its natural ligands (Linsley, P. S. , et al., (1991) J. Exp. Med. 174:561-569; International Application WO93/00431; and Freeman G. J. , et al. (1993) Science 262:909-911).
- The importance of the B7:CD28/CTLA4 costimulatory pathway has been demonstrated in vitro and in several in vivo model systems. Blockade of this costimulatory pathway results in the development of antigen specific tolerance in murine and human systems (Harding, F. A., et al. (1992)Nature 356:607-609; Lenschow, D. J., et al. (1992) Science 257:789-792; Turka, L. A., et al. (1992) Proc. Natl. Acad. Sci. USA 89:11102-11105; Gimmi, C. D., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6586-6590; Boussiotis, V., et al. (1993) J. Exp. Med. 178:1753-1763). Conversely, transfection of a B7-1 gene into B7-1 negative murine tumor cells to thereby express B7-1 protein on the tumor cell surface induces T-cell mediated specific immunity accompanied by tumor rejection and long lasting protection to tumor challenge (Chen, L., et al. (1992) Cell 71:1093-1102; Townsend, S. E. and Allison, J. P. (1993) Science 259:368-370; Baskar, S., et al. (1993) Proc. Natl. Acad. Sci. USA 90:5687-5690.). Therefore, approaches which manipulate the B7:CD28/CTLA4 interaction to thereby stimulate or suppress immune responses would be beneficial therapeutically.
- This invention pertains to CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant (IgC) region-mediated effector functions and to nucleic acids encoding the proteins. In one embodiment, the fusion proteins of the present invention have been constructed by fusing a peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region to create a CTLA4Ig fusion protein. In another embodiment, the variable regions of immunoglobulin heavy and light chains have been replaced by the B7-binding extracellular domain of CTLA4 to create CTLA4-Ab fusion proteins. As used herein, the term “CTLA4-immunoglobulin fusion protein” refers to both the CTLA4Ig and CTLA4-Ab forms. In a preferred embodiment, the fusion proteins of the invention have been modified to reduce their ability to activate complement and/or bind to Fc receptors. In one embodiment, an IgC region of an isotype other than Cγ1 is used in the fusion protein and the modified effector function(s) can be assessed relative to a Cγ1-containing molecule (e.g., an IgG1 fusion protein). In another embodiment, a mutated IgC region (of any isotype) is used in the fusion protein and the modified effector function can be assessed relative to an antibody or Ig fusion protein containing the non-mutated form of the IgC region.
- The CTLA4-immunoglobulin fusion proteins of the invention are useful for inhibiting the interaction of CTLA4 ligands (e.g., B7 family members such as B7-1 and B7-2) with receptors on T cells (e.g., CD28 and/or CTLA4) to thereby inhibit delivery of a costimulatory signal in the T cells and thus downmodulate an immune response. Use of the CTLA4-immunoglobulin fusion proteins of the invention is applicable in a variety of situations, such as to inhibit transplant rejection or autoimmune reactions in a subject. In these situations, immunoglobulin constant region-mediated biological effector mechanisms, such as complement-mediated cell lysis, Fc receptor-mediated phagocytosis or antibody-dependent cellular cytotoxicity, may induce detrimental side effects in the subject and are therefore undesirable. The CTLA4-immunoglobulin fusion proteins of the invention exhibit reduced IgC region-mediated effector functions compared to a CTLA4-immunoglobulin fusion protein in which the IgG1 constant region is used and, thus are likely to have improved immunoinhibitory properties. These compositions can also be used for immunomodulation, to produce anti-CTLA4 antibodies, to purify CTLA4 ligands and in screening assays. The CTLA4-Ab fusion proteins are particularly useful when bivalent preparations are preferred, i.e. when crosslinking is desired.
- One aspect of the invention pertains to isolated nucleic acid molecules encoding modified CTLA4-immunoglobulin fusion proteins. The nucleic acids of the invention comprise a nucleotide sequence encoding a first peptide having a CTLA4 activity and a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function. A peptide having a CTLA4 activity is defined herein as a peptide having at least one biological activity of the CTLA4 protein, e.g., the ability to bind to the natural ligand(s) of the CTLA4 antigen on immune cells, such as B7-1 and/or B7-2 on B cells, or other known or as yet undefined ligands on immune cells, and inhibit (e.g., block) or interfere with immune cell mediated responses. In one embodiment, the peptide having a CTLA4 activity binds B7-1 and/or B-2 and comprises an extracellular domain of the CTLA4 protein. Preferably, the extracellular domain includes amino acid residues 20-144 of the human CTLA4 protein (amino acid positions 20-144 of SEQ ID NO: 24, 26 and 28).
- The present invention also contemplates forms of the extracellular domain of CTLA4 which are expressed without Ig constant regions and are expressed inE. coli. These soluble forms of the CTLA4 extracellular domain, although not glycosylated, are fully functional and have similar uses as the CTLA4 immunoglobulin fusion proteins of the invention.
- The nucleic acids of the invention further comprise a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one Ig constant region-mediated biological effector function. Preferably, the immunoglobulin constant region comprises a hinge region, a CH2 domain and a CH3 domain derived from Cγ1, Cγ2, Cγ3 or Cγ4. In one embodiment, the constant region segment is altered (e.g., mutated at specific amino acid residues by substitution, deletion or addition of amino acid residues) to reduce at least one IgC region-mediated effector function. In another embodiment, a constant region other than Cγ1 that exhibits reduced IgC region-mediated effector functions relative to Cγ1 is used in the fusion protein. In a preferred embodiment, the CH2 domain is modified to reduce a biological effector function, such as complement activation, Fc receptor interaction, or both complement activation and Fc receptor interaction. For example, to reduce Fc receptor interaction, at least one amino acid residue selected from a hinge link region of the CH2 domain (e.g., amino acid residues at positions 234-237 of an intact heavy chain protein) is modified by substitution, addition or deletion of amino acids. In another embodiment, to reduce complement activation ability, a constant region which lacks the ability to activate complement, such as Cγ4 or Cγ2 is used in the fusion protein (instead of a Cγ1 constant region which is: capable of activating complement). In another embodiment the variable region of the heavy and light chain is replaced with a polypeptide having CTLA4 activity creating a CTLA4-Ab molecule. In a preferred embodiment the heavy chain constant region of the CTLA4-Ab molecule comprises a hinge region, a CH2 domain and a CH3 domain derived from Cγ1, Cγ2, Cγ3 or Cγ4. In a preferred embodiment the light chain constant region of the CTLA4-Ab molecule comprises an Ig signal sequence, the CTLA4 extracellular domain, and the light chain (kappa or lambda) constant domain.
- The nucleic acids obtained in accordance with this invention can be inserted into various expression vectors, which in turn direct the synthesis of the corresponding protein in a variety of hosts, particularly eucaryotic cells, such as mammalian or insect cell culture and procaryotic cells, such asE. coli. Expression vectors within the scope of the invention comprise a nucleic acid as described herein and a promotor operably linked to the nucleic acid. Such expression vectors can be used to transfect host cells to thereby produce fusion proteins encoded by nucleic acids as described herein.
- Another aspect of the invention pertains to isolated CTLA4-immunoglobulin fusion proteins comprising a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. A preferred CTLA4-immunoglobulin fusion protein comprises an extracellular domain of the CTLA4 protein (e.g., amino acid positions 20-144 of the human CTLA4-immunoglobulin fusion protein shown in SEQ ID NO: 24, 26 and 28) linked to an immunoglobulin constant region comprising a hinge region, a CH2 domain and a CH3 domain derived from Cγ1, Cγ2, Cγ3 or Cγ4. A preferred constant domain used to reduce the complement activating ability of the fusion protein is Cγ4. In one embodiment, the CH2 domain of the immunoglobulin constant region is modified to reduce at least one biological effector function, such as complement activation or Fc receptor interaction. In a particularly preferred embodiment, the CTLA4-immunoglobulin fusion protein includes a CH2 domain which is modified by substitution of an amino acid residue at
position - The CTLA4-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) and a receptor therefor (e.g., CD28 and/or CTLA4) on the surface of a T cell, to thereby suppress cell-mediated immune responses in vivo. Inhibition of the CTLA4 ligand/receptor interaction may be useful for both general immunosuppression and to induce antigen-specific T cell tolerance in a subject for use in preventing transplantation rejection (solid organ, skin and bone marrow) or graft versus host disease, particularly in allogeneic bone marrow transplantation. The CTLA4-immunoglobulin fusion proteins can also be used therapeutically in the treatment of autoimmune diseases, allergy and allergic reactions, transplantation rejection and established graft versus host disease in a subject. Moreover, the CTLA4-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-CTLA4 antibodies in a subject, to purify CTLA4 ligands and in screening assays to identify molecules which inhibit the interaction of CTLA4 with a CTLA4 ligand.
- FIG. 1 is a schematic diagram of the “zip up” polymerase chain reaction (PCR) procedure used to contrust gene fusions.
- FIG. 2A-B show the amino acid mutations introduced into the hinge and CH2 domains of hCTLA4-IgG1m (panel A) and hCTLA4-IgG4m (panel B). Mutated amino acid residues are underlined.
- FIG. 3 is a schematic diagram of the expression vector pNRDSH.
- FIG. 4A-B are graphic representations of competition ELISAs depicting the ability of unlabeled hCTLA4-IgG1 or unlabeled hCTLA4-IgG4m to compete for the binding of biotinylated hCTLA4-IgG1 to hB7-1-Ig (panel A) or hB7-2-Ig (panel B).
- FIG. 5A-B are graphic representations of Fc receptor binding assays depicting the ability of CTLA4-IgG1 or CTLA4-IgG4 to bind to Fc receptors. In panel A, the ability of unlabeled CTLA4-IgG1 or unlabeled CTLA4-IgG4 to compete for the binding of125I-labeled CTLA4-IgG1 to FcRI-positive U937 cells is depicted. In panel B, the percent specific activity of unlabeled CTLA4-IgG1, CTLA4-IgG4 or hIgG1 used to compete itself for binding to U937 cells is depicted.
- FIG. 6A-C are graphic representations of complement activation assays depicting the ability of CTLA4-IgG1, CTLA4-IgG4m or anti-B7-1 mAb (4B2) to activate complement-mediated lysis of CHO-B7-1 cells. In panel A, guinea pig complement is used as the complement source. In panel B, human serum is used as the complement source. In panel C, control untransfected CHO cells are used as the target for complement-mediated lysis.
- FIG. 7 is a graphic representation of the binding of CTLA4-IgG1, CTLA4-IgG4m or anti-B7-1 mAb (4B2) to CHO-B7-1 cells, demonstrating that despite the inability of CTLA4-IgG4m to activate complement it can still bind to CHO-B7-1 cells.
- FIG. 8 is a graphic representation of a competition curve demonstrating that soluble CTLA4 expressed inE. coli is functional and competes with unlabeled CTLA4Ig for binding to plate-bound B7-1.
- This invention features isolated CTLA4-immunoglobulin fusion proteins which have been modified to reduce immunoglobulin constant (IgC) region-mediated effector functions. The invention also features isolated nucleic acids encoding the proteins, methods for producing the CTLA4-immunoglobulin fusion proteins of the invention and methods for using the CTLA4-immunoglobulin fusion proteins of the invention for immunomodulation.E. coli-expressed forms of CTLA4 are also disclosed. These and other aspects of the invention are described in further detail in the following subsections:
- I. Chimeric CTLA4-Immunoglobulin Gene Fusions
- The invention provides isolated nucleic acids encoding CTLA4-immunoglobulin fusion proteins. The CTLA4-immunoglobulin fusion proteins are comprised of two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which, in certain embodiments is modified to reduce at least one constant region-mediated biological effector function. Accordingly, the isolated nucleic acids of the invention comprise a first nucleotide sequence encoding the first peptide having a CTLA4 activity and a second nucleotide sequence encoding the second peptide comprising an immunoglobulin constant region which, in a preferred embodiment, is modified to reduce at least one constant region-mediated biological effector function. In the case of CTLA4Ig forms, the first and second nucleotide sequences are linked (i.e., in a 5′ to 3′ orientation by phosphodiester bonds) such that the translational frame of the CTLA4 and IgC coding segments are maintained (i.e., the nucleotide sequences are joined together in-frame). Thus, expression (i.e., transcription and translation) of the nucleotide sequences produces a functional CTLA4Ig fusion protein. In the case of the CTLA4-Ab fusion proteins, the heavy chain gene is constructed such that the CTLA4 extracellular binding domain is linked to a 5′ signal sequence and a 3′ immunoglobulin CH1, hinge, CH2, and CH3 domain. CTLA4-light chain constructs are prepared in which an Ig signal sequence, an intron, the CTLA4 extracellular domain, an intron, and the light chain constant domain are linked. The DNA encoding the heavy and light chains is then expressed using an appropriate expression vector as described in the Examples.
- The term “nucleic acid” as used herein is intended to include fragments or equivalents thereof. The term “equivalent” is intended to include nucleotide sequences encoding functionally equivalent CTLA4-immunoglobulin fusion proteins, i.e., proteins which have the ability to bind to the natural ligand(s) of the CTLA4 antigen on immune cells, such as B7-1 and/or B7-2 on B cells, and inhibit (e.g., block) or interfere with immune cell mediated responses.
- The term “isolated” as used throughout this application refers to a nucleic acid or fusion protein substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. An isolated nucleic acid is also free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the organism from which the nucleic acid is derived.
- The nucleic acids of the invention can be prepared by standard recombinant DNA techniques. For example, a chimeric CTLA4-immunoglobulin gene fusion can be constructed using separate template DNAs encoding CTLA4 and an immunoglobulin constant region and a “zip up” polymerase chain reaction (PCR) procedure as described in Example 1 and illustrated schematically in FIG. 1. Alternatively, a nucleic acid segment encoding CTLA4 can be ligated in-frame to a nucleic acid segment encoding an immunoglobulin constant region using standard techniques. A nucleic acid of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which has been automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Pat. No. 4,598,049; Caruthers et al. U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071, incorporated by reference herein).
- The nucleic acid segments of the CTLA4-immunoglobulin gene fusions of the invention are described in further detail below:
- A. CTLA4 Gene Segment
- An isolated nucleic acid of the invention encodes a first peptide having a CTLA4 activity. The phrase “peptide having a CTLA4 activity” or “peptide having an activity of CTLA4” is used herein to refer to a peptide having at least one biological activity of the CTLA4 protein, i.e., the ability to bind to the natural ligand(s) of the CTLA4 antigen on immune cells, such as B7-1 and/or B7-2 on B cells, or other known or as yet undefined ligands on immune cells, and which, in soluble form, can inhibit (e.g., block) or interfere with immune cell mediated responses. In one embodiment, the CTLA4 protein is a human CTLA4 protein, the nucleotide and amino acid sequences of which are disclosed in Harper, K., et al. (1991)J. Immunol. 147:1037-1044 and Dariavich, et al. (1988) Eur. J. Immunol. 18(12): 1901-1905. In another embodiment, the peptide having a CTLA4 activity binds B7-1 and/or B7-2 and comprises at least a portion of an extracellular domain of the CTLA4 protein. Preferably, the extracellular domain includes amino acid residues 1-125 of the human CTLA4 protein (amino acid positions 20-144 of SEQ ID NO: 24, 26 and 28). CTLA4 proteins from other species (e.g., mouse) are also encompassed by the invention. The nucleotide and amino acid sequences of mouse CTLA4 are disclosed in Brunet, J. F., et al., (1987) Nature 328:267-270.
- The nucleic acids of the invention can be DNA or RNA. Nucleic acid encoding a peptide having a CTLA4 activity may be obtained from mRNA present in activated T lymphocytes. It is also possible to obtain nucleic acid encoding CTLA4 from T cell genomic DNA. For example, the gene encoding CTLA4 can be cloned from either a cDNA or a genomic library in accordance with standard protocols. A cDNA encoding CTLA4 can be obtained by isolating total mRNA from an appropriate cell line. Double stranded cDNAs can then prepared from the total mRNA. Subsequently, the cDNAs can be inserted into a suitable plasmid or bacteriophage vector using any one of a number of known techniques. Genes encoding CTLA4 can also be cloned using established polymerase chain reaction techniques in accordance with the nucleotide sequence information provided by the invention (see Example 1). For example, a DNA vector containing a CTLA4 cDNA can be used as a template in PCR reactions using oligonucleotide primers designed to amplify a desired region of the CTLA4 cDNA, e.g., the extracellular domain, to obtain an isolated DNA fragment encompassing this region using standard techniques.
- It will be appreciated by those skilled in the art that various modifications and equivalents of the nucleic acids encoding the CTLA4-immunoglobulin fusion proteins of the invention exist. For example, different cell lines can be expected to yield DNA molecules having different sequences of bases. Additionally, variations may exist due to genetic polymorphisms or cell-mediated modifications of the genetic material. Furthermore, the nucleotide sequence of a CTLA4-immunoglobulin fusion protein of the invention can be modified by genetic techniques to produce proteins with altered amino acid sequences that retain the functional properties of CTLA4 (e.g., the ability to bind to B7-1 and/or B7-2). Such sequences are considered within the scope of the invention, wherein the expressed protein is capable of binding a natural ligand of CTLA4 and, when in the appropriate form (e.g., soluble) can inhibit B7:CD28/CTLA4 interactions and modulate immune responses and immune function. In addition, it will be appreciated by those of skill in the art that there are other B7-binding ligands and the fusion of these alternative molecules (such as CD28) to form immuonglobulin fusion proteins or expressed in soluble form inE. coli is also contemplated by the present invention.
- To express a CTLA4-immunoglobulin fusion protein of the invention, the chimeric gene fusion encoding the CTLA4-immunoglobulin fusion protein typically includes a nucleotide sequence encoding a signal sequence which, upon transcription and translation of the chimeric gene, directs secretion of the fusion protein. A native CTLA4 signal sequence (e.g., the human CTLA4 signal sequence disclosed in Harper, K., et al. (1991)J. Immunol. 147, 1037-1044) can be used or alternatively, a heterologous signal sequence can be used. For example, the oncostatin-M signal sequence (Malik N., et al. (1989) Mol. Cell. Biol. 9(7), 2847-2853) or an immunoglobulin signal sequence (e.g.,
amino acid positions 1 to 19 of SEQ ID NO: 24, 26 and 28) can be used to direct secretion of a CTLA4-immunoglobulin fusion protein of the invention. A nucleotide sequence encoding a signal sequence can be incorporated into the chimeric gene fusion by standard recombinant DNA techniques, such as by “zip up” PCR (described further in Example 1) or by ligating a nucleic acid fragment encoding the signal sequence in-frame at the 5′ end of a nucleic acid fragment encoding CTLA4. - B. Immunoglobulin Gene Segment
- The CTLA4-immunoglobulin fusion protein of the invention further comprises a second peptide linked to the peptide having a CTLA4 activity. In one embodiment the second peptide comprises a light chain constant region. In a preferred embodiment the light chain is a kappa light chain.
- In another embodiment the second peptide comprises a heavy chain constant region. In a preferred embodiment the constant region comprises an immunoglobulin hinge region, a CH2 domain and a CH3 domain. In another embodiment the constant region also comprises a CH1 domain. The constant region is preferably derived from Cγ1, Cγ2, Cγ3 or Cγ4. In a preferred embodiment the heavy chain constant region is modified to reduce at least one constant region-mediated biological effector function. In one embodiment, the constant region segment (either Cγ1 or another isotype) is altered (e.g., mutated from the wild-type sequence at specific amino acid residues by substitution, deletion or addition of amino acid residues) to reduce at least one IgC region-mediated effector function. The effector functions of this altered fusion protein can be assessed relative to an unaltered IgC region-containing molecule (e.g., a whole antibody or Ig fusion protein). In another embodiment, a constant region other than Cγ1 that exhibits reduced IgC region-mediated effector functions is used in the fusion protein. The effector functions of this fusion protein can be assessed relative to a Cγ1-containing molecule (e.g., an IgG1 antibody or IgG1 fusion protein). In a particularly preferred embodiment, the fusion protein comprises a constant region other than Cγ1 that is also mutated to further reduce effector function. For example, a preferred IgC region is a mutated Cγ4 region.
- The term “immunoglobulin constant (IgC) region-mediated biological effector function” is intended to include biological responses which require or involve, at least in part, the constant region of an immunoglobulin molecule. Examples of such effector functions include complement activation, Fc receptor interactions, opsonization and phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), release of reactive oxygen intermediates and placental transfer. While such effector functions are desirable in many immune responses, they are undesirable in situations where an immune response is to be downmodulated. The CTLA4-immunoglobulin fusion proteins of the invention exhibit reduced IgC region-mediated biological effector functions and thus are efficient agents for downregulating immune responses. Additionally, the CTLA4-immunoglobulin fusion proteins of the invention display a long plasma half life in vivo. The long plasma half-life makes the proteins particularly useful as therapeutic agents.
- All immunoglobulins have a common core structure of two identical light and heavy chains held together by disulfide bonds. Both the light chains and the heavy chains contain a series of repeating, homologous units, each about 110 amino acid residues in length, which fold independently in a common globular motif, called an immunoglobulin domain. In each chain, one domain (V) has a variable amino acid sequence depending on the antibody specificity of the molecule. The other domains (C) have a constant sequence common among molecules of the same isotype. Heavy chains are designated by the letter of the Greek alphabet corresponding to the overall isotype of the antibody: IgA1 contains α1 heavy chains; IgA2, α2; IgD, δ; IgE, ε; IgG1, γ1; IgG2, γ2; IgG3, γ3; IgG4, γ4; and IgM, μ. Each heavy chain includes four domains; an amino terminal variable, or VH domain which displays the greatest sequence variation among heavy chains and three domains which form the constant region (CH1, CH2 and CH3) in order from the amino to the carboxy terminus of the heavy chain. In γ, α and δ heavy chains, there is a nonglobular region of amino acid sequence, known as the hinge, located between the first and second constant region domains (CH1 and CH2) permitting motion between these two domains.
- To modify a CTLA4-immunoglobulin fusion protein; such that it exhibits reduced binding to the FcRI receptor, the immunoglobulin constant region segment of the CTLA4-immunoglobulin fusion protein can be mutated at particular regions necessary for Fc receptor (FcR) interactions (see Canfield, S. M. and S. L. Morrison (1991)J. Exp. Med. 173:1483-1491; and Lund, J. et al. (1991) J. of Immunol. 147:2657-2662). Reduction in FcR binding ability of a CTLA4-immunoglobulin fusion protein will also reduce other effector functions which rely on FcR interactions, such as opsonization and phagocytosis and antigen-dependent cellular cytotoxicity. To reduce FcR binding, in one embodiment, the constant region is mutated within a region of the CH2 domain referred to as the “hinge link” or “lower hinge” region. This region encompasses amino acid residues 234-239 in a full-length native immunoglobulin heavy chain. It should be appreciated that all IgC region amino acid residue positions described herein refer to the position within the full-length intact native immunoglobulin heavy chain; it will be apparent to those skilled in the art that depending upon the length of the CTLA4 segment used in the CTLA4-immunoglobulin fusion protein, the positions of the corresponding IgC amino acid residues within the fusion protein will vary (Kabat, E. A, T. T. Wu, M. Reid-Miller, H. M. Perry, and K. S. Gottesman eds. (1987) “Sequences of Proteins of Immunological Interest” National Institutes of Health, Bethesda, Md.). The hinge link region can be mutated by substitution, addition or deletion of amino acid residues. A preferred CTLA4-immunoglobulin fusion protein of the invention is one in which the IgG1 constant region has substitution mutations at
positions positions 235 and/or 237 of the Cγ4 segment. Preferably, Leu at 235 is substituted with Glu and Gly at 237 is substituted with Ala (see Example 1). - In another embodiment, the Fc receptor binding capability of the CTLA4-immunoglobulin fusion protein is reduced by mutating a region of the CH2 domain referred to as the “hinge-proximal bend” region (amino acid residues at positions 328-333 within a full-length intact heavy chain). This region can be mutated by substitution, addition or deletion of amino acid residues. In a preferred embodiment, position 331 of Cγ1 or Cγ3 is mutated. A preferred mutation in Cγ1 or Cγ3 is substitution of Pro with Ser.
- To modify a CTLA4-immunoglobulin fusion protein such that it exhibits reduced complement activation ability, the immunoglobulin constant region segment of the fusion protein can be mutated at particular regions important for complement activation, such as regions involved in IgC region binding to the C1q component of complement. In one embodiment, one or more residues present within the CH2 domain of IgG subclasses that are involved in C1q binding are altered. In a preferred embodiment, positions 318, 320 and/or 322 are mutated (see Duncan and Winter (1988)Nature 332, 738-740). Preferably, Glu at 318 is substituted with Ala or Val, Lys at 320 is substituted with Ala or Gln and/or Lys at 322 is substituted with Ala or Gln.
- Alternatively, to reduce complement activation by the CTLA4-immunoglobulin fusion protein, a constant region which lacks the ability to activate complement can be used in the fusion protein. For example, it is known that both IgG1 and IgG3, but not IgG2 and IgG4 activate the classical complement cascade in the presence of human complement. Accordingly, a CTLA4-immunoglobulin fusion protein utilizing a Cγ4 constant region exhibits reduced complement activation ability relative to a CTLA4-immunoglobulin fusion protein comprising IgG1 (as demonstrated in Example 2).
- In yet another embodiment, the hinge region of the IgC segment is altered to inhibit complement activation ability. The hinge regions of the human IgG molecules vary in amino acid sequence and composition as well as length. For example, IgG1, IgG2 and IgG4 have hinge regions consisting of 12 to 15 amino acids, whereas IgG3 has an extended hinge region, consisting of 62 amino acids. The hinge region is believed to be essential for binding with the first component of complement, C1q (see Tan et al. (1990)Proc. Natl. Acad. Sci. USA 87:162-166). A number of chimeric human IgG3 and IgG4 molecules with different hinge lengths and amino acid composition have been produced, confirming the role of the hinge region in C1q binding and complement activation. To reduce or interfere with the ability of a CTLA4-immunoglobulin (IgG1) or CTLA4-immunoglobulin (IgG3) construct to activate complement, it may be necessary to modify, by substitution, addition or deletion, at least one amino acid residue in the hinge region. In one embodiment, the hinge region of Cγ1 or Cγ3 is substituted with a hinge region derived from Cγ2 or Cγ4, each of which lack the ability to activate complement.
- In addition to modifying the CTLA4-immunoglobulin fusion proteins of the invention to reduce IgC region-mediated biological effector functions, the fusion proteins can be further modified for other purposes, e.g., to increase solubility, enhance therapeutic or prophylactic efficacy, or stability (e.g., shelf life ex vivo and resistance to proteolytic degradation in vivo). Such modified proteins are considered functional equivalents of the CTLA4-immunoglobulin fusion proteins as defined herein. For example, amino acid residues of the CTLA4 portion of the fusion protein which are not essential for CTLA4 ligand interaction can be modified by being replaced by another amino acid whose incorporation may enhance, diminish, or not affect reactivity of the fusion protein. Alternatively, a CTLA4-immunoglobulin fusion protein which binds only B7-1 or B7-2 but not both could be created by mutating residues involved in binding to one ligand or the other. Another example of a modification of a CTLA4-immunoglobulin fusion protein is substitution of cysteine residues, preferably with alanine, serine, threonine, leucine or glutamic acid residues, to minimize dimerization via disulfide linkages. A particularly preferred modification is substitution of cysteine residues in the hinge region of the immunoglobulin constant region with serine. In addition, amino acid side chains of a CTLA4-immunoglobulin fusion protein can be chemically modified.
- A particularly preferred embodiment of the invention features a nucleic acid encoding a CTLA4-immunoglobulin fusion protein comprising a nucleotide sequence encoding a first peptide having a CTLA4 activity and a nucleotide sequence encoding a second peptide comprising an IgG4 immunoglobulin constant region, Cγ4. Preferably, the nucleic acid is a DNA and the first peptide comprises an extracellular region of CTLA4 which binds B7-1. Such a CTLA4-IgG4 construct can comprise a nucleotide sequence show in SEQ ID NO: 25 and an amino acid sequence shown in SEQ ID NO: 26. In an even more preferred embodiment, the CH2 domain of the Cγ4 portion of this CTLA4IgG4 fusion protein is modified to reduce Fc receptor interaction. For example, the CH2 domain can be modified by substitution of Leu at position 235 (e.g., with Glu) and/or substitution of Gly at position 237 (e.g., with Ala). A particularly preferred CTLA4-IgG4 fusion protein comprises the extracellular domain of human CTLA4 (i.e., amino acid residues 1-125), has reduced Fc receptor interaction due to two substitutions in the CH2 domain (i.e., substitution of Leu at
position 235 with Glu and substitution of Gly atposition 237 with Ala). Such a CTLA4-IgG4 fusion protein comprises an amino acid sequence shown in SEQ ID NO: 28 and a nucleotide sequence shown in SEQ ID NO: 27. This construct, referred to as CTLA4-IgG4m, exhibits markedly reduced complement activation ability and FcR binding activity relative to a wild-type CTLA4-IgG1 construct (see Example 2). - Another preferred embodiment of the invention features a nucleic acid encoding a CTLA4-IgG1 fusion protein comprising a nucleotide sequence encoding a first peptide having a CTLA4 activity and a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region, Cγ1, which is modified to reduce at least one constant region-mediated biological effector functions. Preferably, the nucleic acid is a DNA and the first peptide comprises an extracellular region of CTLA4 which binds B7-1. To reduce Fc receptor interaction the CH2 domain of Cγ1 is modified by substitution of one or more of the following amino acid residues: Leu at
position 235; Leu atposition 234; and Gly atposition 237. A particularly preferred CTLA4-IgG1 fusion protein comprises the extracellular domain of human CTLA4 (i.e., amino acid residues 1-125), has reduced Fc receptor interaction due to three substitutions in the CH2 domain (i.e., substitution of Leu atposition 234 with Ala, substitution of Leu atposition 235 with Glu and substitution of Gly atposition 237 with Ala). Such a CTLA4-IgG1 fusion protein, referred to herein as CTLA4-IgG1m, comprises an amino acid sequence shown in SEQ ID NO: 24 and a nucleotide sequence shown in SEQ ID NO: 23. - Nucleic acid encoding a peptide comprising an immunoglobulin constant region can be obtained from human immunoglobulin mRNA present in B lymphocytes. It is also possible to obtain nucleic acid encoding an immunoglobulin constant region from B cell genomic DNA. For example, DNA encoding Cγ1 or Cγ4 can be cloned from either a cDNA or a genomic library or by polymerase chain reaction (PCR) amplification in accordance with protocols herein described. The nucleic acids of the invention can be DNA or RNA. A preferred nucleic acid encoding an immunoglobulin constant region comprises all or a portion of the following: the DNA encoding human Cγ1 (Takahashi, N. S. et al. (1982)Cell 29:671-679), the DNA encoding human Cγ2 (Kabat, E. A, T. T. Wu, M. Reid-Miller, H. M. Perry, and K. S. Gottesman eds. (1987) “Sequences of Proteins of Immunological Interest” National Institutes of Health, Bethesda, Md.); the DNA encoding human Cγ3 (Huck, S., et al. (1986) Nucl. Acid Res. 14:1779); and the DNA encoding human Cγ4 (Kabat et al., supra).
- A number of processes are known in the art for modifying a nucleotide or amino acid sequence to thereby mutate the IgC regions as described herein. For example, mutations can be introduced into a DNA by any one of a number of methods, including those for producing simple deletions or insertions, systematic deletions, insertions or substitutions of clusters of bases or substitutions of single bases, to generate CTLA4-immunoglobulin fusion proteins of the invention and equivalents thereof. Preferably, amino acid substitutions, deletions or additions, such as in the CH2 domain of the immunoglobulin constant region, are created by PCR mutagenesis as described in Example 1 or by standard site-directed mutagenesis. Site directed mutagenesis systems are well known in the art. For example, protocols and reagents can be obtained commercially from Amersham International PLC, Amersham, U.K.
- II. Expression Vectors and Host Cells
- The CTLA4-immunoglobulin fusion proteins of the invention can be expressed by incorporating a chimeric CTLA4-immunoglobulin fusion gene described herein into an expression vector and introducing the expression vector into an appropriate host cell. Accordingly, the invention further pertains to expression vectors containing a nucleic acid encoding a CTLA4-immunoglobulin fusion protein and to host cells into which such expression vectors have been introduced. An expression vector of the invention, as described herein, typically includes nucleotide sequences encoding the CTLA4-immunoglobulin fusion protein operably linked to at least one regulatory sequence. “Operably linked” is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence in a host cell (or by a cell extract). Regulatory sequences are art-recognized and can be selected to direct expression of the desired protein in an appropriate host cell. The term regulatory sequence is intended to include promoters, enhancers, polyadenylation signals and other expression control elements. Such regulatory sequences are known to those skilled in the art and are described in Goeddel,Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transfected and/or the type and/or amount of protein desired to be expressed.
- An expression vector of the invention can be used to transfect cells, either procaryotic or eucaryotic (e.g., mammalian, insect or yeast cells) to thereby produce fusion proteins encoded by nucleotide sequences of the vector. Expression in procaryotes is most often carried out inE. coli with vectors containing constitutive or inducible promotors. Certain E. coli expression vectors (so called fusion-vectors) are designed to add a number of amino acid residues to the expressed recombinant protein, usually to the amino terminus of the expressed protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the target recombinant protein; and 3) to aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. Examples of fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia) and pMAL (New England Biolabs, Beverly, Mass.) which fuse glutathione S-tranferase and maltose E binding protein, respectively, to the target recombinant protein. Accordingly, a chimeric CTLA4-immunoglobulin fusion gene may be linked to additional coding sequences in a procaryotic fusion vector to aid in the expression, solubility or purification of the fusion protein. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the target recombinant protein to enable separation of the target recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
- Inducible non-fusion expression vectors include pTrc (Amann et al., (1988)Gene 69:301-315) and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter. Target gene expression from the pET11d vector relies on transcription from the T7 gn10-
lac 0 fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 under the transcriptional control of thelacUV 5 promoter. - One strategy to maximize expression of recombinant CTLA4-immunoglobulin fusion protein inE. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Another strategy would be to alter the nucleotide sequence of the CTLA4-immunoglobulin fusion protein to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed E. coli proteins (Wada et al., (1992) Nuc. Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences are encompassed by the invention and can be carried out by standard DNA synthesis techniques.
- In another preferred embodiment a soluble CTLA4 extracellular domain is expressed inE coli using an appropriate expression vector. These forms, although not glycosylated, remain fully functional and represent an advantage because of the ease with which bacterial cells are grown.
- Alternatively, a CTLA4-immunoglobulin fusion protein can be expressed in a eucaryotic host cell, such as mammalian cells (e.g., Chinese hamster ovary cells (CHO) or NS0 cells), insect cells (e.g., using a baculovirus vector) or yeast cells. Other suitable host cells may be found in Goeddel, (1990) supra or are known to those skilled in the art. Eucaryotic, rather than procaryotic, expression of a CTLA4-immunoglobulin fusion protein may be preferable since expression of eucaryotic proteins in eucaryotic cells can lead to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of a recombinant protein. For expression in mammalian cells, the expression vector's control functions are often provided by viral material. For example, commonly used promoters are derived from polyoma,
Adenovirus 2, cytomegalovirus andSimian Virus 40. To express a CTLA4-immunoglobulin fusion protein in mammalian cells, generally COS cells (Gluzman, Y., (1981) Cell 23:175-182) are used in conjunction with such vectors as pCDM8 (Seed, B., (1987) Nature 329:840) for transient amplification/expression, while CHO (dhfr− Chinese Hamster Ovary) cells are used with vectors such as pMT2PC (Kaufman et al. (1987), EMBO J. 6:187-195) for stable amplification/expression in mammalian cells. A preferred cell line for production of recombinant protein is the NS0 myeloma cell line available from the ECACC (catalog #85110503) and described in Galfre, G. and Milstein, C. ((1981) Methods in Enzymology 73(13):3-46; and Preparation of Monoclonal Antibodies: Strategies and Procedures, Academic Press, New York, N.Y.). Examples of vectors suitable for expression of recombinant proteins in yeast (e.g., S. cerivisae) include pYepSec1 (Baldari. et al, (1987) Embo J. 6:229-234), pMFa (Kudjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.). Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow, V. A., and Summers, M. D., (1989) Virology 170:31-39). - Vector DNA can be introduced into procaryotic or eucaryotic cells via conventional transformation or transfection techniques such as calcium phosphate or calcium choloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.
- For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small faction of cells may integrate DNA into their genomes. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker may be introduced into a host cell on the same plasmid as the gene of interest or may be introduced on a separate plasmid. Cells containing the gene of interest can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die). The surviving cells can then be screened for production of CTLA4-immunoglobulin fusion proteins by, for example, immunoprecipitation from cell supernatant with an anti-CTLA4 monoclonal antibody.
- The invention also features methods of producing CTLA4-immunoglobulin fusion proteins. For example, a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding a CTLA4-immunoglobulin fusion protein can be cultured in a medium under appropriate conditions to allow expression of the protein to occur. In one embodiment, a recombinant expression vector containing DNA encoding a CTLA4-IgG1 fusion protein having modified constant region-mediated effector functions is produced. In another embodiment, a recombinant expression vector containing DNA encoding a CTLA4-IgG4 fusion protein having modified constant region-mediated effector functions is produced. In addition, one or more expression vector containing DNA encoding, for example, a CTLA4-IgG1 fusion protein and another fusion protein such as a CTLA4-IgG4 fusion protein can be used to transfect a host cell to coexpress these fusion proteins. Fusion proteins produced by recombinant technique may be secreted and isolated from a mixture of cells and medium containing the protein. Alternatively, the protein may be retained cytoplasmically and the cells harvested, lysed and the protein isolated. A cell culture typically includes host cells, media and other byproducts. Suitable mediums for cell culture are well known in the art. Protein can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins.
- III. Isolation and Characterization of CTLA4-Immunoglobulin Fusion Proteins
- Another aspect of the invention pertains to CTLA4-immunoglobulin fusion proteins having modified effector functions compared to a CTLA4-IgG1 protein. Such proteins comprise a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. A peptide having a CTLA4 activity has been previously defined herein. In a preferred embodiment, the first peptide comprises an extracellular domain of the human CTLA4 protein (e.g., amino acid residues 20-144 of SEQ ID NO: 24, 26 and 28) and binds B7-1 and/or B7-2. The second peptide comprising an immunoglobulin constant region preferably includes a hinge region, a CH2 domain and a CH3 domain derived from Cγ1, Cγ2, Cγ3, or Cγ4. Typically, the CH2 domain is modified to reduce constant region-mediated biological effector functions, such as complement activation and/or Fc receptor interaction as previously described in detail herein.
- Another embodiment of the invention provides a substantially pure preparation of a CTLA4-immunoglobulin fusion protein as described herein. Such a preparation is substantially free of proteins and peptides with which the protein naturally occurs in a cell or with which it naturally occurs when secreted by a cell.
- CTLA4-immunoglobulin fusion proteins, expressed in mammalian cells or elsewhere, can be purified according to standard procedures of the art, including ammonium sulfate precipitation, fractionation column chromatography (e.g., ion exchange, gel filtration, electrophoresis, affinity chromatography, etc.) and ultimately, crystallization (see generally, “Enzyme Purification and Related Techniques”,Methods in Enzymology, 22:233-577 (1971)). Preferably, the CTLA4-immunoglobulin fusion proteins are purified using an immobilized protein A column (Repligen Corporation, Cambridge, Mass.). Once purified, partially or to homogeneity, the recombinantly produced CTLA4-immunoglobulin fusion proteins or portions thereof can be utilized in compositions suitable for pharmaceutical administration as described in detail herein.
- In one embodiment the CTLA4-immunoglobulin fusion protein is an antibody form in which the heavy and light chains have been replaced with the extracellular domain of CTLA4. This molecule has a different valency and higher affinity for CTLA4 ligands, thus making it possible to obtain similar results while using less of the agent. The fact that this molecule has a true antibody tail which is fully glycosylated means that numerous cell lines for producing the CTLA4Ab fusion protein and data regarding the clinical use of antibodies may be relied on.
- Screening of CTLA4-immunoglobulin fusion proteins which have been modified to reduce at least one constant region-mediated biological effector function as described herein can be accomplished using one or more of several different assays which measure different effector functions. For example, to identify a CTLA4-immunoglobulin fusion protein having reduced Fc receptor interaction, a monomeric IgG binding assay can be conducted (see Example 2). A cell which expresses an Fc receptor, such as a mononuclear phagocyte or the U937 cell line (FcγRI expression), a hematopoietic cell (FcγRII expression; Rosenfeld, S. I., et al. (1985)J. Clin. Invest. 76:2317-2322) or a neutrophil (FcγRIII expression; Fleit, H. B., et al. (1982) Proc. Natl. Acad. Sci. USA 79:3275-3279 and Petroni, K. C., et al. (1988) J. Immunol. 140:3467-3472) is contacted with, for example, 125I-labeled immunoglobulin of the IgG1 isotype in the presence or absence of a modified CTLA4-immunoglobulin fusion protein of the invention and in the presence or absence of an appropriate control molecule (e.g., an unlabeled IgG1 antibody or a CTLA4-IgG1 fusion protein). The amount of 125I-labeled IgG1 bound to the cells and/or the amount of free 125I-labeled IgG in the supernatant is determined. A CTLA4-immunoglobulin fusion protein having reduced Fc receptor binding is identified by a reduced ability (or lack of ability) to inhibit binding of the 125I-labeled IgG1 to the cells (relative to the control molecule). Monomeric IgG binding assay are described further in Lund, J., et al. (1991) J. Immunol. 147:2657-2662; and Woof, J. M., et al. (1986) Mol. Immunol. 23:319.
- To identify a CTLA4-immunoglobulin fusion protein with a reduced ability to activate the complement cascade, a complement activation assay such as that described in Example 2 can be used. In this assay, a cell which expresses a CTLA4 ligand (e.g., B7-1 or B7-2) on its surface is loaded with a detectable substance, e.g., a fluorescent dye, and then contacted with the CTLA4-immunoglobulin fusion protein and a complement source (e.g., purified guinea pig complement or human serum as a source of human complement). Cell lysis, as determined by release of the fluorescent dye from the cells, is determined as an indication of activation of the complement cascade upon binding of CTLA4-immunoglobulin to the CTLA4 ligand on the cell surface. Cells which do not express a CTLA4 ligand on their surface are used as a negative control. A CTLA4-immunoglobulin fusion protein with reduced ability (or lack of the ability) to activate complement relative to an appropriate control molecule (e.g., anti-B7-1 antibody of the IgG1 isotype or a CTLA4-IgG1 fusion protein) is identified by a reduction in or absence of cell lysis of labeled, CTLA4 ligand positive cells when incubated in the presence of the CTLA4-immunoglobulin fusion protein of the invention and complement compared to cells incubated in the presence of the control molecule and complement.
- In another complement activation assay, the ability of a CTLA4-immunoglobulin fusion protein to bind the first component of the complement cascade, C1q, is assessed. For example, C1q binding can be determined using a solid phase assay in which125I-labeled human C1q is added to an amount of CTLA4-immunoglobulin fusion protein complexed with a CTLA4 ligand, such as B7-1 or B7-2, and the amount of bound 125I-labeled human C1q quantitated. A CTLA4-immunoglobulin fusion protein having a reduced complement activation activity (or lack of complement activation activity) is identified by a reduction in or absence of the ability to bind the 125I-labeled human C1q relative to an appropriate control molecule (e.g., an IgG1 antibody or a CTLA4-IgG1 fusion protein). C1q binding assays are described further in Tan. L. K., et al. (1990) Proc. Natl. Acad. Sci. USA 87:162-166; and Duncan, A. R. and G. Winter (1988) Nature 332:738-740.
- Additional assays for other immunoglobulin constant region-mediated effector functions, such as opsonization and phagocytosis, antibody-dependent cellular cytotoxicity and release of reactive oxygen intermediates, have been described in the art and are known to the skilled artisan.
- Screening for CTLA4-immunoglobulin fusion proteins which have a CTLA4 activity as described herein can be accomplished using one or more of several different assays. For example, the fusion proteins can be screened for specific reactivity with an anti-CTLA4 antibody (e.g., a monoclonal or polyclonal anti-CTLA4 antibody) or with a soluble form of a CTLA4 ligand, such as a B7-1 or B7-2 fusion protein (e.g., B7-1Ig or B7-2Ig). For example, appropriate cells, such as CHO or NS0 cells, can be transfected with a DNA encoding a CTLA4-immunoglobulin fusion protein and the cell supernatant analyzed for expression of the resulting fusion protein using an anti-CTLA4 monoclonal antibody or B7-1Ig or B7-2Ig fusion protein in a standard immunoprecipitation assay. Alternatively, the binding of a CTLA4-immunoglobulin fusion protein to a cell which expresses a CTLA4 ligand, such as a B7-1 or B7-2, on its surface can be assessed. For example, a cell expressing a CTLA4 ligand, such as a CHO cell transfected to express B7-1, is contacted with the CTLA4-immunoglobulin fusion protein and binding detected by indirect immunostaining using, for example, a FITC-conjugated reagent (e.g., goat anti-mouse Ig serum for murine monoclonal antibodies or goat anti-human IgCγ serum for fusion proteins) and fluorescence analyzed by FACS® analysis(Becton Dickinson & Co., Mountain View, Calif.).
- Other suitable assays take advantage of the functional characteristics of the CTLA4-immunoglobulin fusion protein. As previously set forth, the ability of T cells to synthesize cytokines depends not only on occupancy or cross-linking of the T cell receptor for antigen (“the primary activation signal provided by, for example antigen bound to an MHC molecule, anti-CD3, or phorbol ester to produce an “activated T cell”), but also on the induction of a costimulatory signal, in this case, by interaction of a B7 family protein (e.g., B7-1 or B7-2) with its ligand (CD28 and/or CTLA4) on the surface of T cells. The B7:CD28/CTLA4 interaction has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2, which in turn stimulates the proliferation of the T lymphocytes. In one embodiment, the CTLA4-immunoglobulin fusion proteins of the invention have the functional property of being able to inhibit the B7:CD28/CTLA4 interaction. Accordingly, other screening assays for identifying a functional CTLA4-immunoglobulin fusion protein involve assaying for the ability of the fusion protein to inhibit synthesis of cytokines, such as interleukin-2, interleukin-4 or other known or unknown novel cytokines and/or the ability to inhibit T cell proliferation by T cells which have received a primary activation signal.
- The ability of a CTLA4-immunoglobulin fusion protein of the invention to inhibit or block an interaction between a B7 family protein (e.g., B7-1 or B7-2) with its receptor on T cells (e.g., CD28 and/or CTLA4) can be assessed in an in vitro T cell culture system by stimulating T cells with a source of ligand (e.g., cells expressing B7-1 and/or B7-2 or a secreted form of B7-1 and/or B7-2) and a primary activation signal such as antigen in association with Class II MHC (or alternatively, anti-CD3 antibodies or phorbol ester) in the presence or absence of the CTLA4-immunoglobulin fusion protein. The culture supernatant is then assayed for cytokine production, such as interleukin-2, gamma interferon, or other known or unknown cytokine. For example, any one of several conventional assays for interleukin-2 can be employed, such as the assay described inProc. Natl. Acad. Sci. USA, 86:1333 (1989). An assay kit for interferon production is also available from Genzyme Corporation (Cambridge, Mass.). T cell proliferation can be measured in vitro by determining the amount of 3H-labeled thymidine incorporated into the replicating DNA of cultured cells. The rate and amount of DNA synthesis and, in turn, the rate of cell division can thus be quantified. A lack of or reduction in the amount of cytokine production and/or T cell proliferation by stimulated T cells upon culture with a CTLA4-immunoglobulin fusion protein of the invention indicates that the fusion protein is capable of inhibiting the delivery of a costimulatory signal to the T cell by inhibiting an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) and a receptor therefor (e.g., CD28 and/or CTLA4).
- The ability of the CTLAIg fusion protein to induce antigen-specific T cell unresponsiveness or anergy can also be assessed using the in vitro T cell culture system described above. Following stimulation of the T cells with a specific antigen bound to MHC molecules on an antigen presenting cell surface and CTLA4 ligand (e.g., B7-1 on the antigen presenting cell surface) in the presence of CTLA4-immunoglobulin fusion protein, the T cells are subsequently restimulated with the antigen in the absence of CTLA4-immunoglobulin fusion protein. A lack of cytokine production and/or T cell proliferation upon antigenic restimulation by T cells previously treated with a CTLA4-immunoglobulin fusion protein of the invention indicates that the fusion protein has induced a state of antigen-specific anergy or non-responsiveness in the T cells. See, e.g., Gimmi, C. D. et al. (1993)Proc. Natl. Acad. Sci. USA 90:6586-6590; and Schwartz (1990) Science 248:1349-1356, for assay systems that can used to examine T cell unresponsiveness in accordance with the present invention.
- In yet another assay, the ability of a CTLA4-immunoglobulin fusion protein of the invention to inhibit T cell dependent immune responses in vitro is determined. The effect of a CTLA4-immunoglobulin fusion protein on Th-induced immunoglobulin production by B cells can be assessed by contacting antigen-specific CD4+ T cells with syngeneic antigen-specific B cells, antigen and the CTLA4-immunoglobulin fusion protein. The cell culture supernatant is assayed for the production of immunoglobulin, such as IgG or IgM, using, for example, a solid phase ELISA or a standard plaque assay. Inhibition of B cell immunoglobulin production by treatment of the culture with the CTLA4-immunoglobulin fusion protein indicates that the protein is capable inhibiting T helper cell responses and, consequently, T cell dependent B cell responses.
- IV. Compositions of CTLA4-Immunoglobulin Fusion Proteins
- The CTLA4-immunoglobulin fusion proteins of the invention can be incorporated into compositions suitable for administration to subjects to thereby modulate immune responses or for other purposes (e.g., antibody production). The CTLA4-immunoglobulin fusion protein in such compositions is in a biologically compatible form suitable for pharmaceutical administration in vivo. By “biologically compatible form suitable for administration in vivo” is meant a form of the protein to be; administered in which any toxic effects are outweighed by the therapeutic effects of the protein. The term subject is intended to include living organisms in which an immune response can be elicited, e.g., mammals. Examples of subjects include humans, monkeys, dogs, cats, mice, rats, and transgenic species thereof. Administration of a CTLA4-immunoglobulin fusion protein as described herein can be in any pharmacological form including a therapeutically active amount of protein and a pharmaceutically acceptable carrier. Administration of a therapeutically active amount of the therapeutic compositions of the invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a CTLA4-immunoglobulin fusion protein may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of protein to elicit a desired response in the individual. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- The active compound (e.g., CTLA4-immunoglobulin fusion protein) may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
- To administer a CTLA4-immunoglobulin fusion protein by other than parenteral administration, it may be necessary to coat the protein with, or co-administer the protein with, a material to prevent its inactivation. For example, a CTLA4-immunoglobulin fusion protein may be administered to an individual in an appropriate carrier, diluent or adjuvant, co-administered with enzyme inhibitors or in an appropriate carrier such as liposomes. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Adjuvant is used in its broadest sense and includes any immune stimulating compound, such as interferon. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water emulsions as well as conventional liposomes (Strejan et al., (1984)J. Neuroimmunol 7:27).
- The active compound may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound (e.g., CTLA4-immunoglobulin fusion protein) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (e.g., peptide) plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- When the active compound is suitably protected, as described above, the protein may be orally administered, for example, with an inert diluent or an assimilable edible carrier. As used herein “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
- V. Uses of CTLA4-Immunoglobulin Fusion Proteins Having Reduced IgC Region-Mediated Biological Effector Functions
- A. Immunomodulation
- Given the role of CTLA4 ligands, such as B7-1 and B7-2, in T cell costimulation and the structure and function of the CTLA4-immunoglobulin fusion proteins disclosed herein, the invention provides methods for downregulating immune responses. The reduced IgC-region mediated biological effector functions exhibited by the mutated CTLA4-immunoglobulin fusion proteins of the invention compared to a CTLA4-IgG1 fusion protein may result in more effective downregulation of immune responses in vivo without unwanted side effects (e.g., complement activation, antibody-dependent cellular cytotoxicity, etc.) than if a CTLA4-IgG1 fusion protein were used. For example, improvements in mutated forms of CTLA4-immunoglobulin fusion proteins can be assessed by a variety of assays known to those skilled in the art, including various animal organ (heart, liver, kidney, bone marrow) transplantation models and in animal autoimmune disease models including, but not limited to lupus, multiple sclerosis, diabetes, and arthritis models.
- Downregulation of an immune response by a CTLA4-immunoglobulin fusion protein of the invention may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells, such as T cell proliferation and cytokine (e.g., IL-2) secretion, may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active process which requires continuous exposure of the T cells to the suppressive agent and is often not antigen-specific. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, T cell unresponsiveness or anergy can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent. Immunosuppression and/or T cell unresponsiveness is achieved by blocking the interaction of a CTLA4 ligand on an antigen presenting cell with CTLA4 itself and/or with another receptor for the CTLA4 ligand (e.g., CD28) on the surface of a T cell, e.g., blocking the interaction of a B7 family protein, such as B7-1 and/or B7-2, with a counter-receptor, such as CD28 or CTLA4, on the surface of a T cell. The term “antigen presenting cell” is intended to include B lymphocytes, professional antigen presenting cells (e.g., monocytes, dendritic cells, Langerhan cells) and others cells (e.g., keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes) which can present antigen to T cells. The CTLA4-immunoglobulin fusion proteins of the invention can be used to inhibit CTLA4 ligand/receptor interactions in many clinical situations, as described further below.
- 1. Organ Transplantation/GVHD: Inhibition of T cell responses by a CTLA4-immunoglobulin fusion protein of the invention is useful in situations of cellular, tissue, skin and organ transplantation and in bone marrow transplantation (e.g., to inhibit graft-versus-host disease (GVHD)). For example, inhibition of T cell proliferation and/or cytokine secretion may result in reduced tissue destruction in tissue transplantation and induction of antigen-specific T cell unresponsiveness may result in long-term graft acceptance without the need for generalized immunosuppression. Typically, in tissue transplants, rejection of the graft is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the graft. Administration of a CTLA4-immunoglobulin fusion protein of the invention to a transplant recipient inhibits triggering of a costimulatory signal in alloantigen-specific T cells, thereby inhibiting T cell responses to alloantigens and, moreover, may induce graft-specific T cell unresponsiveness in the recipient. The transplant recipient can be treated with the CTLA4-immunoglobulin fusion protein alone or together with one or more additional agents that inhibit the generation of stimulatory signals in the T cells (e.g., anti-B7-1 and/or anti-B7-2 antibodies, an anti-IL-2 receptor antibody) or induce general immunosuppression (e.g., cyclosporin A or FK506).
- Use of a CTLA4-immunoglobulin fusion protein to inhibit triggering of a costimulatory signal in T cells can similarly be applied to the situation of bone marrow transplantation to specifically inhibit the responses of alloreactive T cells present in donor bone marrow and thus inhibit GVHD. A CTLA4-immunoglobulin fusion protein can be administered to a bone marrow transplant recipient to inhibit the alloreactivity of donor T cells. Additionally or alternatively, donor T cells within the bone marrow graft can be tolerized to recipient alloantigens ex vivo prior to transplantation. For example, donor bone marrow can be cultured with cells from the recipient (e.g., irradiated hematopoietic cells) in the presence of a CTLA4-immunoglobulin fusion protein of the invention prior to transplantation. Additional agents that inhibit the generation of stimulatory signals in the T cells (e.g., anti-B7-1 and/or anti-B7-2 antibodies, an anti-IL-2R antibody etc., as described above) can be included in the culture. After transplantation, the recipient may be further treated by in vivo administration of CTLA4-immunoglobulin (alone or together with another agent(s) which inhibits the generation of a costimulatory signal in T cells in the recipient or inhibits the production or function of a T cell growth factor(s) (e.g., IL-2) in the recipient).
- The efficacy of a particular CTLA4-immunoglobulin fusion protein in inhibiting organ transplant rejection or GVHD can be assessed using animal models that may be predictive of efficacy in humans. Given the homology between CTLA4 molecules of different species, the functionally important aspects of CTLA4 are believed to be conserved structurally among species thus allowing animal systems to be used as models for efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4-IgG1 fusion proteins in vivo as described in Lenschow et al.,Science, 257: 789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci. USA, 89: 11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of treatment with a CTLA4-immunoglobulin fusion protein of the invention on the development of that disease.
- As an illustrative embodiment, a CTLA4-immunoglobulin fusion protein of the invention can be used in a rat model of organ transplantation to ascertain the ability of the fusion protein to inhibit alloantigen responses in vivo. Recipient Lewis rats receive a Brown-Norway rat strain cardiac allograft which is anastamosed to vessels in the neck as described in Bolling, S. F. et al.,Transplant. 453:283-286 (1992). Grafts are monitored for mechanical function by palpation and for electrophysiologic function by electrocardiogram. Graft rejection is said to occur on the last day of palpable contractile function. As an initial test, animals are treated with daily injections of a CTLA4-immunoglobulin fusion protein of interest, an isotype-matched control Ig fusion protein and/or CTLA4-IgG1 (for comparison purposes) for 7 days. Fusion proteins are administered at a dosage range between approximately 0.015 mg/day and 0.5 mg/day. Untreated Lewis rats typically reject heterotopic Brown-Norway allografts in about 7, days. The rejection of allografts by fusion protein-treated animals is assessed in comparison to untreated controls.
- An untreated animal and a fusion protein-treated animal are sacrificed for histological examination. Cardiac allografts are removed from the untreated animal and the treated animal four days after transplantation. Allografts are fixed in formalin, and tissue sections are stained with hematoxylin-eosin. The heart tissue of the untreated and treated animals is examined histologically for severe acute cellular rejection including a prominent interstitial mononuclear cell infiltrate with edema formation, myocyte destruction, and infiltration of arterlolar walls. The effectiveness of the fusion protein treatment in inhibiting graft rejection is supported by a lack of an acute cellular rejection in the heart tissue of the fusion protein treated animals.
- To determine whether fusion protein therapy establishes long term graft acceptance that persists following treatment, animals treated for 7 days with daily injections of fusion protein are observed without additional therapy until cessation of graft function. Graft survival is assessed daily as described above. Allografts are examined histologically from animals in which the graft stops functioning as described above. Induction of graft tolerance by fusion protein treatment is indicated by the continued functioning of the graft following the cessation of treatment with the fusion protein.
- After prolonged graft acceptance, a fusion protein-treated animal can be sacrificed and the lymphocytes from the recipient can be tested for their functional responses. These responses are compared with those of lymphocytes from a control (non-transplanted) Lewis rat, and results are normalized as a percentage of the control response. The T cell proliferative response to ConA and to cells from a Brown-Norway rat and a third party ACI rat can be examined. Additionally, the thymus and spleen from the untreated and treated animals can be compared in size, cell number and cell type (e.g. by flow cytometic analyses of thymus, lymph nodes and spleen cells). Specific nonresponsiveness in the treated animals to alloantigens, as a result of specific clonal deletion of alloreactive cells, is indicated by the ability of the T cells to respond to ConA and third party stimulators (e.g., ACI rat cells) but not to Brown-Norway rat cells. Prolonged acceptance of allografts, including continued graft acceptance following CTLA4-immunoglobulin treatment, in this model system may be predictive of the therapeutic efficacy of the CTLA4-immunoglobulin fusion proteins of the invention in human transplant situations.
- 2. Autoimmune Diseases: Inhibition of T cell responses by a CTLA4-immunoglobulin fusion protein of the invention may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue (i.e., reactive against autoantigens) and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells thus may reduce or eliminate disease symptoms. Administration of a CTLA4-immunoglobulin fusion protein of the invention to a subject suffering from or susceptible to an autoimmune disorder may inhibit autoantigen-specific T cell responses and induce autoantigen-specific T cell unresponsiveness, thereby inhibiting or preventing production of autoantibodies or T cell-derived cytokines which may be involved in the disease process.
- To treat an autoimmune disorder, a CTLA4-immunoglobulin fusion protein of the invention is administered to a subject in need of treatment. For autoimmune disorders with a known autoantigen, it may be desirable to coadminister the autoantigen with the CTLA4-immunoglobulin to the subject. This method can be used to treat a variety of autoimmune diseases and disorders having an autoimmune component, including diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, including keratoconjunctivitis sicca secondary to Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis.
- The efficacy of a CTLA4-immunoglobulin fusion protein of the invention in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed.,Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).
- Experimental Autoimmune Encephalomyelitis (EAE) is a rodent and primate model for multiple sclerosis. In an illustrative embodiment utilizing the passive EAE model, donor mice are immunized with 0.4 mg Myelin Basic Protein (MBP) in Complete Freund's Adjuvant (CFA), divided over four quadrants. The draining axillary and inguinal lymph nodes are removed eleven days later. Lymph node cells (4×106/ml) are plated in 2 ml cultures in 24 well plates, in the presence of 25 μg/ml MBP. After four days in culture, 30×106 of the treated cells are injected into the tail vein of each naive, syngeneic recipient mouse.
- The recipient mice develop a remitting, relapsing disease and are evaluated utilizing the following criteria:
0 normal, healthy 1 limp tail, incontinence; occasionally the first sign of the disease is a “tilt” 2 hind limb weakness, clumsiness 3 mild paraparesis 4 severe paraparesis 5 quadriplegia 6 death - Using the passive model of EAE, the effect of CTLA4-immunoglobulin treatment of the donor cells on resulting disease severity in a recipient animal is tested in mice (e.g., the PLSJLF1/J strain). Culture of lymph node cells in vitro with MBP is performed either in the presence or the absence of about 30 μg/ml of a CTLA4-immunoglobulin fusion protein of the invention, an isotype matched control Ig fusion protein or CTLA4IgG1 (for comparison purposes). The treated cells are then introduced into a syngeneic recipient mouse. The effect of fusion protein treatment of donor cells on the severity of the recipient's first episode of disease as compared to mice receiving untreated cells can be determined using the above-described criteria to assess disease severity. In addition, ensuing relapses in the mice receiving fusion protein-treated cells versus untreated cells can be assessed using the above-described criteria.
- The effect of treating both the donor mice and the cultured donor cells with CTLA4-immunoglobulin on the clinical disease severity in the recipient can further be assessed. In these experiments, donor mice (e.g., of the SJL/J strain) immunized with MBP are given either 100 μg of CTLA4-immunoglobulin fusion protein, an isotype matched control Ig fusion protein or CTLA4-IgG1 (for comparison) intraperitoneally each day for eleven days. Cells are then isolated from lymph nodes of these donors and cultured with MBP in vitro in the presence of either 30 μg/ml of CTLA4-immunoglobulin fusion protein or control fusion proteins. The treated cells are then introduced into a syngeneic recipient. The effect of fusion protein treatment on the severity of the ensuing disease in the recipient is then assessed using the above-described criteria.
- Studies using a direct (active) model of EAE can also conducted. In these experiments, a CTLA4-immunoglobulin fusion protein of the invention or control fusion protein is directly administered to mice immunized with MBP and treated with pertussis toxin (PT). Mice (e.g., the PLSJLFI/J strain) are immunized with MBP on
day 0, injected with PT intravenously ondays days 0 to 7. The effect of direct fusion protein treatment of the MBP-immunized mice on the severity of the ensuing disease is then assessed using the above-described criteria. A reduced severity in disease symptoms in the passive and/or active EAE model as a result of CTLA4-immunoglobulin treatment may be predictive of the therapeutic efficacy of the CTLA4-immunoglobulin fusion proteins of the invention in human autoimmune diseases. - 3. Allergy:
- The IgE antibody response in atopic allergy is highly T cell dependent and, thus, inhibition of CTLA4 ligand/receptor induced T cell activation may be useful therapeutically in the treatment of allergy and allergic reactions. A CTLA4-immunoglobulin fusion protein of the invention can be administered to an allergic subject to inhibit T cell mediated allergic responses in the subject. Inhibition of costimulation of T cells through inhibition of a CTLA4 ligand/receptor interaction may be accompanied by exposure to allergen in conjunction with appropriate MHC molecules. Exposure to the allergen may be environmental or may involve administering the allergen to the subject. Allergic reactions may be systemic or local in nature, depending on the route of entry of the allergen and the pattern of deposition of IgE on mast cells or basophils. Thus, it may be necessary to inhibit T cell mediated allergic responses locally or systemically by proper administration of a CTLA4-immunoglobulin fusion protein of the invention. For example, in one embodiment, a CTLA4-immunoglobulin fusion protein of the invention and an allergen are coadminstered subcutaneously to an allergic subject.
- 4. Virally Infected or Malignant T Cells: Inhibition of T cell activation through blockage of the interaction of a CTLA4 ligand with a receptor therefor on T cells may also be important therapeutically in viral infections of T cells. For example, in the acquired immune deficiency syndrome (AIDS), viral replication is stimulated by T cell activation. Blocking a CTLA4 ligand/receptor interaction, such as the interaction of B7-1 and/or B7-2 with CD28 and/or CTLA4 could lead to a lower level of viral replication and thereby ameliorate the course of AIDS. Surprisingly, HTLV-I infected T cells express B7-1 and B7-2. This expression may be important in the growth of HTLV-I infected T cells and the blockage of B7-1 function together with the function of B7-2 with a CTLA4-immunoglobulin fusion protein, possibly in conjunction with another blocking reagent (such as an anti-B7-2 blocking antibody or a CD28Ig fusion protein) may slow the growth of HTLV-I induced leukemias. In addition, some tumor cells are responsive to cytokines and the inhibition of T cell activation and cytokine production could help to inhibit the growth of these types of cancer cells.
- 5. Antigen-Specific T Cell Unresponsiveness: The methods of the invention for inhibiting T cell responses can essentially be applied to any antigen (e.g., protein) to clonally delete T cells responsive to that antigen in a subject. For example, in one study, administration of a CTLA4-IgG1 fusion protein to mice in vivo suppressed primary and secondary T cell-dependent antibody responses to antigen (Linsley P. S., et al. (1992)Science 257, 792-795). Thus, a subject treated with a molecule capable of inducing a T cell response can be treated with CTLA4-immunoglobulin fusion protein to inhibit T cell responses to the molecule. This basic approach has widespread application as an adjunct to therapies which utilize a potentially immunogenic molecule for therapeutic purposes. For example, an increasing number of therapeutic approaches utilize a proteinaceous molecule, such as an antibody, fusion protein or the like, for treatment of a clinical disorder. A limitation to the use of such molecules therapeutically is that they can elicit an immune response directed against the therapeutic molecule in the subject being treated (e.g., the efficacy of murine monoclonal antibodies in human subjects is hindered by the induction of an immune response against the antobodies in the human subject). Administration of a CTLA4-immunoglobulin fusion protein to inhibit antigen-specific T cell responses can be applied to these therapeutic situations to enable long term usage of the therapeutic molecule in the subject without elicitation of an immune response. For example, a therapeutic antibody (e.g., murine mAb) is administered to a subject (e.g., human), which typically activates T cells specific for the antibody in the subject. To inhibit the T cell response against the therapeutic antibody, the therapeutic antibody is administered to the subject together with a CTLA4-immunoglobulin fusion protein of the invention.
- When used therapeutically, a CTLA4-immunoglobulin fusion protein of the invention can be used alone or in conjunction with one or more other reagents that influence immune responses. A CTLA4-immunoglobulin fusion protein and another immunomodulating reagent can be combined as a single composition or administered separately (simultaneously or sequentially) to downregulate T cell mediated immune responses in a subject. Examples of other immunomodulating reagents include blocking antibodies, e.g., against B7-1, B7-2 or other B cell surface antigens or cytokines, other fusion proteins, e.g., CD28Ig, or immunosuppressive drugs, e.g., cyclosporine A or FK506.
- The CTLA4-immunoglobulin fusion proteins of the invention may also be useful in the construction of therapeutic agents which block immune cell function by destruction of the cell. For example, by linking a CTLA4-immunoglobulin fusion protein to a toxin such as ricin or diptheria toxin, an agent capable of preventing immune cell activation would be made. Infusion of one or a combination of immunotoxins into a patient would result in the death of immune cells, particularly of activated B cells that express higher amounts of B7-1 and/or B7-2.
- B. Screening Assays
- Another application of the CTLA4-immunoglobulin fusion proteins of the invention is the use the protein in screening assays to discover as yet undefined molecules which inhibit an interaction between CTLA4 and a CTLA4 ligand, such as B7-1 or B7-2. For example, the CTLA4-immunoglobulin fusion protein can be used in a solid-phase binding assay in which panels of molecules are tested. In one embodiment, the screening method of the invention involves contacting a CTLA4-immunoglobulin fusion protein of the invention with a CTLA4 ligand and a molecule to be tested. Either the CTLA4-immunoglobulin fusion protein or the CTLA4 ligand is labeled with a detectable substance, such as a radiolabel or biotin, which allows for detection and quantitation of the amount of binding of CTLA4-immunoglobulin to the CTLA4 ligand. After allowing CTLA4-immunoglobulin and the CTLA4 ligand to interact in the presence of the molecule to be tested, unbound labeled CTLA4-immunoglobulin fusion protein or unbound labeled CTLA4 ligand is removed and the amount of CTLA4-immunoglobulin fusion protein bound to the CTLA4 ligand is determined. A reduced amount of binding of CTLA4-immunoglobulin fusion protein to the CTLA4 ligand in the presence of the molecule tested relative to the amount of binding in the absence of the molecule is indicative of an ability of the molecule to inhibit binding of CTLA4 to the CTLA4 ligand. Suitable CTLA4 ligands for use in the screening assay include B7-1 or B7-2 (e.g., B7-1Ig or B7-2Ig fusion proteins can be used). Preferably, either the unlabeled CTLA4-immunoglobulin fusion protein or the unlabeled CTLA4 ligand is immobilized on a solid phase support, such as a polystyrene plate or bead, to facilitate removal of the unbound labeled protein from the bound labeled protein.
- C. Antibody Production
- The CTLA4-immunoglobulin fusion proteins produced from the nucleic acid molecules of the invention can also be used to produce antibodies specifically reactive with the fusion protein and in particular with the CTLA4 moiety thereof (i.e., anti-CTLA4 antibodies). For example, by immunization with a CTLA4-immunoglobulin fusion protein, anti-CTLA4 polyclonal antisera or monoclonal antibodies can be made using standard methods. A mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with an immunogenic form of the fusion protein which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on a protein include conjugation to carriers or other techniques well known in the art. For example, the protein can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies. An ELISA or other immunoassay which distinguishes antibodies reactive with the CTLA4 portion of the fusion protein from those which react with the IgC region are preferred (e.g., the extracellular domain of CTLA4 alone can be used in a standard ELISA to detect anti-CTLA4 antibodies).
- Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera. To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art. Examples include the hybridoma technique originally developed by Kohler and Milstein (Nature (1975) 256:495-497) as well as other techniques such as the human B-cell hybridoma technique (Kozbar et al., Immunol. Today (1983) 4:72), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al. Monoclonal Antibodies in Cancer Therapy (1985) (Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody libraries (Huse et al., Science (1989) 246:1275). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with CTLA4 and monoclonal antibodies isolated.
- The term antibody as used herein is intended to include fragments thereof which are also specifically reactive with a CTLA4-immunoglobulin fusion protein as described herein. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab′)2 fragments can be generated by treating antibody with pepsin. The resulting F(ab′)2 fragment can be treated to reduce disulfide bridges to produce Fab′ fragments. The term “antibody” is further intended to include bispecific and chimeric molecules having an anti-CTLA4-immunoglobulin fusion protein portion, chimeric, antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region, and humanized antibodies in which parts of the variable regions, especially the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Techniques for preparing chimeric or humanized antibodies are well known in the art (see e.g., Morrison et al., Proc. Natl. Acad. Sci. U.S.A. 81:6851 (1985); Takeda et al., Nature 314:452 (1985), Cabilly et al., U.S. Pat. No. 4,816,567; Boss et al., U.S. Pat. No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom Patent GB 2177096B, Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80:7308-7312 (1983); Kozbor et al., Immunology Today, 4:7279 (1983); Olsson et al., Meth. Enzymol., 92:3-16 (1982); PCT Publication WO92/06193 and EP 0239400). Another method of generating specific antibodies, or antibody fragments, reactive against a CTLA4-immunoglobulin fusion protein is to screen expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with a fusion protein produced from the nucleic acid molecules of the invention. For example, complete Fab fragments, V
H regions, FV regions and single chain FV regions can be expressed in bacteria using phage expression libraries. See for example Ward et al., Nature, 341: 544-546: (1989); Huse et al., Science, 246: 1275-1281 (1989); and McCafferty et al., Nature, 348: 552-554 (1990). Screening such libraries with, for example, a CTLA4-immunoglobulin fusion protein can identify immunoglobin fragments reactive with the protein, in particular the CTLA4 portion thereof. - An anti-CTLA4 antibody generated using the CTLA4-immunoglobulin fusion proteins described herein can be used therapeutically to inhibit immune cell activation through blocking receptor:ligand interactions necessary for stimulation of the cell. These so-called “blocking antibodies” can be identified by their ability to inhibit T cell proliferation and/or cytokine production when added to an in vitro costimulation assay as described herein. The ability of blocking antibodies to inhibit T cell functions may result in immunosuppression and/or tolerance when these antibodies are administered in vivo.
- D. Protein Purification
- The CTLA4-immunoglobulin fusion proteins of the invention can be used to isolate CTLA4 ligands from cell extracts or other preparations. For example, a CTLA4-immunoglobulin fusion protein can be used to immunoprecipitate B7-1, B7-2 or an as yet unknown CTLA4 ligand from a whole cell, cytosolic or membrane protein extract prepared from B cells or other antigen presenting cell using standard techniques. Additionally, anti-CTLA4 polyclonal or monoclonal antibodies prepared as described herein using a CTLA4-immunoglobulin fusion protein as an immunogen can be used to isolate the native CTLA4 antigen from cells. For example, antibodies reactive with the CTLA4 portion of the CTLA4-immunoglobulin fusion protein can be used to isolate the naturally-occurring or native form of CTLA4 from activated T lymphocytes by immunoaffinity chromatography using standard techniques.
- This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references and published patent applications cited throughout this application are hereby incorporated by reference.
- The extracellular portion of the T cell surface receptor CTLA4 was prepared as a fusion protein coupled to an immunoglobulin constant region. The immunoglobulin constant region was genetically modified to reduce or eliminate effector activity inherent in the immunoglobulin structure. Briefly, DNA encoding the extracellular portion of CTLA4 was joined to DNA encoding the hinge, CH2 and CH3 regions of human IgCγ1 or IgCγ4 modified by directed mutagenesis. This was accomplished as follows:
- 1. Preparation of Gene Fusions
- DNA fragments corresponding to the DNA sequences of interest were prepared by polymerase chain reaction (PCR) using primer pairs described below. In general, PCR reactions were prepared in 100 μl final volume composed of Taq polymerase buffer (Gene Amp PCR Kit, Perkin-Elmer/Cetus, Norwalk, Conn.) containing primers (1 μM each), dNTPs (200 μM each), 1 ng of template DNA, and Taq polymerase (Saiki, R. K., et al. (1988)Science 239:487-491). PCR DNA amplifications were run on a thermocycler (Ericomp, San Diego, Calif.) for 25 to 30 cycles each composed of a denaturation step (1 minute at 94° C.), a renaturation step (30 seconds at 54° C.), and a chain elongation step (1 minute at 72° C.).
- To create gene fusions encoding hybrid proteins, “zip up” PCR was used. This procedure is diagrammed schematically in FIG. 1. A first set of forward (A) and reverse (C) primers was used to amplify the first gene segment of the gene fusion. A second set of forward (B) and reverse (D) primers was used to amplify the second gene segment of the gene fusion. Primers B and C were designed such that they contained complimentary sequences capable of annealing. The PCR products amplified by primers A+C and B+D are combined, annealed and extended (“zipped up”). The full-length gene fusion was then amplified in a third PCR reaction using the “zip up” fragment as the template and primers A and D as the forward and reverse primers, respectively.
- The structure of each CTLA4 genetic fusion consisted of a signal sequence, to facilitate secretion, coupled to the extracellular domain of CTLA4 and the hinge, CH2 and CH3 domains of human IgCγ1 or IgCγ4. The IgCγ1 and IgCγ4 sequences were modified to contain nucleotide changes within the hinge region to replace cysteine residues available for disulfide bond formation and to contain nucleotide changes in the CH2 domain to replace amino acids thought to be required for IgC binding to Fc receptors and complement activation. The hinge region and CH2 domain amino acid mutations introduced into IgCγ1 and IgCγ4 are illustrated in FIGS. 2A and 2B, respectively.
- A. Construction of CTLA4-Ig Fusion Genes
- 1. Preparation of the Signal Sequence Gene Segment
- PCR amplification was used to generate an immunoglobulin signal sequence suitable for secretion of the CTLA4-Ig fusion protein from mammalian cells. The Ig signal sequence was prepared from a plasmid containing the murine IgG heavy chain gene (described in Orlandi, R., et al. (1989)Proc. Natl. Acad. Sci. USA 86:3833-3837) using the
oligonucleotide 5′CATTCTAGAACCTCGACAAGCTTGAGATCACAGT (SEQ ID NO: 1) TCTCTCTAC-3′ - as the forward primer and the
oligonucleotide 5′CAGCAGGCTGGGCCACGTGCATTGCGGAGTGGAC (SEQ ID NO: 2) ACCTGTGGAGAG-3′ - as the reverse PCR primer. The forward PCR primer (SEQ ID NO: 1) contains recognition sequences for restriction enzymes XbaI and HindIII and is homologous to
sequences 5′ to the initiating methionine of the Ig signal sequence. The reverse PCR primer (SEQ ID NO: 2) is composed of sequences derived from the 5′ end of the extracellular domain of CTLA4 and the 3′ end of the Ig signal sequence. PCR amplification of the murine Ig signal template DNA using these primers resulted in a 233 bp product which is composed of XbaI and HindIII restriction sites followed by the sequence of the Ig signal region fused to the first 25 nt of the coding sequence of the extracellular domain of CTLA4. The junction between the signal sequence and CTLA4 is such that protein translation beginning at the signal sequence will continue into and through CTLA4 in the correct reading frame. - 2. Preparation of the CTLA4 Gene Segment
- The extracellular domain of the CTLA4 gene was prepared by PCR amplification of plasmid phCTLA4. This plasmid contained the sequences corresponding to the human CTLA4 cDNA (see Darivach, P., et al., (1988)Eur. J. Immunol. 18:1901 1905; Harper, K., et al., (1991) J. Immunol. 147: 1047-1044) inserted into the multiple cloning site of vector pBluescript (Stratagene, La Jolla, Calif.) and served as the template for a PCR amplification using the
oligonucleotide 5′-CTCTCCACAGGTGTCCACTCCGCAATGCACGTG (SEQ ID NO: 3) GCCCAGCCTGCTG-3′ - as the forward PCR primer and the
oligonucleotide 5′-TGTGTGTGGAATTCTCATTACTGATCAGAATCT (SEQ ID NO: 4) GGGCACGGTTCTG-3′ - as the reverse PCR primer. The forward PCR primer (SEQ ID NO: 3) was composed of sequences derived from the 3′ end of the Ig signal sequence and the 5′ end of the extracellular domain of CTLA4. This PCR primer is the complementary to murine Ig signal reverse PCR primer (SEQ ID NO: 2). The reverse PCR primer (SEQ ID NO: 4) was homologous to the 3′ end of the extracellular domain of CTLA4, added a BclI restriction site and an additional G nucleotide at the end of the extracellular domain. This created a unique BclI restriction site and added a glutamine codon to the C-terminus of the extracellular domain. The final PCR product was 413 bp.
- 3. Fusion of the Immunoglobulin Signal Sequence and CTLA4 Gene Segments
- The PCR fragments containing the signal and CTLA4 sequences were joined together via a third PCR reaction. Both PCR fragments (1 ng each) were mixed together along with the Ig signal forward PCR primer (SEQ ID NO: 1) and the CTLA4 reverse PCR primer (SEQ ID NO: 4) and PCR amplified as described. In this reaction, the 3′ end of the Ig signal fragment hybridizes with the 5′ end of the CTLA4 fragment and the two strands are extended to yield a full length 600 bp fragment. Subsequent PCR amplification of this fragment using forward (SEQ ID NO: 1) and reverse (SEQ ID NO: 4) yielded sufficient amounts of the signal-CTLA4 gene fusion fragment for cloning. This fragment contains a 5′ XbaI and a 3′ BclI restriction sites flanking the Ig signalCTLA4 gene fusion segment for subsequent cloning.
- 4. Cloning of Immunoglobulin Constant Domain Gene Segments
- Plasmid pSP721gG1 was prepared by cloning the 2000 bp segment of human IgG1 heavy chain genomic DNA (Ellison, J. W., et al., (1982)Nucl. Acids. Res. 10:4071-4079) into the multiple cloning site of cloning vector pSP72 (Promega, Madison, Wis.). Plasmid pSP721gG1 contained genomic DNA encoding the CH1, hinge, CH2 and CH3 domain of the heavy chain human IgCγ1 gene. PCR primers designed to amplify the hinge-CH2-CH3 portion of the heavy chain along with the intervening genomic DNA were prepared as follows. The forward PCR primer,
5′-GCATTTTAAGCTTTTTCCTGATCAGGAGCCCAA (SEQ ID NO: 5) ATCTTCTGACAAAACTCACACATCTCCACCGTCTCC AGGTAAGCC-3′, - contained HindIII and BclI restriction sites and was homologous to the hinge domain sequence except for five nucleotide substitutions which changed the three cysteine residues to serines. The reverse PCR primer,
5′-TAATACGACTCACTATAGGG-3′, (SEQ ID NO: 6) - was identical to the commercially available T7 primer (Promega, Madison, Wis.). Amplification with these primers yielded a 1050 bp fragment bounded on the 5′ end by HindIII and BclI restriction sites and on the 3′ end by BamHI, SmaI, KpnI, SacI, EcoRI, ClaI, EcoR5 and BglII restriction sites. This fragment contained the IgCγ1 hinge domain in which the three cysteine codons had been replaced by serine codons followed by an intron, the CH2 domain, an intron, the CH3 domain and additional 3′ sequences. After PCR amplification, the DNA fragment was digested with HindIII and EcoRI and cloned into expression vector pNRDSH (Repligen; Cambridge, Mass. (diagrammed in FIG. 3)) digested with the same restriction enzymes. This created plasmid pNRDSH/IgG1.
- A similar PCR based strategy was used to clone the hinge-CH2-CH3 domains of human IgCγ4 constant regions. A plasmid, p428D (Medical Research Council, London, England) containing the complete IgCγ4 heavy chain genomic sequence (Ellison, J., et al., (1981)DNA 1: 11-18) was used as a template for PCR
amplification using oligonucleotide 5′GAGCATTTTCCTGATCAGGAGTCCAAATATGGTC (SEQ ID NO: 7) CCCCACCCCATCATCCCCAGGTAAGCCAACCC-3′ - as the forward PCR primer and
oligonucleotide 5′GCAGAGGAATTCGAGCTCGGTACCCGGGGATCCC (SEQ ID NO: 8) CAGTGTGGGGACAGTGGGACCCGCTCTGCCT CCC-3′ - as the reverse PCR primer. The forward PCR primer (SEQ ID NO: 7) contains a BclI restriction site followed by the coding sequence for the hinge domain of IgCγ4. Nucleotide substitutions have been made in the hinge region to replace the cysteines residues with serines. The reverse PCR primer (SEQ ID NO: 8) contains a PspAI restriction site. PCR amplification with these primers results in a 1179 bp DNA fragment. The PCR product was digested with BclI and PspAI and ligated to pNRDSH/IgG1 digested with the same restriction enzymes to yield plasmid pNRDSH/IgG4. In this reaction, the IgCγ4 domain replaced the IgCγ1 domain present in pNRDSH/IgG1.
- 5. Modification of Immunoglobulin Constant Domain Gene Segments
- Modification of the CH2 domain in IgC to replace amino acids thought to be involved in binding to Fc receptor was accomplished as follows. Plasmid pNRDSH/IgG1 served as template for modifications of the IgCγ1 CH2 domain and plasmid pNRDSH/IgG4 served as template for modifications of the IgCγ4 CH2 domain. Plasmid pNRDSH/IgG1 was PCR amplified using a forward PCR primer (SEQ ID NO: 5) and
oligonucleotide 5′-GGGTTTTGGGGGGAAGAGGAAGACTGACGGTGC (SEQ ID NO: 9) CCCC TCGGCTTCAGGTGCTGAGGAAG-3′ - as the reverse PCR primer. The forward PCR primer (SEQ ID NO: 5) has been previously described and the reverse PCR primer (SEQ ID NO: 9) was homologous to the amino terminal portion of the CH2 domain of IgG1 except for five nucleotide substitutions designed to change
amino acids - Plasmid pNRDSH1IgG1 was also PCR amplified with the
oligonucleotide 5′-CATCTCTTCCTCAGCACCTGAAGCCGAGGGG (SEQ ID NO: 10) GCACCGTCAGTCTTCCTCTTCCCCC-3′ - as the forward primer and oligonucleotide (SEQ ID NO: 6) as the reverse PCR primer. The forward PCR primer (SEQ ID NO: 10) is complementary to primer (SEQ ID NO: 9) and contains the five complementary nucleotide changes necessary for the CH2 amino acid replacements. The reverse PCR primer (SEQ ID NO: 6) has been previously described. Amplification with these primers yields a 875 bp fragment consisting of the modified portion of the CH2 domain, an intron, the CH3 domain, and 3′ additional sequences.
- The complete IgCγ1 segment consisting of modified hinge domain, modified CH2 domain and CH3 domain was prepared by an additional PCR reaction. The purified products of the two PCR reactions above were mixed, denatured (95° C., 1 minute) and then renatured (54° C., 30 seconds) to allow complementary ends of the two fragments to anneal. The strands were filled in using dNTP and Taq polymerase and the entire fragment amplified using forward PCR primer (SEQ ID NO: 5) and reverse PCR primer (SEQ ID NO: 6). The resulting fragment of 1050 bp was purified, digested with HindIII and EcoRI and ligated to pNRDSH previously digested with the same restriction enzymes to yield plasmid pNRDSH/IgG1m.
- Two amino acids at
immunoglobulin positions oligonucleotide 5′CGCACGTGACCTCAGGGGTCCGGGAGATCATG (SEQ ID NO: 11) AGAGTGTCCTTGGGTTTTGGGGGGAACAGGAAGA CTGATGGTGCCCCCTCGAACTCAGGTGCTGAG G-3′ - as the reverse primer. The forward primer has been previously described and the reverse primer was homologous to the amino terminal portion of the CH2 domain, except for three nucleotide substitutions designed to replace the amino acids described above. This primer also contained a PmlI restriction site for subsequent cloning. Amplification with these primers yields a 265 bp fragment composed of the modified hinge region, and intron, and the modified 5′ portion of the CH2 domain.
- Plasmid pNRDSH/IgG4 was also PCR amplified with the
oligonucleotide 5′-CCTCAGCACCTGAGTTCGAGGGGGCACCATC (SEQ ID NO: 12) AGTCTTCCTGTTCCCCCCAAAACCCAAGGACACT CTCATGATCTCCCGGACCCCTGAGGTCACGTGC G-3′ - as the forward primer and oligonucleotide (SEQ ID NO: 8) as the reverse PCR primer. The forward PCR primer (SEQ ID NO: 12) is complementary to primer (SEQ ID NO: 11) and contains the three complementary nucleotide changes necessary for the CH2 amino acid replacements. The reverse PCR primer (SEQ ID NO: 8) has been previously described. Amplification with these primers yields a 1012 bp fragment consisting of the modified portion of the CH2 domain, an intron, the CH3 domain, and 3′ additional sequences.
- The complete IgCγ4 segment consisting of modified hinge domain, modified CH2 domain and CH3 domain was prepared by an additional PCR reaction. The purified products of the two PCR reactions above were mixed, denatured (95° C., 1 minute) and then renatured (54° C., 30 seconds) to allow complementary ends of the two fragments to anneal. The strands were filled in using dNTP and Taq polymerase and the entire fragment amplified using forward PCR primer (SEQ ID NO: 7) and reverse PCR primer (SEQ ID NO: 8). The resulting fragment of 1179 bp was purified, digested with BclI and PspAI and ligated to pNRDSH previously digested with the same restriction enzymes to yield plasmid pNRDSH/IgG4m.
- 6. Assembly of CTLA4-Immunoglobulin Fusion Genes
- The PCR fragment corresponding to the Ig signal-CTLA4 gene fusion prepared as described above (sections 1-3) was digested with HindIII and BclI restriction enzymes and ligated to pNRDSH/IgG1, pNRDSH/IgG1m, pNRDSH/IgG4, and pNRDSH/IgG4m previously digested with the same restriction enzymes to create expression plasmids in which the signal-CTLA4-IgG gene fusion segment is placed-under the control of the CMV promoter. The ligated plasmids were transformed intoE. coli JM109 using CaCl2 competent cells and transformants were selected on L-agar containing ampicillin (50 μg/ml; as described in Molecular Cloning: A Laboratory Manual (1982) Eds. Maniatis, T., Fritsch, E. E., and Sambrook, J. Cold Spring Harbor Laboratory). Plasmids isolated from the transformed E. coli were analyzed by restriction enzyme digestion. Plasmids with the expected restriction pattern were sequenced to verify all portions of the signal-CTLA4-IgG gene fusion segments. The final plasmids were named pNRDSH/sigCTLA4-IgG1, pNRDSH/sigCTLA4-IgG1m, pNRDSH/sigCTLA4-IgG4 and pNRDSH/sigCTLA4-IgG4m. The signal-CTLA4-IgG gene fusion segments from each of these constructs were also transferred to the pEE12 expression vector (Biotechnology (1992) 10:169-175).
- The nucleotide and predicted amino acid sequences of the signal-CTLA4-IgG gene fusion segments are shown in the Sequence Listing as follows: sigCTLA4-IgGm-SEQ ID NOS: 23 and 24, sigCTLA4-IgG4-SEQ ID NOS: 25 and 26 and sigCTLA4-IgG4m-SEQ ID NOS: 27 and 28.
- B. Construction of a CTLA4Ab Fusion Gene
- The extracellular domain of CTLA4 is an immunoglobulin superfamily member and is responsible for binding to its ligands B7-1 and B7-2. The replacement of the heavy and light chain variable domains of an antibody molecule with the extracellular domain of CTLA4 will result in an antibody-like protein which can bind specifically to B7-1, B7-2 and other CTLA4 ligands with high affinity. The construction of such a molecule using human IgG1 antibody heavy and light chains is described below.
- 1. Construction of the Heavy Chain Gene
- The Ig signal sequence was prepared from template plasmid pSP72IgG1 by PCR
amplification using oligonucleotide 5′CATTCGCTTACCTCGACAAGCTTGAGATCAC AGTTCTCTCTAC-3′ (SEQ ID NO: 13) as the forward PCR primer andoligonucleotide 5′-GGAGTGGACACCTGTGGAGAG-3′ (SEQ ID NO: 14) as the reverse primer. The forward PCR primer (SEQ ID NO: 13) contains a Hindi restriction site and part of the 5′ untranslated segment of the Ig signal domain. The reverse PCR primer (SEQ ID NO: 14) corresponds to the C-terminus of the natural Ig signal peptide. Amplification with these primers resulted in a 208 bp fragment encoding the entire Ig signal sequence. - The CTLA4 extracellular domain was prepared from plasmid phCTLA4, which contained the entire CTLA4 cDNA sequence, by PCR
amplification using oligonucleotide 5′-CTCCACAGGTGTCCACTCCGCAATGCACGTGGCCCAGCC-3′ (SEQ ID NO: 15) as the forward PCR primer andoligonucleotide 5′GAGGTTGTAAGGACTCACCTGAAA TCTGGGCTCCGTTGC-3′ (SEQ ID NO: 16) as the reverse primer. The forward primer (SEQ ID NO: 15) contained sequences homologous to the 5′ end of the CTLA4 extracellular domain and to the 3′ end of the Ig signal domain. The reverse primer (SEQ ID NO: 16) contained the 3′ end of the CTLA4 extracellular domain and intervening sequences, including a splice acceptor site. Amplification with these primers yielded a 379 bp fragment containing the CTLA4 extracellular domain. - An intervening sequence DNA fragment derived from the intron between the antibody variable and constant (CH1) domains was prepared by PCR
amplification using oligonucleotide 5′GCAACGGAGCCCAGATTTCAGGTGAGTCCTTACAACCTC-3′ (SEQ ID NO: 17) as the forward PCR primer andoligonucleotide 5′GGCTAGATATCTCTAGACT ATAAATCTCTGGCCATGAAG-3′ (SEQ ID NO: 18) as the reverse PCR primer. The forward PCR primer (SEQ ID NO: 17) contains intron sequence and is complementary to the 3′ end of the extracellular domain of CTLA4 and is complimentary to the CTLA4 reverse PCR primer (SEQ ID NO: 16). The reverse primer (SEQ ID NO: 18) contains intron sequences and an additional XbaI restriction site. Amplification with these primers yields a 197 bp fragment. - The PCR fragments encoding the Ig signal, CTLA4 extracellular domain and the intervening sequence were mixed, denatured and renatured to allow hybridization of complementary ends. The strands were filled in and the product amplified using forward (SEQ ID NO: 13) and reverse (SEQ ID NO: 18) PCR primers. The product was a 764 bp fragment which encoded the Ig signal, the CTLA4 extracellular domain, an intron sequence flanked by HindIII and XbaI restriction sites. This DNA fragment was digested with HindIII and XbaI and ligated to pSP72IgG1, resulting in the CTLA4 extracellular domain being linked to a 5′ Ig signal sequence and a 3′ antibody CH1, hinge, CH2, and CH3 domains.
- The nucleotide and predicted amino acid sequences of the assembled CTLA4-heavy chain are shown in SEQ ID NOS: 29 and 30, respectively.
- 2. Construction of the Light Chain Gene
- The replacement of a human immunoglobulin antibody light chain variable domain (Hieter, P. A., et al., (1980)Cell 22:197) with the CTLA4 extracellular domain proceeded as follows. The Ig signal fragment was prepared as for the heavy chain replacement, described above. The CTLA4 extracellular domain was prepared using a forward PCR primer (SEQ ID NO: 15) previously described and
oligonucleotide 5′GGCACTAGGTCGACTCTAGAAACTGAGGAAGC (SEQ ID NO: 19) AAAGTTTAAATTCTACTCACGTTTAATCTGGGCT CCGTTGC-3′ - as the reverse primer. The reverse primer contained sequences of the 3′ end of the CTLA4 extracellular domain, a splice receptor, and intervening sequence DNA containing an XbaI restriction site. The Ig signal fragment and the CTLA4 extracellular domain were joined by mixing the DNA fragment, denaturing, and renaturing to anneal their complementary ends. The strands were filled in and the fragment PCR amplified using forward (SEQ ID NO: 13) and reverse (SEQ ID NO: 19) PCR primers previously described. The resulting DNA fragment was digested with the HindIII and XbaI and ligated to immunoglobulin light chain vector pαLYS17 digested with the same enzymes. The resulting plasmid pCTLA4kappa contains an Ig signal sequence, an intron, the CTLA4 extracellular domain, an intron, and the light chain (kappa) constant domain.
- The nucleotide and predicted amino acid sequences of the assembled CTLA4-light chain are shown in SEQ ID NOS: 31 and 32, respectively.
- The DNA segments encoding the recombinant heavy and light chains were transferred to the pEE12 vector or the pNRDSH vector and stable NS0 or CHO expression cell lines established as described below. CHO and NS0 supernatants were assayed for the production of CTLA4 light chain and CTLA4 heavy chain fusion proteins by ELISA and binding to B7-1 was measured using CHO/hB7-1 expressing cells and FACS (as described in Example 2). It is also contemplated that the heavy and light chain constructs of the present invention be expressed in the same vector and host cells transfected in one step.
- C. Expression of CTLA4 Fusion Proteins in CHO and NS0 Cells
- The various CTLA4-immunoglobulin fusion proteins were expressed in CHO cells as follows. Briefly, 5×105 CHO-DG44 cells (subline of CHO-K1, available from ATCC) were transfected with 10 μg of the appropriate expression plasmid (pNRDSH series) by the calcium phosphate method (described in Molecular Cloning: A Laboratory Manual (1982) Eds. Maniatis, T., Fritsch, E. E., and Sambrook, J. Cold Spring Harbor Laboratory) using a commercially available kit (5 Prime to 3′ Prime Inc., Boulder, Colo.) according to the manufacturer's instructions. The transfected cells were allowed to recover in nonselective media (alpha MEM medium containing 10% heat inactivate fetal bovine serum (FBS), Gibco/BRL, Gaithersburg, Md.) for two days and then plated in selective media (alpha MEM minus nucleoside medium containing 10% FBS and 550 μg/ml G418; Gibco/BRL, Gaithersburg, Md.). Individual subclones were obtained by dilution cloning in selective media. Culture media was assayed for the presence of secreted CTLA4-immunoglobulin by a standard ELISA designed to detect human IgG.
- The various CTLA4-immunoglobulin and CTLA4Ab fusion proteins were expressed in NS0 cells (Golfre, G. and Milstein C. P. (1981) Methods Enzymol. 73B: 3-46) as follows. Briefly, 107 NS0 cells were transfected by electroporation (using a BioRad Gene Pulser, Hercules, Calif.) with 40 μg of the appropriate expression plasmid (pEE12 series) previously linearized by digestion with SalI restriction endonuclease. The transfected cells were selected using DMEM media deficient in glutamine (Gibco/BRL, Gaithersberg Md.). Individual subclones were isolated by dilution cloning in selective media. Culture media assayed for the presence of secreted CTLA4-Ig or CTLA4Ab fusion protein by a standard ELISA assay designed to detect human IgG.
- As a representative example, transfection of either the pNRDSH/sigCTLA4-IgG4m and pEE12/sigCTLA4-IgG4m expression vector into CHO or NS0 host cells resulted in selected subclones that secreted hCTLA4IgG4m fusion protein into culture supernatants at a concentration of 75-100 μg/ml.
- D. Purification of CTLA4 Fusion Proteins
- The CTLA4-Ig and CTLA4Ab fusion proteins are purified from the culture medium of transfected CHO or NS0 cells as follows. Culture medium was concentrated 10 fold by ultra filtration (Ultrasette, Filtron Technology Corp., Northborough, Mass.) and batch bound overnight to immobilized protein A (IPA-300, Repligen Corp., Cambridge, Mass.). The protein-bound resin was poured into a chromatography column, washed with 10 column volumes of optimal binding buffer (1.5 M glycine, 3M NaCl, pH 8.9) and the bound CTLA4-Ig or CTLA4Ab was eluted by the addition of 0.1 M Na citrate, pH 3.0. Fractions were collected and neutralized with the addition of 1 M Tris base to pH of 7.0. The Abs280nm was monitored for each fraction and peak fractions were analyzed by SDS-PAGE, followed by Coomassie Blue staining and Western blot analysis using an anti-CTLA4 polyclonal antiserum (described in Lindsten, T. et al. (1993) J. Immunol. 151:3489-3499). Fractions containing CTLA4-Ig or CTLA4Ab were pooled and dialyzed against 200 volumes of 0.5× PBS overnight at 4° C. The purified protein was assayed for binding to its ligand (B7-1 and/or B7-2) as described in Example 2.
- The ability of the various CTLA4-Ig forms and CTLA4Ab to bind to their counter receptors B7-1 (Freeman, G. F., et al. (1988)J. Immunol. 143:2714-2722) and B7-2 (Freeman, G. F., et al., (1993) Science 262: 909-911) was demonstrated using the following assays.
- A. Fluorescence Activated Cell Staining (FACS).
- Purified preparations of the various recombinant CTLA4 forms were tested for their ability to bind to transfected COS cell transiently expressing hB7-1 or hB7-2 or transfected CHO cells stably expressing hB7-1 or hB7-2. The recombinant CTLA4 protein (10 μg/ml) was incubated with B7 expressing cells (2×106 cells) for 1 hr on ice in FACS wash solution (1% bovine serum albumin in PBS). The cells were washed 3 times with FACS wash solution. The cell bound CTLA4 was detected by reaction with anti-human Ig-FITC (Dako Corporation, Carpintera, Calif.) or protein A-FITC (Dako) for 30 mintues on ice in the dark. The cells were washed twice with FACS wash solution and then fixed in 1% paraformaldehyde in PBS. The cells were analyzed for fluorescence intensity using a Becton Dickinson (San Jose, Calif.) FACS analyzer. Murine anti-human mAbs reactive with either hB7-1 or hB7-2 served as positive control reagents for the hB7-1 and hB7-2 receptor expressing cells. These mAbs were detected using goat anti-murine IgG-FITC (Dako corporation, Carpintera, Calif.) and analyzed as above. Untransfected COS and CHO cells served as negative controls for each cell line. The results of this experiment demonstrated that CTLA4 immunoglobulin fusion proteins bind to CHO cells transfected to express CTLA4 ligands.
- B. Competitive Binding ELISA
- The ability of the various recombinant CTLA4 forms to bind to hB7-1 or hB7-2 was assessed in a competitive binding ELISA assay. This assay was established as follows. Purified recombinant hB7-Ig (50 μl at 20 μg/ml in PBS) was bound to a Costar EIA/RIA 96 well microtiter dish (Costar Corp, Cambridge Mass., USA) overnight at room temperature. The wells were washed three times with 200 μl of PBS and the unbound sites blocked by the addition of 1% BSA in PBS (200 μl/well) for 1 hour at room temperature. The wells were washed again as above. Biotinylated hCTLA4-IgG1 (prepared according to manufacturers instructions (Pierce, Rockford, Ill.) at 10 μg/ml serially diluted in twofold steps to 15.6 ng/ml; 50 μl/well) was added to each well and incubated for 2.5 hours at room temperature. The wells were washed again as above. The bound biotinylated hCTLA4IgG1 was detected by the addition of 50 μl of a 1:2000 dilution of streptavidin-HRP (Pierce Chemical Co., Rockford, Ill.) for 30 minutes at room temperature. The wells were washed as above and 50 μl of ABTS (Zymed, Calif.) added and the developing blue color monitored at 405 nm after 30 min.
- The ability of the various forms of CTLA4 to compete with biotinylated CTLA4-IgG1 was assessed by mixing varying amounts of the competing protein with a quantity of biotinylated CTLA4-IgG1 shown to be non-saturating (i.e., 70 ng/ml; 1.5 nM) and performing the binding assays as described above. A reduction in the signal (Abs405nm) expected for biotinylated CTLA4-IgG1 indicated a competition for binding to plate-bound hB7-1 or hB7-2. A graphic representation of a typical binding assay illustrating the competition of biotinylated hCTLA4-IgG1 with hCTLA4-IgG1 (itself) or hCTLA4-IgG4m is shown in FIG. 4A for binding to hB7-1 and FIG. 4B for binding to hB7-2. The competition curves show that the mutant IgG4 form competes with hCTLA4-IgG1 for binding to B7-1 or B7-2 with the same binding kinetics as the unlabeled IgG1 form itself. Accordingly, mutation of the hinge region and CH2 domain of IgCγ4 in the CTLA4 fusion protein as described herein does not detrimentally affect the ligand binding activity of the CTLA4 fusion protein.
- C. SDS-PAGE and Western Blotting
- The various CTLA4 forms were analyzed by SDS-PAGE followed by detection using Coomassie Blue staining or Western blotting. The CTLA4 proteins were separated on both reducing and non-reducing SDS-PAGE gels (9, 12, or 15% gels with 5% stacking gel) and stained with Coomassie Blue using standard methods. Protein size was estimated from comparison to commercial size standards (BioRad, Hercules, Calif.). Western blots were performed using standard procedures and Immobilon blotting membranes (Millipore, New Bedford, Mass.). The CTLA4 was detected using a polyclonal antisera raised in rabbit immunized with the extracellular domain of CTLA4 produced inE. coli (described in Lindsten, T. et al. (1993) J. Immunol. 151:3489-3499). The CTLA4 was visualized using [125I]-protein A (Dupont NEN, Boston, Mass.) followed by autoradiography or using protein A-HRP. The results indicated the presence of an immunoreactive band at approximately 50 kD.
- D. Measurement of Fc Receptor Binding
- The binding of the various CTLA4-Ig forms and CTLA4Ab to Fc receptors was assessed by using a competitive binding assay as described in Alegre, M.-L., et al., (1992)J. Immunol. 148:3461 3468. Human cell line U937 was used as a source of the FcRI and FcRII receptors (Looney, R. J., et al., (1986) J. Immunol. 36:1641). U937 cells were grown with 500 U/ml IFN-γ to upregulate expression of FcR1. The U937 cells were used at a concentration of 6.25×106 cells/ml. Preparations of unlabeled CTLA4-IgG1, CTLA4-IgG4 and human IgG1 were serially diluted to a concentration of 2×10−10 M. To each serial dilution, a fixed amount of 125I-labeled protein (e.g., CTLA4-IgG1, CTLA4-IgG4 or human IgG1) was added. The U937 cells were then added to the mixture and incubated for three hours. The cells were separated from unbound labeled and unlabeled protein by centrifugation through silicone oil for one minute at 14000×g. The tips of the tubes with the pelleted cells were then cut off and analyzed in a gamma counter. Maximal binding of labeled protein to U937 cells was determined in the absence of unlabeled competitor protein. Percent specific activity represents the percentage of labeled protein bound in the presence of unlabeled competitor protein relative to maximal binding. FIG. 5A graphically illustrates the amount of labeled CTLA4-IgG1 bound to U937 cells (expressed in counts per minute) in the presence of unlabeled CTLA4-IgG1 or CTLA4-IgG4. Unlabeled CTLA4-IgG1 was able to compete with labeled CTLA4-IgG for binding to FcR1 on U937 cells (i.e., the amount of bound labeled protein was reduced), whereas unlabeled CTLA4-IgG4 did not compete for binding. FIG. 5B graphically illustrates the percent specific activity of labeled human IgG1, CTLA4-IgG1 and CTLA4-IgG4 being competed with themselves (unlabeled). The IC50 for human IgG1 was approximately 7.5×10−8 M. The IC50 for CTLA4-IgG1 was approximately 7×10−8 M. An IC50 for CTLA4-IgG4 could not be determined because this protein did not bind to the FcR1. These results demonstrate that use of an IgCγ4 constant region in a CTLA4-Ig fusion protein essentially eliminates the ability of the fusion protein to bind to Fc receptors.
- E. Measurement of Complement Activation
- CTLA4-immunoglobulin forms were tested in a ligand-specific assay for complement activation. CHO cells expressing hB7-1 on their surface were grown to confluence in tissue culture dishes. After washing away serum and medium, the cells were exposed to BCECF/AM ([2′,7-bis-(carboxyethyl)-5,(6′)-carboxylfluorescein acetoxymethyl)-ester] Calbiochem, La Jolla, Calif.) a fluorescent dye that irreversibly loads into the cells. The cells (5×105) were then incubated with hCTLA4-immunoglobulin fusion proteins or a monoclonal antibody specific for hB7-1 (4B2). Unbound protein was washed away and a complement source was added and allowed to react with the cells for 30 minutes. Complement sources tested included guinea pig complement and human serum (as a source of human complement). After incubation with the complement source, lysis was measured by monitoring the release of the fluorescent dye from the cells using a fluorometer. Controls included parallel experiments with hB7-1 negative CHO cells. Identical cultures were also tested for their ability to bind the hCTLA4 forms under similar assay conditions. Additionally, to distinguish a lack of an ability to activate complement from a lack of an ability to bind B7-1, an ELISA-type assay of CTLA4 binding to CHO-B7-1 cells was performed as a control (described further below).
- The results of typical complement activation assays are shown in FIGS.6A-C. FIG. 6A graphically illustrates guinea pig complement-mediated lysis of CHO-B7-1 cells by CTLA4-IgG1, CTLA4-IgG4m and the anti-B7-1 monoclonal antibody 4B2. hCTLA4-IgG1 reproducibly activated guinea pig complement as well or better than the 4B2 mAb. The hCTLA4-IgG4m did not activate complement in this assay, even at concentration 100-fold higher than that needed for CTLA4-IgG1. The results were confirmed by repeating the work with human serum as the complement source, shown in FIG. 6B. Human complement produced a higher percentage lysis than the guinea pig complement, however, otherwise the results were the same, with the hCTLA4-IgG4m exhibiting a markedly reduced ability to activate complement in comparison to CTLA4-IgG1. The effect of the CTLA4 fusion proteins on complement activation is specific for the B7-1 ligand, as untransfected CHO cells were not substrates for complement activation by any of the proteins tested, illustrated in FIG. 6C (using guinea pig complement as the complement source).
- In order to verify that the hCTLA4-IgG4m form was still able to bind to membrane bound hB7-1, an experiment was performed by a similar method as for the complement activation study. Antibody or hCTLA4 forms were bound to washed CHO-B7-1 cells under conditions identical to those used in the complement activation studies except that instead of adding complement in the final step, an HRP-conjugated anti-Ig Fc (Calbiochem, La Jolla, Calif.) was used. Bound HRP was detected by washing the cells, adding ABTS substrate and measuring absorbence at 405 nm (as described above for the competition ELISA assay). The results are shown graphically in FIG. 7. All three B7-1 specific proteins (mAb 4B2, hCTLA4-IgG1 and hCTLA4-IgG4m) bound to the cells. The corresponding experiment using untransfected CHO cells showed no binding of the proteins to the cells. The difference in the maximal O.D. signals for the different proteins is likely due to the different affinities of the forms of Fc regions for the HRP-conjugated secondary antibodies.
- F. Inhibition of T Cell Proliferation
- The ability of the CTLA4-Ig forms and CTLA4Ab to inhibit the proliferation of T cells in a costimulation proliferation assay was measured. CD4+ T cells are prepared from human blood by density gradient centrifugation on Ficoll-Hypaque (Sigma, St. Louis, Mo.). Monocytes were removed by adherence to plastic and the CD4+ cells further enriched by removal of residual monocytes, B cells, NK cells and CD8+ T cells by lysis with complement and mAbs (anti-CD14, antiCD11b, anti-CD20, anti-CD16 and anti-CD8) or by negative selection using the same immunomagnetic beads (Advanced Magnetics, Cambridge, Mass.) (as described in Boussioutis, V. A., et al., (1993) J. Exp. Med. 178:1758-1763). CD4+ T cells (105) were cultured in the presence of immobilized anti-CD3 mAb (coated at 1 ug/well, overnight) and CHO cells expressing hB7-1 or hB7-2 (2×104) in a microtiter plate with or without one of the CTLA4 forms and incubated for 3 days. Thymidine incorporation as a measure of mitogenic activity was assessed after overnight incubation in the presence of [3H] thymidine (Gimmi, C. D., et al., (1991) Proc. Natl. Acad. Sci USA 88:6575-6579). Inhibition was calculated as a percent of proliferation in control cultures. The data show that both the CTLA4IgG1 and CTLA4Ig4m performed well, inhibiting T cell proliferation to the same extent when used in equivalent amounts, i.e. the two compounds were indistinguishable in potentcy.
- G. Pharmacokinetic Studies
- The effect of mutating the IgG4 heavy chain, as described herein, on the pharmacokinetics of a CTLA4Ig in rats was examined. Pharmacokinetics were performed on two CTLA4If differing only in their heavy chain constant domains, where one form contained the wild type human IgG1Ig (referred to as hCTLA4IgG1) and the second antibody contained the mutated version of human IgG4 (referred to as hCTLA4IgG4m). Two Sprague-Dawley male rats weighing 0.3-0.4 kg were used for each protein. The CTLA4Ig forms were infused at a dose of 2 mg/kg via a Teflon angiocath which was placed in the marginal ear vein. Two control animals received an infusion of PBS (Ca++Mg++ free) in the same manner. Blood samples were drawn at 0, 15, 30, 60, 90, 360, 480 minutes, 24, 36, 48 hours, 7, 14 and 28 days. The concentration of free antibody in heparinized plasma was determined by a standard ELISA. Antibody clearance rates were determined. α and β t1/2values were calculated using the P-Fit subroutine of the BIOSOFT Fig-p figure processor/parameter fitter. The results are shown below:
- hCTLA4IgG1
- α t1/2=4.2 min
- β t1/2=288 min
- hCTLA4IgG4m
- α t1/2=16.6 min
- β t1/2=214.2 min
- Both CTLA4IgG1 and CTLA4IgG4m have similar clearance rates, with a rapid (4-16 min) α phase and a more prolonged (214-288 min) β phase indicating a serum half life of approximately 4 hours.
- A. Intracellular Expression of CTLA4 inE. coli
- 1. Cloning and Expression of CTLA4 Extracellular Domain
- The extracellular domain of CTLA4 was expressed inE. coli after cloning into expression vector pETCm11a. This vector was derived from expression vector pET-11a (Novagen Inc., Madison Wis.) by cloning a chloramphenicol resistance gene cassette into the ScaI restriction site within the ampicillin resistance gene. The extracellular domain of CTLA4 was prepared from plasmid phCTLA4 by PCR
amplification using oligonucleotide 5′GCAGAGAGACAT ATGGCAATGCACGTGGCCC (SEQ ID NO: 20) AGCCTGCTGTGG-3′ - as forward primer and
oligonucleotide 5′-GCAGAGAGAGGATCCTCAGTCAGTTAGT (SEQ ID NO: 21) CAGAATCTGGGCACGGTTCTGG-3′ - as reverse primer. The forward PCR primer (SEQ ID NO: 20) contains an NdeI restriction site in which the ATG sequence in the NdeI restriction site is followed immediately by the codon for the first amino acid of mature CTLA4 (Dariavach, P., et al. (1988)Eur. J. Immunol. 18:1901). The reverse PCR primer (SEQ ID NO: 21) contains a BamHI restriction site preceded by translation stop codons in all three reading frames preceded by the last amino acid just prior to the CTLA4 transmembrane domain. PCR amplification with these primer yields a 416 bp fragment bounded by NdeI and BamHI restriction sites which contains DNA sequences encoding the extracellular domain of CTLA4 preceded by a methionine codon. The PCR product was digested with NdeI plus BamHI and ligated to expression vector pETCm11a digested with the same restriction enzymes.
- The ligated DNA was transfected intoE. coli strains BL21, HMS 174, RGN714 and RGN715 containing the lambda DE3 helper phage by standard techniques. Transformants were selected in L-agar containing chloramphenicol at 50 ug/ml. Individual transformants were selected and tested for CTLA4 expression after induction by treatment of cells with 0.5 mM IPTG. Whole cell extracts were analyzed on SDS-PAGE gel followed by Coomassie Blue staining and Western blot analysis. The majority of the CTLA4 protein in these cells was found in inclusion bodies.
- 2. Purification of CTLA4 from Inclusion Bodies
- Recombinant CTLA4 was recovered from cell pellets by treating the washed cells in lysis buffer (50 mM Tris-HCl pH 8.0, 1 mM PMSF, 5 mM EDTA, 0.5% Triton X-100, and lysozyme at 0.3 mg/ml) followed by sonication. The inclusion bodies were recovered by centrifugation at 20,000×g and solubilized by treatment with solubilization buffer (50 mM Tris-HCl pH8.0, 8 M urea, 50 mM 2-mercaptoethanol (2-ME)). The solubilization was assisted by mixing for two hours at room temperature. The soluble fraction contained CTLA4. The CTLA4 was purified by chromatography on S-sepharose (Pharmacia, Piscataway, N.J.) as follows. The CTLA4 containing supernatant was adjusted to pH 3.4 by the addition of glacial acetic and applied to a S-sepharose column equilibrated in column buffer (100 mM Na-acetate, pH6.5, 8 M urea, 50 mM 2-ME, and 5 mM EDTA). The column was washed with column buffer and the bound CTLA4 eluted with a linear salt gradient (NaCl, 0 to 1 M) prepared in column buffer. Peak fractions exhibiting high Abs280nm values were pooled and dialyzed against dialysis buffer (100 mM Tris-HCl, pH8.0, 8 M urea, 50 mM, 2-ME, 5 mM EDTA). Remaining contaminating proteins were eliminated by chromatography on a Sephacryl S-100 (Pharmacia, Piscataway, N.J.) sizing column. The resulting preparation was greater than 95% pure CTLA4 as estimated by SDS-PAGE followed by Coomassie Blue staining and Western blot analysis. Since the estimated size of monomeric recombinant CTLA4 produced in E. coli was approximately 15 kDa, all steps of the purification protocol were tested for the presence of a 15 kDa protein by SDS-PAGE and the presence of CTLA4 verified by Western blotting.
- 3. Refolding of Denatured CTLA4
- The CTLA4 protein purified from inclusion bodies is fully reduced and denatured and must be properly refolded in a physiological buffer, with intact disulfide bridges, to be in “active” form (i.e., able to bind hB7-1). To avoid solubility problems a step gradient dialysis procedure was used to remove urea, detergents and reductants. The most successful refolding was obtained when the secondary and tertiary protein structure was encouraged first, by gradient dialysis, removing all urea and detergent while in the presence of the reductant DTT. Subsequent slow removal of the DTT appeared to reduce the number of random intradisulfide bonds. As a control, a sample of CTLA4 was dialyzed directly from gel filtration buffer to PBS.
- The success of refolding was estimated by immunoprecipitation. 5 μg of hB7-1-Ig, bound to protein A resin, was used to pull down active CTLA4 from a 10 μg aliquot of each refolding trial. Precipitated protein was run on a reducing SDS-PAGE, transferred to an Immobilon membrane (Millipore, New Bedford, Mass.) and probed with polyclonal antisera to CTLA4 (antisera 1438, described in Lindsten, T. et al. (1993)J. Immunol. 151:3489-3499). The relative amount of protein detected at 15 kDa was indicative of the success of the refolding process. Refolding was also evaluated by assaying CTLA4 binding activity in a competition ELISA as described in Example 2. A successful refolding consisted of approximately 5% active protein, or about 2 mg of active protein from a 1 L bacterial culture.
- B. Preparation of Secreted CTLA4 fromE. coli
- A secreted form of CTLA4 was prepared fromE. coli as follows. The extracellular domain of CTLA4 was joined to the pelB signal sequence (Lei. S.-P., et al., (1987) J. Bacteriol. 169: 4379-4383) by PCR using plasmid phCTLA4 as template and
oligonucleotide 5′GGCACTAGTCATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACT (SEQ ID NO: 20) CGCTGCCCAACCAGCGATGGCCGCAGCAATGCACGTGGCCCAGCCTGCTGTGG3′ - as the forward primer and a reverse primer (SEQ ID NO: 21) previously described. The
forward PCR primer 5′-GGCACTAGTCATGAAATACCTATTGCCT (SEQ ID NO: 22) ACGGCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCGATGGCCGCAGCAA TGCACGTGGCCCAGCCTGCTGTGG-3′ - contains a unique BspHI restriction site, the complete pelB signal sequence and the 5′ end of the extracellular domain of CTLA4. The reverse PCR primer (SEQ ID NO: 21) contains a unique BamH1 restriction site preceded by translational stop codons in all three reading frames preceded by the last amino acid before the transmembrane domain of CTLA4. PCR amplification with these primers yielded a 480 by fragment bounded by unique BspHI and BamHI restriction sites encoding the pelB signal sequence joined to the CTLA4 extracellular domain.
- After PCR amplification, the DNA fragment was digested with BspHI and BamHI and ligated to expression vector pTrc99A (Pharmacia, Piscataway, N.J.) previously digested with NcoI and BamHI. This resulted in a plasmid in which the expression of the pelB-CTLA4 protein was driven by the pTrc promoter present in the pTrc99A expression vector.E. coli host strains transformed with the ligated DNA were selected on L-agar containing ampicillin (50 μg/ml) and individual clones isolated. The expression of CTLA4 in these strains was induced by the treatment of exponentially growing cultures with IPTG (0.5 mM) overnight. Extracts were prepared from the culture medium after concentration or by release from periplasm. To prepare periplasmic extracts, cells were incubated in 20% sucrose, 10 mM Tris-HCl pH7.5 for 15 minutes at room temperature, collected by centrifugation, and resuspended in 4° C. water and held on ice for 10 min. Extracts were assayed for the presence of CTLA4 by SDS-PAGE, Western blotting and competitive B7-1binding ELISA (as described in Example 2). As shown in FIG. 8, soluble CTLA4 prepared from periplasmic extracts of E. coli or from the media of these cultures was able to compete for binding to B7-1 with unlabelled CTLA4Ig. In contrast, periplasmic extracts from E coli transfected with the vector alone or media from these cultures was not able to compete for binding to B7-1.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
-
0 SEQUENCE LISTING TABLE The sequences referred to in the specification above are provided in the following table. SEQ ID NO: 1 5′ -CATTCTAGAACCTCGACAAGCTTGAGATCACAGTTCTCTCTAC-3′ SEQ ID NO: 2 5′ -CAGCAGGCTGGGCCACGTGCATTGCGGAGTGGACACCTGTGGAGAG-3′ SEQ ID NO: 3 5′ -CTCTCCACAGGTGTCCACTCCGCAATGCACGTGGCCCAGCCTGCTG-3′ SEQ ID NO: 4 5′ -TGTGTGTGGAATTCTCATTACTGATCAGAATCTGGGCACGGTTCTG-3′ SEQ ID NO: 5 5′ -GCATTTTAAGCTTTTTCCTGATCAGGAGCCCAAATCTTCT GACAAAACTCACACATCTCCACCGTCTCCAGGTAAGCC-3′ SEQ ID NO: 6 5′TAATACGACTCACTATAGGG-3′ SEQ ID NO: 7 5′GAGCATTTTCCTGATCAGGAGTCCAAATATGGTCCCCCACCCC ATCATCCCCAGGTAAGCCAACCC-3′ SEQ ID NO: 8 5′GCAGAGGAATTCGAGCTCGGTACCCGGGGATCCCCAGTGTGGGG ACAGTGGGACCCGCTCTGCCTCCC-3′ SEQ ID NO: 9 5′ -GGGTTTTGGGGGGAAGAGGAAGACTGACGGTGCCCCCTCGGCTT CAGGTGCTGAGGAAG-3′ SEQ ID NO: 10 5′ -CATCTCTTCCTCAGCACCTGAAGCCGAGGGGGCACCGTCAGTCT TCCTCTTCCCCC-3′ SEQ ID NO: 11 5′ -CGCACGTGACCTCAGGGGTCCGGGAGATCATGAGAGTGTCCTTG GGTTTTGGGGGGAACAGGAAGACTGATGGTGCCCCCTCGAACTCAG GTGCTGAGG-3′ SEQ ID NO: 12 5′ -CCTCAGCACCTGAGTTCGAGGGGGCACCATCAGTCTTCCTGTTCCC CCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCA CGTGCG-3′ SEQ ID NO: 13 5′CATTCGCTTACCTCGACAAGCTTGAGATCACAGTTCTCTCTAC-3′ SEQ ID NO: 14 5′ -GGAGTGGACACCTGTGGAGAG-3′ SEQ ID NO: 15 5′ -CTCCACAGGTGTCCACTCCGCAATGCACGTGGCCCAGCC-3′ SEQ ID NO: 16 5′GAGGTTGTAAGGACTCACCTGAAATCTGGGCTCCGTTGC-3′ SEQ ID NO: 17 5′ -GCAACGGAGCCCAGATTTCAGGTGAGTCCTTACAACCTC-3′ SEQ ID NO: 18 5′ -GGCTAGATATCTCTAGACTATAAATCTCTGGCCATGAAG-3′ SEQ ID NO: 19 5′ -GGCACTAGGTCGACTCTAGAAACTGAGGAAGCAAAGTTTAAATTCTAC TCACGTTTAATCTGGGCTCCGTTGC-3′ SEQ ID NO: 20 5′GCAGAGAGACATATGGCAATGCACGTGGCCCAGCCTGCTGTGG-3′ SEQ ID NO: 21 5′ -GCAGAGAGAGGATCCTCAGTCAGTTAGTCAGAATCTGGGCACGGTT CTGG-3′ SEQ ID NO: 22 5′ -GGCACTAGTCATGAAATACCTATTGCCTACGGCAGCCGCTGGA TTGTTATTACTCGCTGCCCAACCAGCGATGGCCGCAGCAA TGCACGTGGCCCAGCCTGCTGTGG-3′ SEQ ID NO: 23 1 CATTCGCTTA CCTCGAGAAG CTTGAGATCA CAGTTCTCTC TACAGTTACT 51 GAGCACACAG GACCTCACCA TGGGATGGAG CTGTATCATC CTCTTCTTGG 101 TAGCAACAGC TACAGGTAAG GGGCTCACAG TAGCAGGCTT GAGGTCTGGA 151 CATATATATG GGTGACAATG ACATCCACTT TGCCTTTCTC TCCACAGGTG 201 TCCACTCCGC AATGCACGTG GCCCAGCCTG CTGTGGTACT GGCCAGCAGC 251 CGAGGCATCG CCAGCTTTGT GTGTGAGTAT GCATCTCCAG GCAAAGCCAC 301 TGAGGTCCGG GTGACAGTGC TTCGGCAGGC TGACAGCCAG GTGACTGAAG 351 TCTGTGCGGC AACCTACATG ATGGGGAATG AGTTGACCTT CCTAGATGAT 401 TCCATCTGCA CGGGCACCTC CAGTGGAAAT CAAGTGAACC TCACTATCCA 451 AGGACTGAGG GCCATGGACA CGGGACTCTA CATCTGCAAG GTGGAGCTCA 501 TGTACCCACC GCCATACTAC CTGGGCATAG GCAACGGAAC CCAGATTTAT 551 GTAATTGATC CAGAACCGTG CCCAGATTCT GATCAGGAGC CCAAATCTTC 601 TGACAAAACT CACACATCTC CACCGTCTCC AGGTAAGCCA GCCCAGGCCT 651 CGCCCTCCAG CTCAAGGCGG GACAGGTGCC CTAGAGTAGC CTGCATCCAG 701 GGACAGGCCC CAGCCGGGTG CTGACACGTC CACCTCCATC TCTTCCTCAG 751 CACCTGAAGC CGAGGGGGCA CCGTCAGTCT TCCTCTTCCC CCCAAAACCC 801 AAGGACACCC TCATGATCTC CCGGACCCCT GAGGTCACAT GCGTGGTGGT 851 GGACGTGAGC CACGAAGACC CTGAGGTCAA GTTCAACTGG TACGTGGACG 901 GCGTGGAGGT GCATAATGCC AAGACAAAGC CGCGGGAGGA GCAGTACAAC 951 AGCACGTACC GGGTGGTCAG CGTCCTCACC GTCCTGCACC AGGACTGGCT 1001 GAATGGCAAG GAGTACAAGT GCAAGGTCTC CAACAAAGCC CTCCCAGCCC 1051 CCATCGAGAA AACCATCTCC AAAGCCAAAG GTGGGACCCG TGGGGTGCGA 1101 GGGCCACATG GACAGAGGCC GGCTCGGCCC ACCCTCTGCC CTGAGAGTGA 1151 CCGCTGTACC AACCTCTGTC CTACAGGGCA GCCCCGAGAA CCACAGGTGT 1201 ACACCCTGCC CCCATCCCGG GATGAGCTGA CCAAGAACCA GGTCAGCCTG 1251 ACCTGCCTGG TCAAAGGCTT CTATCCCAGC GACATCGCCG TGGAGTGGGA 1301 GAGCAATGGG CAGCCGGAGA ACAACTACAA GACCACGCCT CCCGTGCTGG 1351 ACTCCGACGG CTCCTTCTTC CTCTACAGCA AGCTCACCGT GGACAAGAGC 1401 AGGTGGCAGC AGGGGAACGT CTTCTCATGC TCCGTGATGC ATGAGGCTCT 1451 GCACAACCAC TACACGCAGA AGAGCCTCTC CCTGTCTCCG GGTAAATGAG 1501 TGCGACGGCC GGCAAGCCCC GCTCCCCGGG CTCTCGCGGT CGCACGAGGA 1551 TGCTTGGCAC GTACCCCCTG TACATACTTC CCGGGCGCCC AGCATGGAAA 1601 TAAAGCACCC AGCGCTGCCC TGGGCCCCTG CGAGACTGTG ATGGTTCTTT 1651 CCACGGGTCA GGCCGAGTCT GAGGCCTGAG TGGCATGAGG GAGGCAGAGC 1701 GGGTC SEQ ID NO: 24 1 MGWSCIILFL VATATGVHSA MHVAQPAVVL ASSRGIASFV CEYASPGKAT 51 EVRVTVLRQA DSQVTEVCAA TYMMGNELTF LDDSICTGTS SGNQVNLTIQ 101 GLRAMDTGLY ICKVELMYPP PYYLGIGNGT QIYVIDPEPC PDSDQEPKSS 151 DKTHTSPPSP APEAEGAPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 201 PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 251 CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK 301 GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 351 NVFSCSVMHE ALHNHYTQKS LSLSPGK* SEQ ID NO: 25 1 CATTCGCTTA CCTCGAGAAG CTTGAGATCA CAGTTCTCTC TACAGTTACT 51 GAGCACACAG GACCTCACCA TGGGATGGAG CTGTATCATC CTCTTCTTGG 101 TAGCAACAGC TACAGGTAAG GGGCTCACAG TAGCAGGCTT GAGGTCTGGA 151 CATATATATG GGTGACAATG ACATCCACTT TGCCTTTCTC TCCACAGGTG 201 TCCACTCCGC AATGCACGTG GCCCAGCCTG CTGTGGTACT GGCCAGCAGC 251 CGAGGCATCG CCAGCTTTGT GTGTGAGTAT GCATCTCCAG GCAAAGCCAC 301 TGAGGTCCGG GTGACAGTGC TTCGGCAGGC TGACAGCCAG GTGACTGAAG 351 TCTGTGCGGC AACCTACATG ATGGGGAATG AGTTGACCTT CCTAGATGAT 401 TCCATCTGCA CGGGCACCTC CAGTGGAAAT CAAGTGAACC TCACTATCCA 451 AGGACTGAGG GCCATGGACA CGGGACTCTA CATCTGCAAG GTGGAGCTCA 501 TGTACCCACC GCCATACTAC CTGGGCATAG GCAACGGAAC CCAGATTTAT 551 GTAATTGATC CAGAACCGTG CCCAGATTCT GATCAGGAGT CCAAATATGG 601 TCCCCCATCC CCATCATCCC CAGGTAAGCC AACCCAGGCC TCGCCCTCCA 651 GCTCAAGGCG GGACAGGTGC CCTAGAGTAG CCTGCATCCA GGGACAGGCC 701 CCAGCCGGGT GCTGACGCAT CCACCTCCAT CTCTTCCTCA GCACCTGAGT 751 TCCTGGGGGG ACCATCAGTC TTCCTGTTCC CCCCAAAACC CAAGGACACT 801 CTCATGATCT CCCGGACCCC TGAGGTCACG TGCGTGGTGG TGGACGTGAG 851 CCAGGAAGAC CCCGAGGTCC AGTTCAACTG GTACGTGGAT GGCGTGGAGG 901 TGCATAATGC CAAGACAAAG CCGCGGGAGG AGCAGTTCAA CAGCACGTAC 951 CGTGTGGTCA GCGTCCTCAC CGTCCTGCAC CAGGACTGGC TGAACGGCAA 1001 GGAGTACAAG TGCAAGGTCT CCAACAAAGG CCTCCCGTCC TCCATCGAGA 1051 AAACCATCTC CAAAGCCAAA GGTGGGACCC ACGGGGTGCG AGGGCCACAC 1101 GGACAGAGGC CAGCTCGGCC CACCCTCTGC CCTGGGAGTG ACCGCTGTGC 1151 CAACCTCTGT CCCTACAGGG CAGCCCCGAG AGCCACAGGT GTACACCCTG 1201 CCCCCATCCC AGGAGGAGAT GACCAAGAAC CAGGTCAGCC TGACCTGCCT 1251 GGTCAAAGGC TTCTACCCCA GCGACATCGC CGTGGAGTGG GAGAGCAATG 1301 GGCAGCCGGA GAACAACTAC AAGACCACGC CTCCCGTGCT GGACTCCGAC 1351 GGCTCCTTCT TCCTCTACAG CAGGCTAACC GTGGACAAGA GCAGGTGGCA 1401 GGAGGGGAAT GTCTTCTCAT GCTCCGTGAT GCATGAGGCT CTGCACAACC 1451 ACTACACACA GAAGAGCCTC TCCCTGTCTC TGGGTAAATG AGTGCCAGGG 1501 CCGGCAAGCC CCCGCTCCCC GGGCTCTCGG GGTCGCGCGA GGATGCTTGG 1551 CACGTACCCC GTCTACATAC TTCCCAGGCA CCCAGCATGG AAATAAAGCA 1601 CCCACCACTG CCCTGGGCCC CTGTGAGACT GTGATGGTTC TTTCCACGGG 1651 TCAGGCCGAG TCTGAGGCCT GAGTGACATG AGGGAGGCAG AGCGGTCCCA 1701 CTGTCCCCAC ACTGGGGATC CCCGGGTACC GAGCTCGATT CCTCTGC SEQ ID NO: 26 1 MGWSCIILFL VATATGVHSA MHVAQPAVVL ASSRGIASFV CEYASPGKAT 51 EVRVTVLRQA DSQVTEVCAA TYMMGNELTF LDDSICTGTS SGNQVNLTIQ 101 GLRAMDTGLY ICKVELMYPP PYYLGIGNGT QIYVIDPEPC PDSDQESKYG 151 PPSPSSPAPE FEGAPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV 201 QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV 251 SNKGLPSSIE KTISKAKGQP REPQVYTLPP SQEEMTKNQV SLTCLVKGFY 301 PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF 351 SCSVMHEALH NHYTQKSLSL SLGK* SEQ ID NO: 27 1 CATTCGCTTA CCTCGAGAAG CTTGAGATCA CAGTTCTCTC TACAGTTACT 51 GAGCACACAG GACCTCACCA TGGGATGGAG CTGTATCATC CTCTTCTTGG 101 TAGCAACAGC TACAGGTAAG GGGCTCACAG TAGCAGGCTT GAGGTCTGGA 151 CATATATATG GGTGACAATG ACATCCACTT TGCCTTTCTC TCCACAGGTG 201 TCCACTCCGC AATGCACGTG GCCCAGCCTG CTGTGGTACT GGCCAGCAGC 251 CGAGGCATCG CCAGCTTTGT GTGTGAGTAT GCATCTCCAG GCAAAGCCAC 301 TGAGGTCCGG GTGACAGTGC TTCGGCAGGC TGACAGCCAG GTGACTGAAG 351 TCTGTGCGGC AACCTACATG ATGGGGAATG AGTTGACCTT CCTAGATGAT 401 TCCATCTGCA CGGGCACCTC CAGTGGAAAT CAAGTGAACC TCACTATCCA 451 AGGACTGAGG GCCATGGACA CGGGACTCTA CATCTGCAAG GTGGAGCTCA 501 TGTACCCACC GCCATACTAC CTGGGCATAG GCAACGGAAC CCAGATTTAT 551 GTAATTGATC CAGAACCGTG CCCAGATTCT GATCAGGAGT CCAAATATGG 601 TCCCCCATCC CCATCATCCC CAGGTAAGCC AACCCAGGCC TCGCCCTCCA 651 GCTCAAGGCG GGACAGGTGC CCTAGAGTAG CCTGCATCCA GGGACAGGCC 701 CCAGCCGGGT GCTGACGCAT CCACCTCCAT CTCTTCCTCA GCACCTGAGT 751 TCGAGGGGGC ACCATCAGTC TTCCTGTTCC CCCCAAAACC CAAGGACACT 801 CTCATGATCT CCCGGACCCC TGAGGTCACG TGCGTGGTGG TGGACGTGAG 851 CCAGGAAGAC CCCGAGGTCC AGTTCAACTG GTACGTGGAT GGCGTGGAGG 901 TGCATAATGC CAAGACAAAG CCGCGGGAGG AGCAGTTCAA CAGCACGTAC 951 CGTGTGGTCA GCGTCCTCAC CGTCCTGCAC CAGGACTGGC TGAACGGCAA 1001 GGAGTACAAG TGCAAGGTCT CCAACAAAGG CCTCCCGTCC TCCATCGAGA 1051 AAACCATCTC CAAAGCCAAA GGTGGGACCC ACGGGGTGCG AGGGCCACAC 1101 GGACAGAGGC CAGCTCGGCC CACCCTCTGC CCTGGGAGTG ACCGCTGTGC 1151 CAACCTCTGT CCCTACAGGG CAGCCCCGAG AGCCACAGGT GTACACCCTG 1201 CCCCCATCCC AGGAGGAGAT GACCAAGAAC CAGGTCAGCC TGACCTGCCT 1251 GGTCAAAGGC TTCTACCCCA GCGACATCGC CGTGGAGTGG GAGAGCAATG 1301 GGCAGCCGGA GAACAACTAC AAGACCACGC CTCCCGTGCT GGACTCCGAC 1351 GGCTCCTTCT TCCTCTACAG CAGGCTAACC GTGGACAAGA GCAGGTGGCA 1401 GGAGGGGAAT GTCTTCTCAT GCTCCGTGAT GCATGAGGCT CTGCACAACC 1451 ACTACACACA GAAGAGCCTC TCCCTGTCTC TGGGTAAATG AGTGCCAGGG 1501 CCGGCAAGCC CCCGCTCCCC GGGCTCTCGG GGTCGCGCGA GGATGCTTGG 1551 CACGTACCCC GTCTACATAC TTCCCAGGCA CCCAGCATGG AAATAAAGCA 1601 CCCACCACTG CCCTGGGCCC CTGTGAGACT GTGATGGTTC TTTCCACGGG 1651 TCAGGCCGAG TCTGAGGCCT GAGTGACATG AGGGAGGCAG AGCGGTCCCA 1701 CTGTCCCCAC ACTGGGGATC CCCGGGTACC GAGCTCGATT CCTCTGC SEQ ID NO: 28 1 MGWSCIILFL VATATGVHSA MHVAQPAVVL ASSRGIASFV CEYASPGKAT 51 EVRVTVLRQA DSQVTEVCAA TYMMGNELTF LDDSICTGTS SGNQVNLTIQ 101 GLRAMDTGLY ICKVELMYPP PYYLGIGNGT QIYVIDPEPC PDSDQESKYG 151 PPSPSSPAPE FEGAPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV 201 QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV 251 SNKGLPSSIE KTISKAKGQP REPQVYTLPP SQEEMTKNQV SLTCLVKGFY 301 PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF 351 SCSVMHEALH NHYTQKSLSL SLGK* SEQ ID NO: 29 1 CATTCGCTTA CCTCGAGAAG CTTGAGATCA CAGTTCTCTC TACAGTTACT 51 GAGCACACAG GACCTCACCA TGGGATGGAG CTGTATCATC CTCTTCTTGG 101 TAGCAACAGC TACAGGTAAG GGGCTCACAG TAGCAGGCTT GAGGTCTGGA 151 CATATATATG GGTGACAATG ACATCCACTT TGCCTTTCTC TCCACAGGTG 201 TCCACTCCGC AATGCACGTG GCCCAGCCTG CTGTGGTACT GGCCAGCAGC 251 CGAGGCATCG CCAGCTTTGT GTGTGAGTAT GCATCTCCAG GCAAAGCCAC 301 TGAGGTCCGG GTGACAGTGC TTCGGCAGGC TGACAGCCAG GTGACTGAAG 351 TCTGTGCGGC AACCTACATG ATGGGGAATG AGTTGACCTT CCTAGATGAT 401 TCCATCTGCA CGGGCACCTC CAGTGGAAAT CAAGTGAACC TCACTATCCA 451 AGGACTGAGG GCCATGGACA CGGGACTCTA CATCTGCAAG GTGGAGCTCA 501 TGTACCCACC GCCATACTAC CTGGGCATAG GCAACGGAGC CCAGATTTCA 551 GGTGAGTCCT TACAACCTCT CTCTTCTATT CAGCTTAAAT AGATTTTACT 601 GCATTTGTTG GGGGGGAAAT GTGTGTATCT GAATTTCAGG TCATGAAGGA 651 CTAGGGACAC CTTGGGAGTC AGAAAGGGTC ATTGGGAGCC CGGGCTGATG 701 CAGACAGACA TCCTCAGCTC CCAGACTTCA TGGCCAGAGA TTTATAGTCT 751 AGAGGATCCC CAGCTTTCTG GGGCAGGCCA GGCCTGACCT TGGCTTTGGG 801 GCAGGGAGGG GGCTAAGGTG AGGCAGGTGG CGCCAGCAGG TGCACACCCA 851 ATGCCCATGA GCCCAGACAC TGGACGCTGA ACCTCGCGGA CAGTTAAGAA 901 CCCAGGGGCC TCTGCGCCTG GGCCCAGCTC TGTCCCACAC CGCGGTCACA 951 TGGCACCACC TCTCTTGCAG CCTCCACCAA GGGCCCATCG GTCTTCCCCC 1001 TGGCACCCTC CTCCAAGAGC ACCTCTGGGG GCACAGCGGC CCTGGGCTGC 1051 CTGGTCAAGG ACTACTTCCC CGAACCGGTG ACGGTGTCGT GGAACTCAGG 1101 CGCCCTGACC AGCGGCGTGC ACACCTTCCC GGCTGTCCTA CAGTCCTCAG 1151 GACTCTACTC CCTCAGCAGC GTGGTGACCG TGCCCTCCAG CAGCTTGGGC 1201 ACCCAGACCT ACATCTGCAA CGTGAATCAC AAGCCCAGCA ACACCAAGGT 1251 GGACAAGAAA GTTGGTGAGA GGCCAGCACA GGGAGGGAGG GTGTCTGCTG 1301 GAAGCAGGCT CAGCGCTCCT GCCTGGACGC ATCCCGGCTA TGCAGCCCCA 1351 GTCCAGGGCA GCAAGGCAGG CCCCGTCTGC CTCTTCACCC GGAGCCTCTG 1401 CCCGCCCCAC TCATGCTCAG GGAGAGGGTC TTCTGGCTTT TTCCCAGGCT 1451 CTGGGCAGGC ACAGGCTAGG TGCCCCTAAC CCAGGCCCTG CACACAAAGG 1501 GGCAGGTGCT GGGCTCAGAC CTGCCAAGAG CCATATCCGG GAGGACCCTG 1551 CCCCTGACCT AAGCCCACCC CAAAGGCCAA ACTCTCCACT CCCTCAGCTC 1601 GGACACCTTC TCTCCTCCCA GATTCCAGTA ACTCCCAATC TTCTCTCTGC 1651 AGAGCCCAAA TCTTGTGACA AAACTCACAC ATGCCCACCG TGCCCAGGTA 1701 AGCCAGCCCA GGCCTCGCCC TCCAGCTCAA GGCGGGACAG GTGCCCTAGA 1751 GTAGCCTGCA TCCAGGGACA GGCCCCAGCC GGGTGCTGAC ACGTCCACCT 1801 CCATCTCTTC CTCAGCACCT GAACTCCTGG GGGGACCGTC AGTCTTCCTC 1851 TTCCCCCCAA AACCCAAGGA CACCCTCATG ATCTCCCGGA CCCCTGAGGT 1901 CACATGCGTG GTGGTGGACG TGAGCCACGA AGACCCTGAG GTCAAGTTCA 1951 ACTGGTACGT GGACGGCGTG GAGGTGCATA ATGCCAAGAC AAAGCCGCGG 2001 GAGGAGCAGT ACAACAGCAC GTACCGGGTG GTCAGCGTCC TCACCGTCCT 2051 GCACCAGGAC TGGCTGAATG GCAAGGAGTA CAAGTGCAAG GTCTCCAACA 2101 AAGCCCTCCC AGCCCCCATC GAGAAAACCA TCTCCAAAGC CAAAGGTGGG 2151 ACCCGTGGGG TGCGAGGGCC ACATGGACAG AGGCCGGCTC GGCCCACCCT 2201 CTGCCCTGAG AGTGACCGCT GTACCAACCT CTGTCCTACA GGGCAGCCCC 2251 GAGAACCACA GGTGTACACC CTGCCCCCAT CCCGGGATGA GCTGACCAAG 2301 AACCAGGTCA GCCTGACCTG CCTGGTCAAA GGCTTCTATC CCAGCGACAT 2351 CGCCGTGGAG TGGGAGAGCA ATGGGCAGCC GGAGAACAAC TACAAGACCA 2401 CGCCTCCCGT GCTGGACTCC GACGGCTCCT TCTTCCTCTA CAGCAAGCTC 2451 ACCGTGGACA AGAGCAGGTG GCAGCAGGGG AACGTCTTCT CATGCTCCGT 2501 GATGCATGAG GCTCTGCACA ACCACTACAC GCAGAAGAGC CTCTCCCTGT 2551 CTCCGGGTAA ATGAGTGCGA CGGCCGGCAA GCCCCGCTCC CCGGGCTCTC 2601 GCGGTCGCAC GAGGATGCTT GGCACGTACC CCCTGTACAT ACTTCCCGGG 2651 CGCCCAGCAT GGAAATAAAG CACCCAGCGC TGCCCTGGGC CCCTGCGAGA 2701 CTGTGATGGT TCTTTCCACG GGTCAGGCCG AGTCTGAGGC CTGAGTGGCA 2751 TGAGGGAGGC AGAGCGGGTC SEQ ID NO: 30 1 MGWSCIILFL VATATGVHSA MHVAQPAVVL ASSRGIASFV CEYASPGKAT 51 EVRVTVLRQA DSQVTEVCAA TYMMGNELTF LDDSICTGTS SGNQVNLTIQ 101 GLRAMDTGLY ICKVELMYPP PYYLGIGNGA QITVAAPSVF IFPPSDEQLK 151 SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS 201 STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC* SEQ ID NO: 31 1 CATTCGCTTA CCTCGAGAAG CTTGAGATCA CAGTTCTCTC TACAGTTACT 51 GAGCACACAG GACCTCACCA TGGGATGGAG CTGTATCATC CTCTTCTTGG 101 TAGCAACAGC TACAGGTAAG GGGCTCACAG TAGCAGGCTT GAGGTCTGGA 151 CATATATATG GGTGACAATG ACATCCACTT TGCCTTTCTC TCCACAGGTG 201 TCCACTCCGC AATGCACGTG GCCCAGCCTG CTGTGGTACT GGCCAGCAGC 251 CGAGGCATCG CCAGCTTTGT GTGTGAGTAT GCATCTCCAG GCAAAGCCAC 301 TGAGGTCCGG GTGACAGTGC TTCGGCAGGC TGACAGCCAG GTGACTGAAG 351 TCTGTGCGGC AACCTACATG ATGGGGAATG AGTTGACCTT CCTAGATGAT 401 TCCATCTGCA CGGGCACCTC CAGTGGAAAT CAAGTGAACC TCACTATCCA 451 AGGACTGAGG GCCATGGACA CGGGACTCTA CATCTGCAAG GTGGAGCTCA 501 TGTACCCACC GCCATACTAC CTGGGCATAG GCAACGGAGC CCAGATTAAA 551 CGTGAGTAGA ATTTAAACTT TGCTTCCTCA GTTTCTAGAA GAATGGCTGC 601 AAAGAGCTCC AACAAAACAA TTTAGAACTT TATTAAGGAA TAGGGGGAAG 651 CTAGGAAGAA ACTCAAAACA TCAAGATTTT AAATACGCTT CTTGGTCTCC 701 TTGCTATAAT TATCTGGGAT AAGCATGCTG TTTTCTGTCT GTCCCTAACA 751 TGCCCTGTGA TTATCCGCAA ACAACACACC CAAGGGCAGA ACTTTGTTAC 801 TTAAACACCA TCCTGTTTGC TTCTTTCCTC AGGAACTGTG GCTGCACCAT 851 CTGTCTTCAT CTTCCCGCCA TCTGATGAGC AGTTGAAATC TGGAACTGCC 901 TCTGTTGTGT GCCTGCTGAA TAACTTCTAT CCCAGAGAGG CCAAAGTACA 951 GTGGAAGGTG GATAACGCCC TCCAATCGGG TAACTCCCAG GAGAGTGTCA 1001 CAGAGCAGGA CAGCAAGGAC AGCACCTACA GCCTCAGCAG CACCCTGACG 1051 CTGAGCAAAG CAGACTACGA GAAACACAAA GTCTACGCCT GCGAAGTCAC 1101 CCATCAGGGC CTGAGCTCGC CCGTCACAAA GAGCTTCAAC AGGGGAGAGT 1151 GTTAGAGGGA GAAGTGCCCC CACCTGCTCC TCAGTTCCAG CCTGACCCCC 1201 TCCCATCCTT TGGCCTCTGA CCCTTTTTCC ACAGGGGACC TACCCCTATT 1251 GCGGTCCTCC AGCTCATCTT TCACCTCACC CCCCTCCTCC TCCTTGGCTT 1301 TAATTATGCT AATGTTGGAG GAGAATGAAT AAATAAAGTG AATCTTTGCA 1351 CCTGTGGTTT CTCTCTTTCC TCAATTTAAT AATTATTATC TGTTGTTTAC 1401 CAACTACTCA ATTTCTCTTA TAAGGGACTA AATATGTAGT CATCCTAAGG 1451 CGCATAACCA TTTATAAAAA TCATCCTTCA TTCTATTTTA CCCTATCATC 1501 CTCTGCAAGA CAGTCCTCCC TCAAACCCAC AAGCCTTCTG TCCTCACAGT 1551 CCCCTGGGCC GTGGTAGGAG AGACTTGCTT CCTTGTTTTC CCCTCCTCAG 1601 CAAGCCCTCA TAGTCCTTTT TAAGGGTGAC AGGTCTTACG GTCATATATC 1651 CTTTGATTCA ATTCCCTGGG AATCAACCAA GGCAAATTTT TCAAAAGAAG 1701 AAACCTGC SEQ ID NO: 32 1 MGWSCIILFL VATATGVHSA MHVAQPAVVL ASSRGIASFV CEYASPGKAT 51 EVRVTVLRQA DSQVTEVCAA TYMMGNELTF LDDSICTGTS SGNQVNLTIQ 101 GLRAMDTGLY ICKVELMYPP PYYLGIGNGA QITVAAPSVF IFPPSDEQLK 151 SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS 201 STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC*
Claims (39)
1. An isolated nucleic acid molecule encoding a CTLA4-immunoglobulin fusion protein, the nucleic acid molecule comprising a nucleotide sequence encoding a first peptide comprising a CTLA4 extracellular domain and a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region which is modified by substitution, addition, or deletion of at least one amino acid residue such that complement activation or Fc receptor interaction is reduced.
2. An isolated nucleic acid molecule of claim 1 , wherein the first peptide comprises amino acid residues 1-125 of the human CTLA4 protein.
3. An isolated nucleic acid molecule of claim 1 , wherein the immunoglobulin constant region comprises a hinge region, a CH2 domain and a CH3 domain.
4. An isolated nucleic acid molecule of claim 3 , wherein the hinge region, the CH2 domain and the CH3 domain are selected from the group consisting of Cγ1, Cγ2, Cγ3 and Cγ4.
5. An isolated nucleic acid molecule encoding a CTLA4-immunoglobulin fusion protein, the nucleic acid molecule comprising a nucleotide sequence encoding a first peptide comprising a CTLA4 extracellular domain and a nucleotide sequence encoding a second peptide comprising an immunoglobulin constant region wherein the immunoglobulin constant region comprises a heavy chain CH1 domain, a hinge region, a CH2 domain and a CH3 domain.
6. The isolated nucleic acid molecule of claim 5 , wherein the immunoglobulin constant region is modified by substitution, addition, or deletion of at least one amino acid residue such that complement activation or Fc receptor interaction is reduced.
7. An isolated nucleic acid molecule of claim 3 , wherein at least one amino acid residue selected from a hinge link region of the CH2 domain is modified by substitution, addition or deletion.
8. An isolated nucleic acid molecule of claim 7 , wherein an amino acid residue of the hinge link region of the CH2 domain located at a position of a full-length intact immunoglobulin heavy chain selected from the group consisting of position 234, position 235 and position 237 is modified.
9. An isolated nucleic acid molecule of claim 8 , wherein the CH2 domain is Cγ1.
10. An isolated nucleic acid molecule of claim 9 , wherein an amino acid residue selected from a hinge link region of the CH2 domain is modified by at least one substitution selected from the group consisting of: substitution of Leu at position 234 with Ala; substitution of Leu at position 235 with Glu; and substitution of Gly at position 237 with Ala.
11. An isolated nucleic acid molecule of claim 10 , wherein Leu at position 234 is substituted with Ala, Leu at position 235 is substituted with Glu and Gly at position 237 is substituted with Ala.
12. An isolated nucleic acid molecule of claim 8 , wherein the CH2 domain is Cγ4.
13. An isolated nucleic acid molecule of claim 12 , wherein an amino acid residue selected from a hinge link region of the CH2 domain is modified by at least one substitution selected from the group consisting of: substitution of Leu at position 234 with Ala; substitution of Leu at position 235 with Glu; and substitution of Gly at position 237 with Ala.
14. An isolated nucleic acid molecule of claim 13 , wherein Leu at position 235 is substituted with Glu and Gly at position 237 is substituted with Ala.
15. An isolated nucleic acid molecule of claim 6 , wherein at least one amino acid residue selected from a hinge-proximal bend region of the CH2 domain is modified by substitution, addition or deletion.
16. An isolated nucleic acid molecule of claim 15 , wherein an amino acid residue at position 331 of an intact immunoglobulin heavy chain is modified by substitution with another amino acid residue.
17. An isolated nucleic acid molecule of claim 16 , wherein the CH2 domain is selected from the group consisting of Cγ1, Cγ2, Cγ3, or Cγ4.
18. An isolated nucleic acid molecule of claim 16 , wherein Pro at position 331 of an intact immunoglobulin heavy chain is substituted with Ser.
19. An isolated nucleic acid molecule of claim 6 , wherein at least one amino acid residue of the CH2 domain located at a position of an intact immunoglobulin heavy chain selected from the group consisting of position 318, position 320 and position 322 is modified by substitution, addition or deletion.
20. An isolated nucleic acid molecule of claim 19 , wherein an amino acid residue of the CH2 domain is modified by at least one substitution selected from the group consisting of: substitution of Glu at position 318 with Ala or Val; substitution of Lys at position 320 with Ala or Gln; and substitution of Lys at position 322 with Ala or Gln.
21. An isolated nucleic acid molecule of claim 20 , wherein Glu at position 318 is substituted with Ala or Val, Lys at position 320 is substituted with Ala or Gln and Lys at position 322 is substituted with Ala or Gln.
22. An isolated nucleic acid molecule of claim 3 , wherein the hinge region is modified to reduce complement activation or Fc receptor interaction.
23. An isolated nucleic acid molecule of claim 22 , wherein at least one amino acid residue located in the hinge region is modified by substitution, addition or deletion.
24. An isolated nucleic acid molecule of claim 23 , wherein the immunoglobulin constant region is Cγ1, Cγ2, Cγ3, or Cγ4.
25. An isolated nucleic acid molecule of claim 24 , wherein the hinge region of Cγ1 or Cγ3 is substituted with a hinge region from Cγ4.
26. An isolated nucleic acid molecule of claim 3 , wherein the CTLA4-immunoglobulin fusion protein comprises an amino acid sequence shown in SEQ ID NO: 26.
27. An isolated nucleic acid molecule of claim 3 , wherein the CH2 domain is modified by substitution of Glu for Leu at position 235 of an intact immunoglobulin heavy chain and by substitution of Ala for Gly at position 237 of an intact immunoglobulin heavy chain.
28. An isolated nucleic acid molecule of claim 27 , wherein the CTLA4-immunoglobulin fusion protein comprises an amino acid sequence shown in SEQ ID NO: 28.
29. An isolated nucleic acid molecule of claim 3 , wherein the CTLA4-immunoglobulin fusion protein comprises an amino acid sequence shown in SEQ ID NO: 24.
30. An isolated nucleic acid molecule encoding a CTLA4-immunoglobulin light chain fusion protein, wherein the nucleic acid molecule comprises a nucleotide sequence encoding a first peptide comprising a CTLA4 extracellular domain and a nucleotide sequence encoding a second peptide comprising an immunoglobulin light chain constant domain.
31. A recombinant expression vector comprising a nucleic acid molecule of claim 1 .
32. A recombinant expression vector comprising a nucleic acid molecule of claim 2 .
33. A recombinant expression vector comprising a nucleic acid molecule of claim 5 .
34. A recombinant expression vector comprising a nucleic acid molecule of claim 6 .
35. A recombinant expression vector comprising a nucleic acid molecule of claim 30 .
36. A host cell transfected with the expression vector of claim 32 .
37. A host cell transfected with the expression vector of claim 33 .
38. A host cell transfected with the expression vector of claim 34 .
39. A host cell transfected with the expression vector of claim 35.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/792,637 US20040151725A1 (en) | 1996-02-02 | 2004-03-02 | CTLA-4 immunoglobulin fusion proteins having modified effector functions and uses therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/595,590 US6750334B1 (en) | 1996-02-02 | 1996-02-02 | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US10/792,637 US20040151725A1 (en) | 1996-02-02 | 2004-03-02 | CTLA-4 immunoglobulin fusion proteins having modified effector functions and uses therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/595,590 Continuation US6750334B1 (en) | 1996-02-02 | 1996-02-02 | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040151725A1 true US20040151725A1 (en) | 2004-08-05 |
Family
ID=24383868
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/595,590 Expired - Fee Related US6750334B1 (en) | 1996-02-02 | 1996-02-02 | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US09/227,595 Expired - Fee Related US6444792B1 (en) | 1996-02-02 | 1999-01-08 | CTLA4-Cγ4 fusion proteins |
US10/027,075 Abandoned US20020114814A1 (en) | 1996-02-02 | 2001-12-20 | CTLA4-Cgamma4 fusion proteins |
US10/792,637 Abandoned US20040151725A1 (en) | 1996-02-02 | 2004-03-02 | CTLA-4 immunoglobulin fusion proteins having modified effector functions and uses therefor |
US10/985,832 Abandoned US20050196402A1 (en) | 1996-02-02 | 2004-11-08 | CTLA4-Cy4 fusion proteins |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/595,590 Expired - Fee Related US6750334B1 (en) | 1996-02-02 | 1996-02-02 | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US09/227,595 Expired - Fee Related US6444792B1 (en) | 1996-02-02 | 1999-01-08 | CTLA4-Cγ4 fusion proteins |
US10/027,075 Abandoned US20020114814A1 (en) | 1996-02-02 | 2001-12-20 | CTLA4-Cgamma4 fusion proteins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/985,832 Abandoned US20050196402A1 (en) | 1996-02-02 | 2004-11-08 | CTLA4-Cy4 fusion proteins |
Country Status (8)
Country | Link |
---|---|
US (5) | US6750334B1 (en) |
EP (2) | EP0877812B1 (en) |
JP (1) | JP2000504564A (en) |
AT (1) | ATE382088T1 (en) |
AU (1) | AU2255497A (en) |
CA (1) | CA2243986A1 (en) |
DE (1) | DE69738418D1 (en) |
WO (1) | WO1997028267A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7482327B2 (en) | 2005-04-06 | 2009-01-27 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules |
US20090258031A1 (en) * | 2007-11-01 | 2009-10-15 | Maxygen, Inc. | Immunosuppressive polypeptides and nucleic acids |
WO2013112986A1 (en) * | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
US9512210B2 (en) | 2007-06-01 | 2016-12-06 | Gliknik Inc. | Immunoglobulin constant region Fc receptor binding agents |
US9683044B2 (en) | 2012-08-20 | 2017-06-20 | Gliknik Inc. | Molecules with antigen binding and polyvalent FC gamma receptor binding activity |
US10233242B2 (en) | 2012-06-27 | 2019-03-19 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
US11040093B2 (en) | 2014-02-25 | 2021-06-22 | Phaim Pharma Ltd | Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity |
US11117940B2 (en) | 2010-07-28 | 2021-09-14 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions |
US11155574B2 (en) | 2016-12-09 | 2021-10-26 | Gliknik Inc. | Manufacturing optimization of GL-2045, a multimerizing stradomer |
Families Citing this family (246)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US20050002902A1 (en) * | 1995-12-28 | 2005-01-06 | Liming Yu | Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CA2246352C (en) * | 1996-03-20 | 2011-11-08 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
WO1999015552A1 (en) * | 1997-09-19 | 1999-04-01 | Yoshitomi Pharmaceutical Industries, Ltd. | Oligopeptide compounds |
EP1037927B1 (en) * | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
CN1318092C (en) * | 1998-04-15 | 2007-05-30 | 利思进药品公司 | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
IL126681A0 (en) * | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA01007170A (en) | 1999-01-15 | 2002-07-30 | Genentech Inc | Polypeptide variants with altered effector function. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0201474A3 (en) * | 1999-05-19 | 2002-11-28 | Lexigen Pharmaceuticals Corp L | Expression and export of interferon-alpha proteins as fc fusion proteins |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
JP4793971B2 (en) * | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | Complex cytokine-antibody complex |
IL147972A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc Ge | Pd-1, a receptor for b7-4 and uses therefor |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
WO2001058957A2 (en) * | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
EP1272526A4 (en) | 2000-04-13 | 2004-10-13 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
CN1438894A (en) * | 2000-06-09 | 2003-08-27 | 布里斯托尔-迈尔斯斯奎布公司 | Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking LFA-1 medicated adhesion |
US20020164600A1 (en) | 2000-06-28 | 2002-11-07 | Gordon Freeman | PD-L2 molecules: novel PD-1 ligands and uses therefor |
RU2272644C2 (en) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Enhancement of immune response wherein fused protein antibody-cytokine is mediator by combined treatment with agents increasing immunocytokine absorption |
SI1935427T1 (en) * | 2000-07-03 | 2018-05-31 | Bristol-Myers Squibb Company | Uses of soluble CTLA4 mutant molecules |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
EP1179587A1 (en) * | 2000-08-09 | 2002-02-13 | Genethor GmbH | Method for diminishing specific immune reactions |
EP1355942B1 (en) * | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteins |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030007968A1 (en) * | 2001-01-26 | 2003-01-09 | Larsen Christian P. | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
PT1366067E (en) | 2001-03-07 | 2012-11-29 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
US7105328B2 (en) | 2001-04-02 | 2006-09-12 | Dana-Farber Cancer Institute | Methods for screening for compounds that modulate pd-1 signaling |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
KR100900166B1 (en) | 2001-05-03 | 2009-06-02 | 메르크 파텐트 게엠베하 | Recombinant tumor specific antibody and use thereof |
MXPA03010568A (en) * | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules. |
KR100453877B1 (en) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR |
CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
HU229098B1 (en) | 2001-12-04 | 2013-07-29 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
US20030144193A1 (en) * | 2001-12-20 | 2003-07-31 | Rottman James B. | TANGO 197 and TANGO 216 compositions and methods |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
AU2003222141A1 (en) * | 2002-03-29 | 2003-10-13 | Repligen Corporation | Ctla4 compositions in the treatment of autism |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
KR20050071564A (en) * | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0317376B8 (en) | 2002-12-17 | 2021-05-25 | Merck Patent Gmbh | antibody-il2 fusion protein designated as hu14.18-il2, uses thereof, vector and pharmaceutical composition |
US7541164B2 (en) * | 2002-12-23 | 2009-06-02 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
MXPA05006522A (en) * | 2002-12-23 | 2006-02-17 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production. |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
AU2004226167A1 (en) | 2003-04-03 | 2004-10-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies with enhanced ability to immunomodulate cell functions |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
CN101974090B (en) | 2003-06-12 | 2015-06-17 | 伊莱利利公司 | GLP-1 analog fusion proteins |
US20070253966A1 (en) * | 2003-06-12 | 2007-11-01 | Eli Lilly And Company | Fusion Proteins |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
EP1670499A4 (en) * | 2003-08-04 | 2009-07-22 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
EP1684791A4 (en) * | 2003-10-27 | 2009-07-01 | Amgen Inc | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
PT2256134E (en) * | 2003-11-13 | 2014-03-05 | Hanmi Science Co Ltd | Igg fc fragment for a drug carrier and method for the preparation thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
US20050191276A1 (en) * | 2003-11-25 | 2005-09-01 | Gregory Gurtner | Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase |
US20050238651A1 (en) * | 2003-11-25 | 2005-10-27 | Gurtner Gregory J | Treatment of inflammatory bowel disease |
PT1699822E (en) | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Il-7 fusion proteins with antibody portions, their preparation and their use |
BRPI0417916A (en) * | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | fc-erythropoietin fusion protein with improved pharmacokinetics |
CA2552590A1 (en) * | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
EP1737890A2 (en) * | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
KR100542605B1 (en) * | 2004-05-28 | 2006-01-11 | 보령제약 주식회사 | 4- 4- Recombinant vector containing gene of hCTLA4-Ig fusion protein and manufacturing process of the protein by using them |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
NZ541496A (en) * | 2004-07-28 | 2007-06-29 | Debra Leonard | Catchment means to enable water precipitate collection from an upper surface of a water storage receptacle |
CN101001873B (en) | 2004-08-04 | 2013-03-13 | 曼璀克生物科技有限责任公司 | Variant fc regions |
WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101027427B1 (en) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | Fc VARIANTS WITH INCREASED BINDING TO FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
ES2342964T3 (en) * | 2004-12-09 | 2010-07-20 | Merck Patent Gmbh | VARIATIONS OF INTERLEUCINE-7 WITH REDUCED IMMUNOGENICITY. |
US20060206947A1 (en) * | 2005-02-28 | 2006-09-14 | Scallon Bernard J | Heterodimeric protein binding compositions |
US20110123440A1 (en) * | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP1912675B1 (en) | 2005-07-25 | 2014-02-12 | Emergent Product Development Seattle, LLC | B-cell reduction using cd37-specific and cd20-specific binding molecules |
PT1919503E (en) | 2005-08-10 | 2015-01-05 | Macrogenics Inc | Identification and engineering of antibodies with variant fc regions and methods of using same |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
JP4860703B2 (en) | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | Optimized anti-CD30 antibody |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
US9868961B2 (en) * | 2006-03-30 | 2018-01-16 | The Regents Of The University Of California | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
ES2489646T3 (en) | 2006-05-26 | 2014-09-02 | Macrogenics, Inc. | Humanized antibodies specific to Fc gamma RIIB and its methods of use |
EP2041178A2 (en) | 2006-06-12 | 2009-04-01 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
SI2029173T1 (en) | 2006-06-26 | 2016-12-30 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
ES2402591T3 (en) | 2006-08-14 | 2013-05-07 | Xencor Inc. | Optimized antibodies that target CD19 |
EP2064240A2 (en) | 2006-09-18 | 2009-06-03 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
CA2981308C (en) * | 2006-09-21 | 2020-12-22 | University Of Rochester | Compositions and methods related to protein displacement therapy for myotonic dystrophy |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
BRPI0814465B1 (en) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION |
AU2008345242B2 (en) | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2009117030A2 (en) | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
JP5541845B2 (en) * | 2008-03-28 | 2014-07-09 | Jcrファーマ株式会社 | Atopic dermatitis treatment |
BRPI0906309A2 (en) | 2008-04-02 | 2020-05-26 | Macrogenics, Inc | IMMUNOGLOBULIN, ANTIBODY, USE OF ANTIBODY AND PHARMACEUTICAL COMPOSITION |
PT2132228E (en) * | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
RU2483081C2 (en) | 2008-07-23 | 2013-05-27 | Ханми Сайенс Ко.,Лтд.,Kr | Polypeptide complex containing non-peptidyl polymer, having three functional ends |
EP2350129B1 (en) | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
CN104740610A (en) * | 2008-08-25 | 2015-07-01 | 安普利穆尼股份有限公司 | PD-1 Antagonists and Methods for Treating Infectious Disease |
EA024877B1 (en) | 2008-10-02 | 2016-10-31 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | Cd86 antagonist multi-target binding proteins |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
SG175004A1 (en) | 2009-04-02 | 2011-11-28 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
JP5616428B2 (en) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | Trivalent bispecific antibody |
KR20110124368A (en) | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | Bispecific anti-erbb-2/anti-c-met antibodies |
EP2417159A1 (en) | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-3/anti-c-met antibodies |
CN102405230A (en) * | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | Antibody fusion proteins with modified fcrn binding sites |
WO2010136172A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
TWI409079B (en) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with bendamustine |
JP2013501741A (en) | 2009-08-14 | 2013-01-17 | ロシュ グリクアート アーゲー | Combination therapy with afucosylated CD20 antibody and fludarabine and / or mitoxantrone |
TWI412375B (en) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | Humanized anti-cdcp1 antibodies |
TW201113037A (en) | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
TR201804897T4 (en) | 2009-10-07 | 2018-06-21 | Macrogenics Inc | POLYPEPTIDES CONTAINING FC REGION WITH ADVANCED EFFECTOR FUNCTION DUE TO CHANGES OF FUCOSILATION SIZE AND METHODS FOR THEIR USE |
MY161909A (en) | 2009-12-22 | 2017-05-15 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
CN106432474A (en) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | CTLA4 proteins and their uses |
CA3079122A1 (en) | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
AR080793A1 (en) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | BISPECIFIC ANTIBODIES |
RU2585489C2 (en) | 2010-04-27 | 2016-05-27 | Рош Гликарт Аг | COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
SG187682A1 (en) | 2010-08-02 | 2013-03-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
AR082693A1 (en) | 2010-08-17 | 2012-12-26 | Roche Glycart Ag | COMBINATION THERAPY OF AN ANTI-CD20 AFUCOSILATED ANTIBODY WITH AN ANTI-VEGF ANTIBODY |
JP5758004B2 (en) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific antibodies comprising Fv fragments stabilized by disulfides |
EP2651976A1 (en) | 2010-12-16 | 2013-10-23 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
EP2681240B1 (en) | 2011-02-28 | 2017-08-16 | F. Hoffmann-La Roche AG | Monovalent antigen binding proteins |
CA2825081A1 (en) | 2011-02-28 | 2012-09-07 | Birgit Bossenmaier | Antigen binding proteins |
CN103476795B (en) | 2011-03-29 | 2016-07-06 | 罗切格利卡特公司 | Antibody Fc variant |
US20140147418A1 (en) * | 2011-04-15 | 2014-05-29 | The Us Of America, As Represented By The Secretary Department Of Health And Human Services | Aav mediated ctla-4 gene transfer to treat sjogren's syndrome |
CA2833623A1 (en) | 2011-04-20 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
WO2012162068A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
ES2765874T3 (en) | 2011-05-25 | 2020-06-11 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory disorders |
CA2845147A1 (en) | 2011-09-23 | 2013-03-28 | Roche Glycart Ag | Bispecific anti-egfr/anti igf-1r antibodies |
US20130302274A1 (en) | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
BR112014019579A2 (en) | 2012-02-10 | 2019-10-15 | Genentech, Inc | SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION |
WO2013148049A1 (en) * | 2012-03-29 | 2013-10-03 | The General Hospital Corporation | Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4) |
BR112014026718B1 (en) | 2012-05-11 | 2021-05-18 | Medimmune Limited. | isolated ctla-4 polypeptide, host cell, composition and use of a ctla-4 polypeptide |
KR20150013188A (en) | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | Multispecific antibodies |
CN104619722B (en) | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | Novel VISTA-IG constructs and use of VISTA-IG for treatment of autoimmune, allergic and inflammatory diseases |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
ES2597228T3 (en) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedure for the selection and production of objectification entities, such as targets, highly selective and multi-specific, customized, which contain at least two different binding entities, and use of these |
BR112014028368A2 (en) | 2012-06-27 | 2017-11-14 | Hoffmann La Roche | method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation |
IN2014DN11157A (en) | 2012-07-13 | 2015-10-02 | Roche Glycart Ag | |
WO2014022759A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
ES2729561T3 (en) | 2012-08-31 | 2019-11-04 | Us Health | Transfer of the aquaporin gene mediated by an adeno-associated virus (aav) for the treatment of Sjögren's syndrome |
AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
TWI635098B (en) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | Antibodies comprising chimeric constant domains |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
RU2721707C2 (en) | 2013-03-14 | 2020-05-21 | Макродженикс, Инк. | Bispecific molecules, immunoreactive with immune effector cells expressing an activating receptor |
AR096891A1 (en) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
KR20160044060A (en) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | Multispecific domain exchanged common variable light chain antibodies |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
PE20170254A1 (en) | 2013-12-24 | 2017-04-12 | Janssen Pharmaceutica Nv | ANTIBODIES AND ANTI-VISION FRAGMENTS |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
UA117289C2 (en) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Multispecific antibodies |
DK3148581T3 (en) | 2014-05-30 | 2020-01-13 | Henlix Biotech Co Ltd | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ANTIBODIES |
CN107073109B (en) | 2014-06-11 | 2021-08-06 | 凯西·A·格林 | Use of VISTA agonists and antagonists to inhibit or enhance humoral immunity |
MX2017004076A (en) | 2014-09-29 | 2017-07-04 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm. |
DK3221359T3 (en) | 2014-11-17 | 2020-06-22 | Regeneron Pharma | Methods for tumor treatment using CD3XCD20 bispecific antibody |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
MX2017007136A (en) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators. |
US11220545B2 (en) | 2014-12-08 | 2022-01-11 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents |
US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
PL3277725T3 (en) | 2015-03-30 | 2021-06-14 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
CN108431045B (en) * | 2015-09-01 | 2022-05-13 | 免疫功坊股份有限公司 | Molecular construct for preventing and/or treating thrombosis |
AU2016326449A1 (en) | 2015-09-21 | 2018-03-22 | Aptevo Research And Development Llc | CD3 binding polypeptides |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
TW202216201A (en) | 2016-02-12 | 2022-05-01 | 比利時商楊森製藥公司 | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
EP3423490A1 (en) | 2016-03-01 | 2019-01-09 | H. Hoffnabb-La Roche Ag | Obinutuzumab and rituximab variants having reduced adcp |
WO2017180813A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
MX2018012469A (en) | 2016-04-15 | 2019-07-04 | Immunext Inc | Anti-human vista antibodies and use thereof. |
EP3257866A1 (en) | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
CN111406073A (en) | 2017-09-29 | 2020-07-10 | 韩美药品株式会社 | Durable protein conjugates with improved efficacy |
US11753458B2 (en) | 2017-10-10 | 2023-09-12 | Alpine Immune Sciences, Inc. | CTLA-4 variant immunomodulatory proteins and uses thereof |
CN110305221B (en) * | 2018-03-27 | 2022-10-11 | 孙嘉琳 | Enhanced anti-tumor fusion protein, preparation method and application |
CN110305220B (en) * | 2018-03-27 | 2022-10-11 | 孙嘉琳 | Cancer-targeted enhanced anti-tumor fusion protein and preparation method and application thereof |
WO2020047389A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
TW202333802A (en) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | Therapeutic rna for lung cancer |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5428130A (en) * | 1989-02-23 | 1995-06-27 | Genentech, Inc. | Hybrid immunoglobulins |
US5434131A (en) * | 1991-06-27 | 1995-07-18 | Bristol Myers Squibb Co. | Chimeric CTLA4 receptor and methods for its use |
US5958403A (en) * | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
US6130316A (en) * | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
EP0665852A1 (en) * | 1993-07-09 | 1995-08-09 | Amgen Boulder Inc. | Recombinant ctla4 polypeptides and methods for making the same |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
WO1996031229A1 (en) | 1995-04-05 | 1996-10-10 | Beth Israel Hospital Association | Inhibiting rejection of a graft |
-
1996
- 1996-02-02 US US08/595,590 patent/US6750334B1/en not_active Expired - Fee Related
-
1997
- 1997-02-03 AT AT97905730T patent/ATE382088T1/en not_active IP Right Cessation
- 1997-02-03 EP EP97905730A patent/EP0877812B1/en not_active Expired - Lifetime
- 1997-02-03 AU AU22554/97A patent/AU2255497A/en not_active Abandoned
- 1997-02-03 DE DE69738418T patent/DE69738418D1/en not_active Expired - Lifetime
- 1997-02-03 WO PCT/US1997/001698 patent/WO1997028267A1/en active IP Right Grant
- 1997-02-03 CA CA002243986A patent/CA2243986A1/en not_active Abandoned
- 1997-02-03 JP JP9527885A patent/JP2000504564A/en active Pending
- 1997-02-03 EP EP07024844A patent/EP1942190A2/en not_active Withdrawn
-
1999
- 1999-01-08 US US09/227,595 patent/US6444792B1/en not_active Expired - Fee Related
-
2001
- 2001-12-20 US US10/027,075 patent/US20020114814A1/en not_active Abandoned
-
2004
- 2004-03-02 US US10/792,637 patent/US20040151725A1/en not_active Abandoned
- 2004-11-08 US US10/985,832 patent/US20050196402A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5428130A (en) * | 1989-02-23 | 1995-06-27 | Genentech, Inc. | Hybrid immunoglobulins |
US5434131A (en) * | 1991-06-27 | 1995-07-18 | Bristol Myers Squibb Co. | Chimeric CTLA4 receptor and methods for its use |
US5958403A (en) * | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
US6130316A (en) * | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7482327B2 (en) | 2005-04-06 | 2009-01-27 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules |
US10208105B2 (en) | 2007-06-01 | 2019-02-19 | Gliknik Inc. | Immunoglobulin constant region Fc receptor binding agents |
US9926362B2 (en) | 2007-06-01 | 2018-03-27 | Gliknik Inc. | Immunoglobulin constant region Fc receptor binding agents |
US10851154B2 (en) | 2007-06-01 | 2020-12-01 | Gliknik Inc. | Immunoglobulin constant region Fc receptor binding agents |
US9512208B2 (en) | 2007-06-01 | 2016-12-06 | Gliknik Inc. | Immunoglobulin constant region FC receptor binding agents |
US9512210B2 (en) | 2007-06-01 | 2016-12-06 | Gliknik Inc. | Immunoglobulin constant region Fc receptor binding agents |
US10941191B2 (en) | 2007-06-01 | 2021-03-09 | University Of Maryland, Baltimore | Immunoglobulin constant region Fc receptor binding agents |
US8268587B2 (en) | 2007-11-01 | 2012-09-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8491899B2 (en) | 2007-11-01 | 2013-07-23 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8071095B2 (en) | 2007-11-01 | 2011-12-06 | Perseid Therapeutics, LLC | Immunosuppressive polypeptides and nucleic acids |
US20110166324A1 (en) * | 2007-11-01 | 2011-07-07 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8283447B2 (en) | 2007-11-01 | 2012-10-09 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8318176B2 (en) | 2007-11-01 | 2012-11-27 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8445230B2 (en) | 2007-11-01 | 2013-05-21 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US20110177071A1 (en) * | 2007-11-01 | 2011-07-21 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8496935B2 (en) | 2007-11-01 | 2013-07-30 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US20110159542A1 (en) * | 2007-11-01 | 2011-06-30 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US20090258031A1 (en) * | 2007-11-01 | 2009-10-15 | Maxygen, Inc. | Immunosuppressive polypeptides and nucleic acids |
US20110129875A1 (en) * | 2007-11-01 | 2011-06-02 | Perseid Therapeutics Llc | Immunosupprressive polypeptides and nucleic acids |
US20110130546A1 (en) * | 2007-11-01 | 2011-06-02 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US20100260759A1 (en) * | 2007-11-01 | 2010-10-14 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US7794718B2 (en) | 2007-11-01 | 2010-09-14 | Perseid Therapeutics, LLC | Immunosuppressive polypeptides and nucleic acids |
US11117940B2 (en) | 2010-07-28 | 2021-09-14 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions |
WO2013112986A1 (en) * | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
US20140220015A1 (en) * | 2012-05-24 | 2014-08-07 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
US10233242B2 (en) | 2012-06-27 | 2019-03-19 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
US20200268883A1 (en) * | 2012-06-27 | 2020-08-27 | Dmnomore | Combinations of modalities for the treatment of diabetes |
US11286303B2 (en) | 2012-06-27 | 2022-03-29 | Phaim Pharma Ltd | CTLA4 fusion proteins for the treatment of diabetes |
US9683044B2 (en) | 2012-08-20 | 2017-06-20 | Gliknik Inc. | Molecules with antigen binding and polyvalent FC gamma receptor binding activity |
US11040093B2 (en) | 2014-02-25 | 2021-06-22 | Phaim Pharma Ltd | Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity |
US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
US11155574B2 (en) | 2016-12-09 | 2021-10-26 | Gliknik Inc. | Manufacturing optimization of GL-2045, a multimerizing stradomer |
US11795193B2 (en) | 2016-12-09 | 2023-10-24 | Gliknik Inc. | Manufacturing optimization of GL-2045, a multimerizing stradomer |
Also Published As
Publication number | Publication date |
---|---|
US6444792B1 (en) | 2002-09-03 |
US6750334B1 (en) | 2004-06-15 |
EP1942190A2 (en) | 2008-07-09 |
CA2243986A1 (en) | 1997-08-07 |
US20020114814A1 (en) | 2002-08-22 |
WO1997028267A1 (en) | 1997-08-07 |
US20050196402A1 (en) | 2005-09-08 |
JP2000504564A (en) | 2000-04-18 |
DE69738418D1 (en) | 2008-02-07 |
ATE382088T1 (en) | 2008-01-15 |
EP0877812B1 (en) | 2007-12-26 |
AU2255497A (en) | 1997-08-22 |
EP0877812A1 (en) | 1998-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6750334B1 (en) | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor | |
WO1997028267A9 (en) | Antibodies and immunoglobulin fusion proteins having modified effector functions and uses therefor | |
KR101900953B1 (en) | CD86 Antagonist multi-target binding proteins | |
KR102392142B1 (en) | Mutimeric IL-15-Based Molecules | |
KR101852245B1 (en) | Mutant interleukin-2 polypetides | |
DK2650020T3 (en) | Trimeric OX40 immunoglobulin fusion protein and methods for applications. | |
KR101715445B1 (en) | Novel immunoconjugates | |
JP5372500B2 (en) | ILT3-binding molecules and uses thereof | |
KR20180009754A (en) | The novel polypeptides | |
KR20180105736A (en) | TCR Complex immunotherapeutics | |
KR20110043643A (en) | Il6 immunotherapeutics | |
CN101679497A (en) | Soluble Il-17RA/RC fusion proteins and related methods | |
KR20190082235A (en) | GITR and CTLA-4 bispecific polypeptides | |
AU773431B2 (en) | Antibodies and immunoglobulin fusion proteins having modified effector functions and uses therefor | |
CN101316861A (en) | IL-17A and IL-17F antagonists and methods of using the same | |
KR20230165829A (en) | Bispecific Molecules and Related Compositions and Methods | |
CN114181309B (en) | Novel polypeptides | |
AU2008201750A1 (en) | Antibodies and immunoglobulin fusion proteins having modified effector functions and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |